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ABSTRACT 
Applications of Machine Learning Methods in Health Outcomes Research: 
Heart Failure in Women 
Khalid Alhussain 
There is robust evidence that heart failure (HF) is associated with substantial mortality, 
morbidity, poor health-related quality of life, healthcare utilization, and economic burden. 
Previous research has revealed that there are sex differences in the epidemiology, etiology, and 
disease burden of HF. However, research on HF among women, especially postmenopausal 
women, is limited. To fill the knowledge gap, the three related aims of this dissertation were to: 
(1) identify knowledge gaps in HF research among women, especially postmenopausal women,
using unsupervised machine learning methods and big data (i.e., articles published in PubMed);
(2) identify emerging predictors (i.e., polypharmacy and some prescription medications) of
incident HF among postmenopausal women using supervised machine learning methods; (3)
identify leading predictors of HF-related emergency room use among postmenopausal women
using supervised machine learning methods with data from a large commercial insurance claims
database in the United States. This study utilized machine learning methods. In the first aim,
non-negative matrix factorization algorithms were used to cluster HF articles based on the
primary topic. Clusters were independently validated and labeled by three investigators familiar
with HF research. The most understudied area among women was atrial fibrillation. Among
postmenopausal women, the most understudied topic was stress-induced cardiomyopathy. For
the second and third aims, a retrospective cohort design and Optum’s de-identified
Clinformatics® Data Mart Database (Optum, Eden Prairie, MN), de-identified health insurance
claims data, were used. In the second aim, multivariable logistic regression and three
classification machine learning algorithms (cross-validated logistic regression (CVLR), random
forest (RF), and eXtreme Gradient Boosting (XGBoost) algorithms) were used to identify
predictors of incident HF among postmenopausal women. The associations of the leading
predictors to incident HF were explored with an interpretable machine learning SHapley
Additive exPlanations (SHAP) technique. The eight leading predictors of incident HF consistent
across all models were: older age, arrhythmia, polypharmacy, Medicare, chronic obstructive
pulmonary disease (COPD), coronary artery disease, hypertension, and chronic kidney disease.
Some prescription medications such as sulfonylureas and antibiotics other than fluoroquinolones
predicted incident HF in some machine learning algorithms. In the third aim, a random forest
algorithm was used to identify predictors of HF-related emergency room use among
postmenopausal women. Interpretable machine learning techniques were used to explain the
association of leading predictors to HF-related emergency room use. Random forest algorithm
had high predictive accuracy in the test dataset (Area Under the Curve: 94%, sensitivity: 93%,
specificity: 77%, and accuracy: 0.81). We found that the number of HF-related emergency room
visits at baseline, fragmented care, age, insurance type (Health Maintenance Organization), and
coronary artery disease were the top five predictors of HF-related emergency room use among
postmenopausal women. Partial dependence plots suggested positive associations of the top
predictors with HF-related emergency room use. However, insurance type was found to be
negatively associated with HF-related emergency room use. Findings from this dissertation
suggest that machine learning algorithms can achieve comparable and better predictive accuracy
compared to traditional statistical models.
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1.1 Background and Significance 
Heart failure and its epidemiology 
Heart failure (HF) is a complex clinical condition that impairs the ability of the heart to 
eject or fill enough blood to meet the body's needs1,2. This condition affects about 64 million 
people globally3, and it is growing in prevalence. The prevalence of HF varies across countries. 
For example, the prevalence of HF ranges from 1% to 6.7% in Asian countries4, 1% to 2.2% in 
European countries4, and 2.2% in the United States (US)5. The epidemiology of HF varies by sex 
and age. American men have a higher overall prevalence of HF than American women (2.4% vs. 
2.1%)5. However, the incidence of HF is higher among older American women than their men 
counterparts5.  
Disease burden of HF 
Although its prevalence seems to be relatively low compared to other cardiovascular 
diseases5, HF is considered a major public health problem. This is because it is associated with 
substantial mortality, morbidity, poor health-related quality of life (HRQoL), healthcare 
utilization, and economic burden5–12. These negative consequences of HF affect men and women 
differently13–15. For example, women have higher HF mortality rates than men5. In the US, there 
were 78,356 deaths due to HF in 2016; about 55% of those deaths were among women5. In terms 
of HRQoL, a study by Dewan et al. revealed that women with HF reported lower scores on 
almost all domains of HRQoL compared to men with HF13. Furthermore, patients with HF have 
high healthcare utilization. HF hospitalizations are still high even after the slight decrease that 




over a million emergency room (ER) visits due to HF in the US7. Most of those hospitalizations 
and ER visits were made by older patients (aged > 65 years), specifically older women. About 
38% (N= 367,779) of hospital admissions and 37% (N= 394,244) of ER visits were made by 
older women7. Because of this, the costs of HF management are high and will remain a 
significant concern for the US healthcare system. In 2012, total healthcare expenditures 
associated with HF were $20.9 billion8. These costs are projected to rise to $53.1 billion in 
20308. 
Etiology of HF in women 
There is evidence that there are differences in HF etiology between men and women14,15. 
Women tend to develop HF at an older age compared to men14,15 because young women are 
protected against the development of HF through the protective effect of female sex hormone, 
estrogen16. However, estrogen levels decrease after menopause. The decline in the level of 
endogenous estrogen can increase the risk of HF in postmenopausal women17,18. This may 
explain why older women (i.e., postmenopausal women) have a higher incidence of HF than 
older men. In addition to the estrogen effect, women and men differ in risk factors for HF. 
Although women and men share some risk factors for HF, these factors may affect them 
differently. For example, a systematic review and meta-analysis of cohort studies found that 
atrial fibrillation conferred higher risk for HF in women than men19. Another study indicated that 
hypertension confers higher HF risk in women, whereas the effect of myocardial infarction as a 
risk factor for HF is higher in men15.  
Research on HF among women, especially postmenopausal women 
Despite the sex differences in HF etiology and disease burden, research on HF among 




participation has not changed over time20,21. A systematic review examining the enrollment of 
women and other minorities in 118 HF clinical trials revealed that women represented only 27% 
of participants in clinical trials for HF, and the participation of older population was low21. 
Considering this information, we speculate that the representation of postmenopausal women in 
HF clinical trials is even lower. With such inclusion disparities, there may be significant 
knowledge gaps in HF research among women, especially postmenopausal women.  
Modifiable risk factors for HF among postmenopausal women 
Given the high incidence of HF in older women (i.e., postmenopausal women)5, 
identification of risk factors for primary prevention of HF is crucial. This can reduce the disease 
burden and improve health outcomes in this population. Several studies have investigated risk 
factors for HF in postmenopausal women22–28, but few included modifiable factors23,28. A study 
by LaMonte et al. examined the association between physical activity and HF incidence in 
postmenopausal women and found that levels of recreational physical activity, including 
walking, are inversely associated with HF risk28. Such finding is helpful for prevention of HF. 
Studies identifying modifiable risk factors for HF in postmenopausal women are needed.  
Emerging risk factors for HF  
There is emerging evidence that polypharmacy may increase the risk of HF29. A study by 
Chen et al. found that polypharmacy was associated with an increased risk for HF among older 
individuals with atrial fibrillation29. This increased risk can occur due to adverse drug reactions, 
drug-drug interactions, or both. Polypharmacy is common among postmenopausal women 
because of their high prevalence of multimorbidity30,31. Postmenopausal women are more likely 
to develop some health conditions such as vasomotor symptoms32,33, diabetes mellitus34,35, 




treated with prescription medications such as oral antidiabetics, antiepileptics, and antibiotics. 
Prescription medication use can be effective to treat conditions that are prescribed for; however, 
they may increase the risk for HF in postmenopausal women41.  
Oral antidiabetic medications 
Previous studies have suggested that some oral antidiabetic medications may increase the 
risk for HF41,42. For example, sulfonylureas, an antidiabetic class that exerts their hypoglycemic 
effects by stimulating insulin secretion from the pancreatic beta cells, have been found to be 
associated with a higher risk for HF compared to metformin42,43. This association was dose-
response; higher doses of sulfonylureas were associated with a higher risk for incident HF43. 
Moreover, thiazolidinediones, an antidiabetic class that acts by improving insulin sensitivity, 
have been shown to increase the risk for HF in several meta-analyses included randomized 
controlled trials and observational studies44–46. Another oral antidiabetic class is dipeptidyl 
peptidase-4 (DPP-4) inhibitors including sitagliptin, saxagliptin, alogliptin, and linagliptin. These 
medications exert their hypoglycemic effects by increasing insulin secretion and decreasing 
glucagon levels through the prevention of the degradation of incretin hormones and glucagon-
like peptide-147. DPP-4 inhibitors have also been linked to HF risk. Results from a meta-analysis 
of all randomized trials of DPP-4 inhibitors indicated that patients using any DPP-4 inhibitor had 
a higher overall risk of acute HF compared to placebo or other classes48. This suggests a possible 
negative effect of this class; however, the mechanism of this effect is unclear. Unlike the above-
mentioned oral antidiabetic medications, metformin may have cardiovascular benefits42. 
Antiepileptic medications 
Pregabalin and gabapentin, structural analogues of the inhibitory neurotransmitter γ-




analgesics in patients with neuropathic pain49. In a case report study, a 54-year-old woman with 
no cardiac history developed HF after a normal dose of pregabalin use50. The mechanism of the 
possible effect of pregabalin on incident HF is not well-understood. This may be because of the 
inhibition of the L-type calcium channels50, which means gabapentin use could lead to the same 
effect51. In a Canadian population-based study, pregabalin was compared to gabapentin in terms 
of HF risk and no statistically significant differences were observed between both medications52.  
Antibiotics 
Recently, concerns regarding the cardiovascular safety of antibiotics have been raised. In 
2019, a study examined the association between antibiotic use and cardiovascular events in 
women53. After a follow-up of 7.6 years, 2.9% developed cardiovascular events. It was found 
that women who took antibiotics for 2 months or longer during late adulthood (age 60 and older) 
were 32% more likely to develop cardiovascular disease, and those used antibiotics for 2 months 
or longer in their middle age were 28% more likely to develop cardiovascular disease compared 
to those who did not use antibiotics in the same life-stage. The increased risk associated with 
antibiotic use could be explained by the alterations in the gut microbiota. In other words, 
antibiotics destroy probiotic bacteria (beneficial bacteria), which may increase the colonization 
of viruses, pathogenic bacteria, or other micro-organisms54. Prior research has linked the 
imbalance in the gut microbiota with inflammation and narrowing of the blood vessels, stroke, 
and heart disease55–58. Furthermore, a case-control study tied fluoroquinolones to the risk of 
aortic and mitral regurgitation, conditions in which the blood backflows into the heart59. This 
increased risk can occur due to the potential adverse effect of fluoroquinolones. The US Food 




stating that these drugs can increase the risk of rupture or dissection of aortic aneurysms60. The 
development of these heart valve disorders can lead to HF. 
Emergency room use among postmenopausal women with HF 
Even though HF is considered a chronic disease, those with HF require emergency care 
for acute symptoms, resulting in a high utilization ER61. A previous study has revealed that about 
one-third of patients with HF use the ER frequently62. Data from 2014 showed that American 
older women have higher HF-related ER visits than their men counterparts7. Such high 
utilization of ER imposes burden on the US healthcare system (i.e., high hospitalization and 
expenditures)62,63. In a study using data from more than 113,000 patients with HF in California 
and Florida hospitals, it was found that in one year $3.08 billion were spent on the ER and 
inpatient services for HF in Florida alone62. This burden can be reduced since the majority of 
HF-related ER use are avoidable64.  
Factors contributing to the emergency room use  
Prior research refuted the common misperception that the uninsured individuals use the 
ER more than the insured individuals65–67. For example, a study using 2013 nationally 
representative survey data from the US found that 14.3% of insured adults (aged 19-64 years) 
had at least one ER visit, whereas 9.6% of uninsured adults used the ER at least once after 
adjusting for demographics and self-reported health status65. This emphasizes that health 
insurance does not guarantee access to primary care; even insured individuals may use ER 
because of the lack of access to primary care. Other patient-level factors associated with ER use 
have been identified in the previous studies68–76. For example, chronic physical conditions71,75, 




use. However, those studies have been conducted among all adults, older individuals, and those 
with specific chronic conditions (e.g., diabetes and COPD). 
Special needs for postmenopausal women that may increase ER use 
Due to the hormonal changes, postmenopausal women may experience vasomotor 
symptoms such as hot flashes and night sweats. A study by Williams et al. indicated that 65% of 
American postmenopausal women experience vasomotor symptoms32. These symptoms can 
increase the probability of ER use77. In addition, postmenopausal women have a high prevalence 
of other factors contributing to ER use (i.e., mental illness)36,37.  
In summary, our literature review suggests the lack of 1) comprehensive review of the 
literature of HF among women, especially postmenopausal women; 2) real-world evidence on 
the effect of polypharmacy and some prescription medications used to treat co-existing health 
conditions among postmenopausal women (i.e., oral antidiabetics, antiepileptics, and antibiotics) 
on incident HF; 3) real-world evidence on predictors of HF-related ER use among 
postmenopausal women. It is imperative to fill these gaps in the literature. Identification of 
knowledge gaps in the literature of HF can provide an overall picture of HF research among 
women, particularly postmenopausal women. Such information can help researchers and funding 
agencies to address research gaps in this population. Furthermore, identification of modifiable 
predictors of HF including emerging risk factors (i.e., polypharmacy and prescription medication 
use) in real-world settings using diverse and representative population-based data can provide 
essential information for clinicians, payers, patients, and other stakeholders to weigh the harms 
and benefits of medications and personalize treatment plans. Moreover, an examination of 
leading predictors of HF-related ER use by utilizing real-world health insurance data can assist 




and develop specific interventions that could decrease ER utilization and improve health 
outcomes.  
1.2 Innovation 
1. There has been a transformational shift in population health landscape in terms of the 
availability of payer data for research and the requirement of electronic health records (EHR) to 
track patient’s health, emphasis on patient outcomes and value-based care. The availability of big 
data due to this transformation has made health analytics an integral part of improving 
population health. The present study uses novel approaches such as topic modeling and 
predictive modeling. 
2. This study represents a series of “firsts”. It is the first study using big data (PubMed) 
and unsupervised machine learning methods to identify research topics in the literature of HF 
among women; the first study includes emerging risk factors (i.e., polypharmacy and 
prescription medication use) to identify predictors of incident HF among postmenopausal 
women. This can help identify those patients at risk for developing HF so that they can benefit 
from preventive care. It is the first study to identify predictors of HF-related ER use among 
postmenopausal women. 
3. Use of natural language processing (NLP) and text mining techniques to screen and 
identify relevant articles and extract the objective(s) of each study from PubMed abstracts. This 








1.3 Specific Aims 
Aim 1: Identify knowledge gaps in heart failure research among women, especially 
postmenopausal women, using unsupervised machine learning methods and big data (i.e., 
articles published in PubMed).   
Aim 2: Identify emerging predictors (i.e., polypharmacy and some prescription 
medications) of incident heart failure among postmenopausal women using supervised 
machine learning methods. 
Hypothesis: Polypharmacy and use of fluoroquinolones, sulfonylureas, thiazolidinediones 
(TZDs), dipeptidyl peptidase-4 (DPP-4) inhibitors, gabapentin, and pregabalin will be positively 
associated with incident heart failure. 
Aim 3: Identify leading predictors of heart failure-related emergency room use among 
postmenopausal women using supervised machine learning methods with data from a large 
commercial insurance claims database in the United States.  
Hypothesis: Polypharmacy and the use of fluoroquinolones, sulfonylureas, dipeptidyl peptidase-
4 (DPP-4) inhibitors, and gabapentin will be positively associated with heart failure-related 
emergency room use. 
1.4 Approach 
Machine learning techniques in health services and outcomes research 
 Machine learning (ML) methods have been in existence since 1950; however, the use of 
alternative, non-parametric ML approaches has risen significantly following the pioneering work 
by Breiman78. Numerous studies in health services and outcomes research have used ML 




Unlike traditional parametric statistical models, ML methods are assumption-free and robust to 
outliers, multicollinearity issues, and high-level interaction terms82. 
Although multivariable logistic regression can be used to create predictive models, the 
predictive ability of logistic regression that uses only statistical significance may not be the best 
compared to ML algorithms. Therefore, we used supervised ML classification algorithms: 1) 
cross-validated logistic regression (CVLR), 2) random forests (RF), and 3) eXtreme Gradient 
Boosting (XGBoost). These algorithms were selected because of their growing popularity in 
clinical settings for prediction of binary outcomes and their ability to detect complex associations 
between the outcome and predictors and interactions between covariates83,84. 
The main advantage of CVLR is its ability to provide meaningful and easy-to-interpret 
results such as odds ratios (ORs), which can provide clinical information on the impact of 
predictors on the occurrence of the event of interest. RF algorithm, a tree-based technique, is 
becoming popular and has been shown to perform very well in medical settings83,84. RF 
algorithm has several advantages including its ability to handle missing data, run efficiently on 
large datasets, handle non-linearity and a large number of independent variables, and produce 
highly accurate and precise estimates88.  
In addition to their predictive abilities, ML methods provide more efficient and less time-
consuming methods for text analysis. Unsupervised ML algorithms enabled us to cluster a large 
number of PubMed articles studying HF among women; this would not be feasible without ML 
methods.  
Conceptual framework 
We used the modified determinants of health outcome and chronic disease model, which 




of the study features (Figure 1), Based on this model, a disease incidence (i.e., HF) can be 
influenced by five domains. These domains include: (1) biological factors (e.g., age), (2) access 
to care factors (e.g., type of insurance), (3) community resources (e.g., geographical region), (4) 
medication-related factors (e.g., cardiovascular disease treatment such as polypharmacy and 
prescription medication use), and (5) health-related risk factors, which consist of two sub-
domain: (a) chronic health conditions such as diabetes, asthma, and chronic obstructive 
pulmonary disease, and (b) lifestyle factors such as substance abuse and obesity) 
Data sources 
Chapter 2: PubMed 
PubMed is a free resource supporting the search and retrieval of biomedical and life 
sciences literature and has been available since 1996. The PubMed database comprises more than 
30 million citations and abstracts of biomedical literature from MEDLINE, life science journals, 
and online books. PubMed was developed and is maintained by the National Center for 
Biotechnology Information (NCBI), at the US National Library of Medicine (NLM), located at 
the National Institutes of Health (NIH)90. 
Chapter 3 & 4: Optum’s de-identified Clinformatics® Data Mart Database (Optum, Eden Prairie, 
MN)  
Data were derived from Optum’s de-identified Clinformatics® Data Mart Database 
(Optum, Eden Prairie, MN). This geographically diverse database contains healthcare claims 
from a 10% sample of 47 million individuals. Of whom, about 80% purchased insurance through 
their employers. The data contain inpatient, outpatient and pharmacy claims, lab results, and 
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2. Identifying Knowledge Gaps in Heart Failure Research among Women Using 
Unsupervised Machine Learning Methods 
2.1 Abstract 
Objective: To identify knowledge gaps in heart failure (HF) research among women, especially 
postmenopausal women. 
Materials & Methods: We retrieved HF articles from PubMed. Natural language processing 
and text mining techniques were used to screen relevant articles and identify study objective(s) 
from abstracts. After text pre-processing, we performed topic modeling with non-negative matrix 
factorization to cluster articles based on the primary topic. Clusters were independently validated 
and labeled by three investigators familiar with HF research.  
Results: Our model yielded 15 topic clusters from articles on HF among women. The smallest 
cluster was about atrial fibrillation. From articles specific to postmenopausal women, 5 clusters 
were identified. The smallest cluster was about stress-induced cardiomyopathy. 













Heart failure (HF) affects at least 26 million people worldwide, and its prevalence has 
been increasing over the past decades1. For example, HF prevalence is expected to rise from 
2.42% in 2012 to 2.97% in 2030 in the United States (US)2. The grown prevalence of HF, along 
with its high mortality and morbidity3 as well as poor health-related quality of life (HRQoL)4 
make HF a major global health problem. HF mortality has been assessed in several countries1. In 
a registry-based study enrolling 12,440 patients with acute or chronic HF from 21 European 
and/or Mediterranean countries, the 1-year mortality rates varied across countries; it ranged from 
21.6% to 36.5% in patients with acute HF, and from 6.9% to 15.6% in those with chronic HF5. In 
the US, the 1-year mortality in patients with HF ranged from 35.1% to 37.5%6. Even if they 
survive, patients with HF have poor HRQoL, both physical and mental components, compared to 
the general population4. In addition, HF has a high economic burden. Healthcare spending on HF 
constitutes 1-2% of the global healthcare budget, mainly due to hospitalization costs7. Cost 
estimates varied from a country to another. For instance, total annual costs per patient with HF 
ranged from $868 for South Korea to $25,532 for Germany7. Regardless of the differences across 
countries, in general, HF has a significant health and economic burden worldwide.  
 With that being said, there is a need to study HF. A major consideration that should be 
taken into account in future studies is the sex differences in HF burden and risk factors. For 
example, women with HF have poorer HRQoL compared to their men counterparts8. 
Furthermore, women tend to develop HF at an older age than men3,9, which can be explained by 
the female sex hormone, estrogen. Estrogen has anti-atherosclerotic and anti-inflammatory 
properties, which positively affects the inner layer of artery wall10,11. However, estrogen levels 




HF in postmenopausal women12,13. In terms of risk factors for HF, hypertension is more common 
in women, whereas myocardial infarction is more prevalent in men9.  
Despite these differences between women and men with HF, women are 
underrepresented in clinical trials for HF14,15. A recent systematic review examined the 
enrollment of women and other minorities in 118 HF clinical trials15. This study revealed that 
women represented only 27% of participants in clinical trials for HF, and women’s participation 
has not significantly changed over time.  
With such underrepresentation of women in HF clinical trials, significant knowledge gaps 
in HF research among women may exist. These knowledge gaps need to be identified and 
addressed. To date, no study has reviewed all published HF research among women, specifically 
among postmenopausal women. Systematic reviews and meta-analysis focus on a single topic 
(example: mortality, treatment, biological markers)16,17. However, conducting a broad search of 
“heart failure” and women in the PubMed database yields over 100,000 articles. Manually 
reading all these articles and summarizing the topics will not be feasible. 
With the wide-spread digital transformation and ability of processing and understanding 
of the text by machine through natural language processing (NLP), it is now possible to use 
digital technology to cluster all HF research among women based on their primary objectives. 
Such approach cannot only save the researchers’ time by substituting computer time18 but also 
discovers knowledge gaps in HF research among women. Therefore, the objective of the current 
study is to identify knowledge gaps in HF research among women, especially postmenopausal 







Data source, search strategies, and procedures  
Our data source was PubMed, a free database comprises more than 30 million citations 
and abstracts of biomedical literature from MEDLINE, life science journals, and online books19. 
We only searched PubMed (i.e., no other databases) because we wanted to assess the feasibility 
of using unsupervised machine learning methods for identifying knowledge gaps. We identified 
articles on HF research in women from the inception (1959) until 3 December 2019. We 
conducted two search strategies: (1) broad, where we focused on all women, and (2) specific, 
where the focus was on postmenopausal women. For search #1, we used the following keywords 
and medical subject headings (MeSH): (“heart failure” OR “congestive heart failure” OR 
“cardiac failure” OR “heart failure therapy” OR “ejection fraction”). For search #2, we used the 
following strategy: (“heart failure” OR “congestive heart failure” OR “cardiac failure” OR “heart 
failure therapy” OR “ejection fraction” AND “postmenopause” OR “menopause”). We included 
“ejection fraction” as one of the search terms because ejection fraction plays a key role in HF 
diagnosis and outcomes20. For both searches, we used PubMed search filters on sex (female), 
species (humans), and text availability (abstract) to enhance our search strategies. For the 
purpose of this study, no restrictions (e.g., study design or country) were used.  
Procedures 
Articles retrieved from the PubMed searches were stored in Comma-separated Values 
files. We removed duplicates based on article titles. We identified relevant articles based on 
“study objectives” because the objectives of an article can provide a clear and exact intent of the 
study. We only included studies having at least one of the HF terms (i.e., “heart failure” and 




As our main interest was in summarizing the HF research in women and postmenopausal 
women, we used “topic models”, a type of statistical model for identifying a set of “topics” that 
best describes a given document (in this case, given PubMed article). Topic modeling is an 
unsupervised machine learning method that automatically clusters a set of documents according 
to “semantic structures” or topics that are similar. It has to be noted that topic modeling can 
group words within the same context as well as distinguish the use of the same words in a 
different context. Furthermore, topic modeling does not require pre-existing knowledge of the 
categories of the articles18. Topic modeling has been applied on different medical datasets 
including lung cancer, breast cancer, and Salmonella PFGE genotyping datasets21. Following the 
framework for smart literature review of big data, we used three key steps: pre-processing, topic 
modeling, and post-processing of outcomes18. All procedures and modeling were conducted with 
Python 3.7. 
Text pre-processing  
Text pre-processing is a crucial step in the process of building any model. Typically, text 
pre-processing helps machine learning algorithms by removing or filtering less useful parts of 
the text through various methods such as punctuation and stop word removal. In the current 
study, we restricted NLP and text mining techniques to the objective(s) of the study rather than 
the full text or abstract of the article. The reason behind this is that a study objective provides 
specific information about the study, while the full text and abstract have information that may 
not be directly related to the primary topic of the study (e.g., literature review and statistical 
analysis). We pre-processed the text using the Natural Language Toolkit (NLTK), one of the 
most powerful platforms for processing human language in Python software. We first removed 




keywords. Examples of such words are “introduction”, “background”, “methods”, “results”, and 
“conclusions” that are used in almost all structured abstracts. After removing unnecessary words, 
we conducted two more steps (i.e., tokenization and lemmatization). Tokenization is the process 
of splitting text into a list of tokens, and lemmatization is a morphological analysis of the words 
(e.g., using the lemma “study” for studies, study, studied, studying). 
Topic modeling with non-negative matrix factorization  
 As topic modeling involves grouping similar word patterns to identify topics, there are 
several algorithms such as Non-Negative Matrix Factorization (NMF) based on linear algebra are 
available. We selected NMF to identify topics and classify the documents according to these 
topics at the same time. NMF computes term frequency-inverse document frequency (TF-IDF), a 
weighting scheme that assigns each word in our dataset (i.e., PubMed abstracts) a weight. The 
higher the weight, the more important the word is. To compute the TF-IDF weighting, we used 
TfidfVectorizer with n-gram range from 1 to 2 from the scikit-learn Python module.  
We performed topic modeling on all studies of women with HF (search#1) and studies 
specific to postmenopausal women (search#2). To identify the optimal number of clusters, we 
ran the algorithm with a different number of topics (n); for example, we specified the value of n 
as 5, 10, 15, 20, and 25. Then, we manually evaluated the outputs from all models and selected 
the most interpretable model. All analyses were performed using Python 3.7. 
Post-processing 
Validation of topic modeling: human intelligence  
During the post-processing, we reviewed the clusters identified to ensure that they are 
interpretable. Moreover, we used an expert evaluation to validate the topic models. Clusters 




with HF research. In case of a disagreement on the cluster label, discussion among the 
investigators was a sensible first step. Disagreements among investigators were resolved by 
consensus. If a disagreement could not be resolved, investigators reviewed that cluster in depth; 
they randomly reviewed the titles and abstracts of 40 articles within that cluster. Finally, we 
reported the frequency and percentage of agreements and disagreements. 
2.4 Results 
Study retrieval and selection 
Automated extraction using search strategy #1 yielded 69,558 articles related to HF in 
women. Of these, 6 articles with no abstract and 53 duplicates were removed. The remaining, 
69,499 articles, were electronically screened for relevance (i.e. study objective(s) must have at 
least one of the HF terms). This process yielded 32,946 eligible HF articles for topic modeling.  
Using a separate search strategy #2, where the focus on postmenopausal women, there 
were 41,519 articles with abstract after 150 duplicates were removed. After electronically 
screening, 41,442 articles were excluded because they were not relevant based on the study 
objective(s) (i.e. absence of all HF terms in the study objective). A final list of 77 articles were 
included in the topic modeling. Flow charts illustrating each step of this process are shown in 
Figure 1. 
Topic clusters  
A description of the topic clusters is shown in Table 1. For search strategy #1, the topic 
model with 15 topic clusters was selected because it was the most interpretable model for HF 
articles in women. In terms of size, the largest topic cluster consisted of 4,578 articles (%13.9), 
whereas the smallest topic cluster consisted of 808 articles (%2.5) (Figure 2). The most studied 




the most interpretable topic model yielded 5 clusters out of 77 articles on HF in postmenopausal 
women. The largest cluster size was 34 articles (44.2%) while the smallest cluster size was 6 
articles (7.8%) (Figure 3). The most studied topic in postmenopausal women was cardiovascular 
risk. (e.g., effects of lipid accumulation product and blood pressure on cardiovascular risk in 
postmenopausal women).  
Understudied research topics in the literature of HF among women  
Based on the cluster size, the three most understudied topics are (1) atrial fibrillation, (2) 
systolic and diastolic dysfunction, and (3) left ventricular ejection fraction phenotypes. The 
knowledge gaps are even greater in the literature of HF among postmenopausal women. Only 6 
articles studied stress-induced cardiomyopathy. The effect of breast cancer and chemotherapy on 
HF was discussed in 12 articles. Also, the incidence of HF in postmenopausal women was 
studied in 12 articles.  
Cluster validation and labeling 
Topic clusters were independently validated and labeled by the first, second, and seventh 
authors. The percentage of agreement among authors on topic labels is presented in Table 2. For 
search strategy #1, the agreement percentage was 80%, which means authors agreed on 12 out of 
15 topic labels. Regarding the other three clusters, disagreements were resolved by reviewing 
those clusters in depth. For search strategy #2, there were no disagreements on the topic labels.  
2.5 Discussion 
The main objective of this study was to explore knowledge gaps in HF research among 
all women and postmenopausal women. We achieved this objective by using topic modeling, an 
unsupervised machine learning method. Our approach saved researchers’ time once the program 




topics. This hybrid approach was more comprehensive and less time-consuming than the expert-
based manual literature review method. For example, a study by Myers et al. was conducted to 
assess the progress of CVD research output between 2002 and 2011 using the expert-based 
manual literature review method22. In that study, a physician read the abstracts and decided 
whether a study was relevant. Although there were 47,897 articles related to CVD in 2002 and 
54,488 articles in 2011, only 3,000 articles randomly selected each year were reviewed. This is 
mainly because it was difficult to manually review more than 100,000 abstracts.  
Our current study has revealed that atrial fibrillation is the most understudied area in the 
literature of HF among women. Prior research in this area has discussed the epidemiology of 
atrial fibrillation, role of natriuretic peptide, and risk of stroke in patients with atrial fibrillation 
and heart failure. Nevertheless, this research area should be further explored for several reasons. 
First, there is a positive association between AF and HF 23,24, and this association can be 
explained by shared risk factors and pathophysiology25. Thus, these two diseases can be 
regularly encountered concomitantly in clinical practice. Patients with concomitant HF and AF 
may have even worse symptoms and poorer prognosis, which means they may respond to 
treatment differently than those with HF or AF alone24,25. Furthermore, the co-occurrence of HF 
and AF may increase the risk of HF hospitalization and all-cause mortality, as previous studies 
shown26,27. With that being said, future research focusing on the comorbidity of HF and AF in 
women is needed. This can improve the health outcomes of women affected by these two 
conditions and the cost-effectiveness of their care.  
Another important finding was that the volume of research on HF in postmenopausal 
women is small. In this study, we only identified 77 articles on HF in postmenopausal women 




understudied topic is stress-induced cardiomyopathy. This may be because this condition is rare. 
In the US, stress-induced cardiomyopathy was diagnosed in about 0.02% of all nationwide 
hospitalizations28. Of those, 90.6% were women. It is well-known that this condition is more 
common in women than men29–33. Therefore, future studies should investigate this topic and 
address knowledge gaps in this area.  
Another major understudied area is the incidence of HF in postmenopausal women. For 
instance, few studies examined risk factors for the incidence of HF in postmenopausal women. 
There is a critical need to identify factors associated with HF incidence in this population and 
address the modifiable risk factors. There may be emerging risk factors such as medication use. 
Medications that may increase the risk of HF should be identified. For example, one of the 
clusters yielded from our model was related to cardio-oncology in advanced breast cancer.  
Identification of research gaps is the first step towards reducing HF risk and improving 
health outcomes in women. Our findings provide an overview of HF research among women. 
Such information can help researchers and funding agencies to prioritize and address research 
gaps. Using data from this study along with the insights of the professional community may 
contribute to the development of a research roadmap for HF in women. 
Potential limitations and strengths of this study should be noted. First, no evaluation 
metrics were used to assess the accuracy of clusters yielded from unsupervised machine learning. 
However, this limitation was addressed by independently validating and labeling clusters yielded 
from our model by three investigators familiar with HF research. Second, we were not able to 
extract the study objective(s) from unstructured abstracts. In that case, we analyzed the full 
abstract. Finally, we only searched one database (i.e., PubMed) to retrieve HF articles, which 




study had several strengths. To our knowledge, this was the first study to use big data (PubMed) 
and unsupervised machine learning methods to identify research topics in the literature of HF 
among women. In addition, we used NLP and text mining techniques to screen and identify 
relevant articles and extract the objective(s) of each study from PubMed abstracts.  
2.6 Conclusion 
The present study was able to identify gaps in the literature of HF among women, 
particularly postmenopausal women, using unsupervised machine learning methods. This 
approach is promising and effective for the discovery of knowledge gaps in medical research. 
Once unsupervised machine learning procedures are established, clustering a large number of 
research articles can be performed within a short time. However, human intelligence is required 
















Table 1: Description of the topic clusters 
Clusters Yielded from Search #1 (n=15) 
Topic/Cluster Label Key Words - Examples No. of 
Articles 
Epidemiology/disease burden of HF “prevalence”, “hf risk”, “factor”, “obesity”, “incident”, “chronic 
hf”, “acute hf”, “systolic hf”, “advanced hf”, “hf preserved”, “hf 
outcome”, “hf hospitalization”, “outpatient”, “mortality”, 
“population” 
4,578 
Heart procedures - mainly valvular “surgery”, “operation”, “valve replacement”, “mitral regurgitation”, 
“aortic valve”, “tricuspid”, “bypass”, “coronary artery”, 
“echocardiography”, “dilated cardiomyopathy”, “stenosis”, 
“treatment”, “cardiac failure”, “congestive heart”, “severe”, 
“underwent”, “complication” 
4,515 
Clinical markers in chronic HF* 'inflammation', 'tnfalpha', 'endothelial', 'cytokine', 'cell', 'marker', 
'activation', 'oxidative', 'sympathetic', 'muscle', 'serum', 'breathing', 
'sdb', 'sleep', 'severity', 'renal', 'copd', 'anemia', 'prognosis', 'elderly', 
'congestive heart', 'chronic heart' 
3,243 
Myocardial infarction “myocardial infarction”, “acute myocardial infarction”, “coronary 
artery”, “cardiac index”, “incidence”, “age”, “diabetes”, “stroke”, 
“outcome”, “hospitalization”, “survival”, “all-cause”, “sudden”, 
“death”, “mortality” 
2,990 
Health-related quality of life (HRQoL) “quality of life”, “health-related quality”, “depressive symptom”, 
“depression”, “physical”, “symptom”, “status”, ”selfcare”, 
“questionnaire”, “program”, “intervention”, “education”, “social”, 
“service”, “caregiver”  
2,909 
Hemodynamic effects* “hemodynamic”, “pulmonary artery”, “pulmonary capillary”, 
“systemic vascular”, “vascular resistance”, “arterial pressure”, 
“heart rate”, “wedge pressure”,  “blood pressure”, “cardiac index”, 
“stroke” 
2,562 
Pharmacotherapy “ace inhibitor”,  “beta-blockers”, “diuretic”, “receptor blocker”, 
“arb”, “captopril”, “digoxin”, “enalapril”, “angiotensin receptor”, 
“antagonist”, “inhibition”, “dose”, “mg”, “placebo”, “drug”, “class” 
1,713 
Cardiac biomarkers “brain natriuretic”, “bnp level”, “anp”, “b-type natriuretic”, “nt-pro-
bnp”, “natriuretic peptide”, “'n-terminal pro-brain”, “serum”, 
“plasma”, “pgml”, “marker”, “concentration”, “measurement”, 





Acute decompensated heart failure “acute decompensated”, “adhf”, “worsening renal”, “wrf”, “renal 
dysfunction”, “aki”, “emergency department”, “inhospital”, 
“admission”, “hospitalized”, “nesiritide”, “diuretic”  
1,545 
Exercise “aerobic”, “cardiopulmonary exercise”,  
“peak exercise”, “training”, “ventilation”, “exercise test”, “exercise 
tolerance”, “functional capacity”, “oxygen uptake”, “oxygen 
consumption”, “peak vo”, “vevco”  
1,469 
Cardiac resynchronization therapy “cardiac resynchronization”, “crt”, “crt-d”, “icd”, “defibrillator”, 
“implantation”, “dyssynchrony”, “pacing”, “bundle branch”, 
“branch block”, “lbbb, 'delay', 'remodeling', 'biventricular', 'lead', 
'qrs duration' 
1,295 
Left ventricular assist device & heart 
transplantation 
“lvad implantation”, “pump”, “bridge”, “mechanical circulatory”, 
“assist device”, “heartmate”, “cardiac transplantation”, “recovery”, 
“experience”, “survival”, “advanced heart”, “end-stage heart” 
1,255 
Left ventricular ejection fraction 
phenotypes 
“hfpef”, “hfmref”, “hfref”, “reduced ef”, “preserved ef”, 
“midrange”, “pathophysiology”, “hypertension”, “prognostic”, 
“outcome”, “ejection fraction”  
1,209 
Systolic & diastolic dysfunction* 'systolic dysfunction', 'diastolic dysfunction', 'lv systolic', 'lv 
dysfunction', 'lv diastolic', 'velocity', 'right ventricular', 'myocardial', 
'doppler', 'pacing', 'filling', 'volume', 'echocardiography', 'diastolic 
function', 'ejection fraction' 
1,201 
Atrial fibrillation “atrial fibrillation”, “af”, “af sinus”, “paroxysmal”, “sinus rhythm”, 
“permanent atrial”, “persistent atrial”, “af hf”, “incidence”, “new-
onset af”, “rate control”, “cardioversion”, “pacing”, “catheter 
ablation”, “digoxin” 
808 
Clusters Yielded from Search #2 (n=5) 
Cardiovascular disease risk “cardiovascular risk”, “risk factor”, “myocardial infarction”, 
“coronary artery”, “sex”, “estrogen”, “hrt”, “postmenopausal 
woman”, “blood pressure”, “hypertension”, “stroke”, “obesity”, 
“diabetes”, “morbidity”, “mortality”, “death” 
34 
Role of female sex hormone in HF “sex hormone”, “female”, “estrogen”, “menopause”, “age”, 
“protective”, “endothelial”, “risk marker”, “lvdd”, “diastolic 
dysfunction”, “preserved ejection”, “ejection fraction”, “hfpef”, 
“microvascular”, “role”, “mechanism” 
13 
Effect of breast cancer and chemotherapy 
on HF  
“breast cancer”, “advanced breast”, “chemotherapy”,  
“cyclophosphamide”, “tamoxifen”, “methotrexate”, “doxorubicin”, 





“drug”, “agent”, “dose”, “toxicity”, “progression”, “remission”, 
“alopecia”, “response” 
HF incidence “hf incidence”, “incident hf”, “incident heart”, “risk incident”, “risk 
heart”, “age”, “early'”, “age menopause”, “effect cardiac”, “cvd”, 
“hf postmenopausal”, “sex hormone”, “hrt”, “deficit”, “vitamin”, 
“supplementation” 
12 
Stress-induced cardiomyopathy “stress”, “takotsubo syndrome”, “takotsubo cardiomyopathy”, “tt”, 
“acute”, “syndrome”, “condition”, “reversible”, “rare”,  “segment”, 
“pathophysiology”, “coronary artery”, “left ventricle”, “activation”, 
“diagnosis”, “imaging”, “admitted”, “morbidity”, “mortality” 
6 
Note: VO₂ is the rate of oxygen consumption measured during incremental exercise, and vevco refers to minute ventilation-to-
carbon dioxide output (VE/VCO2). * indicates a cluster that was reviewed in depth.  
Abbreviations: hf: heart failure; tnfalpha: tumor necrosis factor alpha; sdb: sleep disordered breathing; copd: chronic obstructive 
pulmonary disease; arb: angiotensin II receptor blocker; mg: milligram; bnp: brain or B-type natriuretic peptide; anp: atrial 
natriuretic peptide; adhf: acute decompensated heart failure; wrf: worsening renal function; aki: acute kidney injury; crt: cardiac 
resynchronization therapy; crt-d: cardiac resynchronization therapy defibrillator; icd: implantable cardioverter defibrillator; 
lbbb: left bundle branch block; lvad: left ventricular assist device; lv: left ventricular; hfpef: heart failure with preserved ejection 
fraction; hfmref: heart failure with mid-range ejection fraction; hfref: heart failure with reduced ejection fraction; ef: ejection 
fraction; af: atrial fibrillation; hrt: hormone replacement therapy; lvdd: left ventricular diastolic dysfunction; cmf: 




































Table 2: Percentage of agreement and disagreement among authors on topic labels 
Search strategy No. of topic clusters Agreements n, (%) Disagreements n, (%) 
Search #1 15 12 (80%) 3 (20%) 
Search #2 5 5 (100%) 0 (0%) 


















































PubMed (MEDLINE)  
through December 4, 2019 
(n = 69,558) 
 
Records after articles without abstract removed  





g Records after duplicates removed  
(n = 69,499) 
Records included at least one of the HF terms in the 
study objective(s) 
(i.e., “heart failure” or “cardiac failure”)  
(n = 32,946) 
Studies included in the topic model  

































































PubMed (MEDLINE)  
through December 4, 2019 
(n = 41,846) 
 
Records after citations without abstract removed  
(n = 41,669) 
Records after duplicates removed  
(n = 41,519) 
Records included at least one of the HF terms in the 
study objective(s) 
(i.e., “heart failure” or “cardiac failure”) 
(n = 77) 
Studies included in the topic model  
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3. Emerging Predictors of Incident Heart Failure (HF) 
among Commercially Insured Postmenopausal Women  
3.1 Abstract 
Objective: To identify emerging predictors (polypharmacy and some prescription medications) 
of incident HF among postmenopausal women using supervised machine learning methods. 
Methods: The current study used a retrospective cohort design with a baseline and follow-up 
period. The baseline period was used to identify risk factors for HF among postmenopausal 
women without HF (N = 152,592). Data were obtained from Optum’s de-identified 
Clinformatics® Data Mart Database (Optum, Eden Prairie, MN), de-identified health insurance 
claims data, for the period (2007 – 2016). The study cohort consisted of postmenopausal women 
(age > 50 years) who were free of HF during the baseline period. The target variable was 
incident HF identified during the two-year follow-up period. Features (i.e., independent 
variables) were selected based on a conceptual framework and published literature. Multivariable 
logistic regression and three classification machine learning algorithms (cross-validated logistic 
regression (CVLR), random forest (RF), and eXtreme Gradient Boosting (XGBoost) algorithms) 
were used to identify predictors of HF. All models were compared in terms of their predictive 
abilities (accuracy, sensitivity, specificity, and Area Under the Curve (AUC)). The associations 
of the leading predictors to incident HF were explored with an interpretable machine learning 
SHapley Additive exPlanations (SHAP) technique.  
Results: About 2.1% of postmenopausal women (N = 3,213) developed HF during the 2-year 
follow-up period. The predictive accuracy was highest in the random forest algorithm with AUC 
of 0.87, sensitivity of 0.87, and specificity of 0.71. The eight leading predictors of incident HF 
consistent across all models were: older age, arrhythmia, polypharmacy, Medicare, COPD, 




as sulfonylureas and antibiotics other than fluoroquinolones also predicted incident HF, but only 
in CVLR and RF for sulfonylureas, and only antibiotic use other than fluoroquinolones predicted 
HF when using XGBoost. 
Conclusion: Machine learning methods identified some novel risk factors for incident HF in 
postmenopausal women. Further research with prospective cohorts is needed to confirm the 












Numerous studies have used statistical or machine learning methods to identify risk 
factors for heart failure (HF) among both men and women, older individuals, and those with 
specific chronic conditions (e.g., diabetes, coronary artery disease)1–6. Although there are sex 
differences in the etiology of HF and late-age onset of HF in women7,8, only 7 studies have 
exclusively focused on incident HF among postmenopausal women9–15. Of those, three used data 
from Women’s Health Initiative (WHI)9–11. These previous studies have shed light on several 
risk factors including medical conditions, lifestyle behaviors such as physical activity, race, sex-
specific risk factors such as number of live births, age at first pregnancy, and age from menarche 
to menopause. However, those studies have several limitations such as not examining 
polypharmacy and prescription medication use9–13,15, not US-based12, specific to certain US 
geographical areas13, or specific to postmenopausal women with coronary artery disease14. 
Although a study by Bibbins-Domingo et al. included medication use, it only examined the effect 
of medications for coronary artery disease (i.e., aspirin, angiotensin-converting-enzyme (ACE) 
inhibitors, beta-blockers, digoxin, diuretics, calcium channel blockers, and statin) on incident HF 
among postmenopausal women with coronary artery disease14.  
There is emerging evidence that polypharmacy can increase incident HF16. A recent study 
using a large healthcare claims database has indicated that polypharmacy is associated with a 
high risk of HF among older individuals with atrial fibrillation16. In addition, some prescription 
medications used to treat the risk factors for HF can increase the risk of HF in addition to their 
risk for adverse drug reactions and drug-drug interactions17–20. For example, a published 
systematic review suggests that among those with diabetes, a risk factor for HF, except 
metformin all other oral antidiabetics were associated with increased risk of HF20. Recently, 




and mitral regurgitation, conditions in which the blood backflows into the heart and may lead to 
HF development21. The significant risk associated with fluoroquinolones can mainly occur due to 
its potential adverse effect of increasing the risk of aortic dissections22. Case reports have also 
suggested that analgesic, antiepileptic, and anxiolytic medications can lead to significant HF23,24. 
Therefore, an examination of the risk of polypharmacy and specific prescription 
medications on incident HF risk after controlling for established risk factors among 
postmenopausal women is needed. In this study, we focused on postmenopausal women for 
many reasons: 1) hormonal changes that may place them at higher risk for HF25; 2) high 
prevalence of established risk factors for HF26,27; and 3) postmenopausal women are more likely 
to use prescription medications for treating prevalent conditions such as diabetes and bacterial 
infections28–30.  
However, to date, no study has included oral antidiabetics, antibiotics, and antiepileptics 
as predictors of incident HF among postmenopausal women. Identification of prescription 
medications that predict incident HF among postmenopausal women can help clinicians, payers, 
patients, and other stakeholders to weigh the harms and benefits of commonly used medications 
and personalize treatment plans. Therefore, this present study used real-world data of 
commercially insured postmenopausal women to examine whether oral antidiabetics, 
antiepileptics, and antibiotics are leading predictors of incident HF using supervised machine 
learning methods. In this study, women aged 50 or older were considered to be postmenopausal 








Study design  
We used a retrospective cohort study design with a 2-year baseline period and a 2-year 
follow-up period. Baseline and follow-up periods were defined using a calendar year approach. 
The HF free cohort was identified using both years of the baseline period and incident HF was 
identified using the 2-year follow-up period. HF risk factors were measured during the 2nd year 
of the baseline period.  
Study cohort 
The cohort consisted of postmenopausal women (age > 50 years) who were free of HF 
during the baseline period. To identify and exclude those with HF during the cohort 
identification period, postmenopausal women who had at least one inpatient claim or two 
outpatient claims (30 days apart) for HF were considered as having HF33. We also excluded 
postmenopausal women with the following heart valvular disorders: mitral valve disease or 
insufficiency, aortic valve disease or insufficiency, and aortic valve or mitral valve regurgitation 
due to their family history. These valve disorders were identified based on ICD-9-CM 
(International Classification of Diseases, Ninth Revision, Clinical Modification) or ICD-10 CM 
(International Classification of Diseases, Tenth Revision, Clinical Modification) diagnosis codes 
(Appendix 6.2). Finally, all postmenopausal women had to be continuously enrolled in a 
commercial insurance plan with both medical and pharmaceutical benefits throughout the 
observation period. We pooled 6 cohorts (2008-2011; 2009-2012; 2010-2013; 2011-2014; 2012-
2015; and 2013-2016) to gain adequate sample. After applying the inclusion/exclusion criteria, 






For this study, we used de-identified health insurance claims data from Optum’s de-
identified Clinformatics® Data Mart Database (Optum, Eden Prairie, MN) for the period from 
January 2007 to December 2016. This geographically diverse database contains healthcare 
claims from a 10% sample of 47 million individuals. Of whom, about 80% purchased insurance 
through their employers; individuals insured in Medicare Advantage plans were also included in 
this dataset. The data contain inpatient, outpatient, and pharmacy claims, as well as, certain 
demographic characteristics that are routinely collected during health insurance enrollment. Use 
of prescription medications was obtained from pharmacy claims. We used National Drug Codes 
(NDCs) and American Hospital Formulary Service (AHFS) classification system codes to 
identify oral antidiabetics, antibiotics, and antiepileptics (Appendix 6.3).  
Outcome 
Incident HF (yes/no) 
The primary outcome was the development of HF (incident HF) during the follow-up 
period, and this was measured as a binary variable to indicate if incident HF occurred during the 
follow-up period (yes or no). Incident HF was identified using ICD-9 and ICD-10 codes (see 
Appendix 6.2). Postmenopausal women who had at least one inpatient claim or two outpatient 
claims (30 days apart) for HF during the follow-up period were classified as having incident HF.  
Risk factors (i.e., features) 
Risk factors for HF, also known as features, were selected based on prior published 
literature and our conceptual framework. We used the modified determinants of health outcome 
and chronic disease model, which was originally proposed by Wilkinson and Marmot34, to create 




case, HF) can be influenced by  (1) biological factors (e.g., age), (2) access to care factors (e.g., 
type of insurance plan), (3) community resources (e.g., geographical region), (4) medication-
related factors (e.g., polypharmacy, defined as > 6 medications excluding antibiotics and 
antidiabetic medications), and (5) health status measured by chronic health conditions such as 
diabetes, asthma, and chronic obstructive pulmonary disease (COPD), coronary artery disease, 
acute myocardial infarction, and hypertension, and 6) lifestyle factors such as substance abuse 
and obesity. Medication use was derived from prescription drugs file using NDCs or AFHS 
classification codes. Three classes of oral antidiabetics were selected (thiazolidines, 
sulfonylureas, and dipeptidyl peptidase-4 (DPP-4) inhibitors) because they have been linked to 
negative cardiovascular diseases, including HF18-24. We also include metformin because it has 
been shown to have protective effects. For antibiotic use, we created a 3-level variable with the 
following categories: 1) any fluoroquinolone use, 2) other antibiotics, and 3) no antibiotics use.  
Analytic approach: machine learning algorithms  
 We used three different supervised machine learning algorithms to identify the leading 
predictors of incident HF among postmenopausal women. First, we used a cross-validated 
logistic regression (CVLR), which is widely used to predict the occurrence of an event in clinical 
research. For the CVLR model, we used a 10-fold cross validation approach. The second method 
is random forest (RF) classification. The third algorithm used in this study is eXtreme Gradient 
Boosting (XGBoost) algorithm.  
Model evaluation   
The predictive abilities of all machine learning algorithms were evaluated by obtaining 
the following measures: accuracy, sensitivity, specificity, and area under the ROC curve (AUC) 




features (i.e., independent variables). This statistical model serves as a base model to compare 
the performance of our machine learning models.  
Model development 
The first step on model development is the random split of training (70%) and test 
datasets (30%). Our dataset was highly imbalanced with only 2.1% (N = 3,213) of 
postmenopausal women with incident HF; such severe imbalance is difficult to model and 
requires specialized techniques (example: under and over sampling). We used an undersampling 
technique by randomly selecting women without HF until we reached a 1:1 ratio of those with 
and without incident HF. The balanced dataset (N= 2,233 with HF and 2,265 without HF) was 
used to train our machine learning models. We used the original test dataset (that did not 
undersample women without HF) to evaluate model performance. 
Tuning of hyperparameters  
An important step in building a machine learning algorithm is the tuning of the 
hyperparameters of the algorithm (e.g., the number of trees in the forest and depth of the decision 
tree). This process can reduce overfitting to training data and improve the predictive ability of 
the algorithm. We used automated methods to adjust the parameters of our machine learning 
algorithms (e.g., grid search) 
Feature importance  
In the CVLR algorithm, the importance of the baseline features was obtained based on 
feature importance. For the RF algorithm, feature importance was obtained using the mean 
decrease in prediction accuracy without the variable in the model and mean decrease in the Gini 




importance in XGBoost is measured by each feature’s gain. In other words, feature importance is 
determined based on the contribution of each feature to the final prediction.  
Interpretable feature associations to incident HF  
To explain the association of leading predictors to incident HF, an interpretable machine 
learning technique called SHapley Additive exPlanations (SHAP) was used. SHAP values derive 
the direction of association and importance of features by using the marginal contribution of each 
of the features with all combinations of other features included in the model. Dataset 
construction was performed using SAS 9.4 (Cary, NC) and all predictive models were built in R 
software (R Development Core Team, Vienna, Austria). 
3.4 Results 
Baseline characteristics of the study cohort 
The characteristics of the study cohort by incident HF in the original dataset (N=152,592) 
are presented in Table 2. In the original dataset, only 2.1% (N = 3,213) of postmenopausal 
women developed HF during the 2-year follow-up period. Women aged 80 years and older had a 
higher percentage (4.4%) of incident HF compared to those aged 50-64 years (0.3%). We found 
that 5.1% of those with polypharmacy had incident HF, whereas only 1.5% of those without 
polypharmacy developed HF during the follow-up period. In terms of prescription medication 
use, a higher proportion of postmenopausal women with fluoroquinolones had incident HF 
compared to those with no fluoroquinolone use (3.2% vs. 1.9%). We observed that 4.8% of those 
with sulfonylurea use developed incident HF compared to 2.0% of those with no sulfonylurea 
use. Among those with DPP-4 inhibitor use, 4.0% developed HF during the follow-up period, 
while 2.1% of those with no DDP-4 inhibitor use had incident HF. We also found that those with 




vs. 2.0%). Regarding chronic conditions, a higher percentage of those with acute myocardial 
infarction (11.6%) developed HF during the follow-up period compared to 2.1% of those without 
acute myocardial infarction. Also, postmenopausal women with coronary artery disease had a 
higher percentage (8.1%) of incident HF than those with no coronary artery disease (1.7%). In 
regard to other factors, we found that obese women had a higher proportion of incident HF 
compared to non-obese women (3.3% vs. 2.0%). 
Performance of machine learning algorithms using test data 
 Table 3 summarizes the performance metrics of all models obtained by testing the models 
with the test dataset. Based on the AUC score, the RF model was the best model for predicting 
incident HF in postmenopausal women. It has an AUC of 87%. The sensitivity was 87%, and the 
specificity was 71%.  The sensitivity ranged from 0.78 in the multivariable logistic regression 
model, 0.78 in CVLR, and 0.82 in XGBoost. Specificity values for these models were: 0.71, 
0.74, and 0.69, respectively.   
Feature importance in machine learning algorithms   
Common leading predictors of incident HF across all machine learning algorithms were 
old age (> 80 years), arrhythmia, polypharmacy, Medicare, Chronic Obstructive Pulmonary 
Disease (COPD), coronary artery disease, hypertension, chronic kidney disease, and diabetes. 
Table 4 summarizes leading predictors of incident HF from all machine learning algorithms. 
Regarding prescription medications, sulfonylurea use was identified as a predictor of incident HF 
in the CVLR and RF models. Adjusted odds ratios and 95% confidence intervals of top 
significant predictors of incident HF yielded from CVLR are presented in Figure 1. Antibiotic 
use (other than fluoroquinolones) ranked 12th in the XGBoost model. Figure 2 shows the top 10 





SHAP summary plot explains the feature effect on the prediction and the direction of 
association of study features to incident HF (Figure 3). In this plot, each observation is 
represented with a single dot, and each dot is presented with a color, either yellow or purple, 
depending on its value. Yellow indicates that the feature value is ” No”, while purple indicates 
that the feature value is “Yes”1. The x-axis of the SHAP summary plot expresses the marginal 
contribution of the feature to the change in the predicted probability of incident HF, and the y-
axis represents leading predictors based on their SHAP values. Our SHAP summary plot 
suggested positive associations of old age, Medicare, polypharmacy, arrhythmia, hypertension, 
COPD, coronary artery disease, and diabetes to incident HF. In contrast, it showed that 
postmenopausal women with hyperlipidemia were less likely to develop incident HF (i.e., 
negative associations).  
3.5 Discussion 
Using machine learning algorithms, this study identified modifiable and non-modifiable 
leading predictors of incident HF among postmenopausal women. Our study confirmed that 
older age is a strong predictor of incident HF, which is an established risk factor4,6,14. Prior 
research has shown that aging is associated with some structural and functional changes (e.g., 
myocardial thickness and a decline in physiological processes) that negatively affect the heart 
and arterial system. These changes increase the risk of cardiovascular disease, including HF35–37.  
In our study, polypharmacy, defined as taking 6 or more medications, was a leading 
predictor in all algorithms (ranked 5 in RF, ranked 3 in XGBoost, and ranked 3 in CVLR). In our 
study cohort, among those with incident HF, 41.1% had polypharmacy compared to 16.4% in 




to the high prevalence of multiple chronic conditions among postmenopausal women38,39. To 
manage these conditions, they may seek healthcare from multiple specialists and providers40. 
This can increase the number of prescriptions medication and duplicate therapies41. Our findings 
have implications for promoting evidence-based methods to reduce polypharmacy; for example, 
engaging pharmacists and incorporating their recommendations, reviewing patients’ medications 
regularly, and educating patients42. 
Furthermore, the presence of chronic health conditions can predict incident HF in this 
population. Our models identified chronic conditions (i.e., arrhythmia, coronary artery disease, 
hypertension, chronic kidney disease, and diabetes) as the leading predictors of HF risk, 
consistent with the literature1,3,14. We also identified COPD and stroke as predictors of incident 
HF among postmenopausal women. This is in line with a previous study showing that COPD 
patients have a higher risk to develop HF compared to those without COPD43. The relationship 
between COPD and cardiovascular diseases, including HF, is complex and includes several 
biological mechanisms44. It has been suggested that severe COPD may lead to HF through 
pulmonary hypertension45. Early identification and good management of COPD may decrease 
the risk of HF in postmenopausal women. For example, screening for COPD may help to reduce 
the risk of HF in this population.  
The prediction of incident HF by specific medications was not consistent. Although they 
were not leading predictors, sulfonylureas predicted incident HF in the CVLR and RF 
algorithms, and antibiotics other than fluoroquinolones were found to predict incident HF in the 
XGBoost algorithm. Further research with prospective cohorts is needed to confirm the effect of 
sulfonylureas and antibiotics on incident HF. Fluoroquinolones were not identified as a predictor 




increase the risk of HF, as shown by a previous case-control study21. These conflicting findings 
may be due to the differences in study designs, analytical approaches, and study populations. 
Other study medications did not predict incident HF. Future research evaluating the 
cardiovascular safety of prescription medications among postmenopausal women may need to 
consider using a prospective design and the cumulative use of medications.  
Our study had both strengths and limitations. We used a representative real-world sample 
of commercially insured postmenopausal women to predict incident HF. This allowed us to 
generate real-world evidence on predictors of incident HF and cardiovascular safety of 
polypharmacy in this understudied population. We examined a comprehensive set of risk factors 
including established and some novel risk factors (e.g., polypharmacy and specific prescription 
medications). We also utilized three classification machine learning methods to increase the 
rigor, robustness, and precision of our investigation. However, these study findings should be 
interpreted in the context of its limitations. Our data lacked some important clinical variables 
(e.g., type and severity of HF, laboratory findings, and severity of chronic conditions), 
socioeconomic characteristics (e.g., income and education), and race. Not including these 
variables might influence the performance of our models.   
3.6 Conclusion  
Findings from this study confirmed established risk factors of incident HF as well as 
some novel risk factors using supervised machine learning algorithms. Among the modifiable 
factors, the negative effect of polypharmacy was highlighted, suggesting that medication 
utilization review may be an important element of HF prevention among postmenopausal 
women. Future studies need to incorporate biological factors to identify the contribution of 





List of Baseline Study Features (N = 37) Considered 
Postmenopausal Women (Age > 50 Years) 
Optum Clinformatics Data Mart 10% Sample (2007 – 2016) 
Feature Measurement Levels Data Source Basis of Measurement    
 Age group A 3-level variable: 1) 
50-64 years; 2) 65-79 




 Medicare insurance Yes/No Enrollment 
file  
 
 HMO Yes/No Enrollment 
file  
 
 ER use during the baseline period Yes/No Outpatient 
claims  
Revenue Center Codes  
 Polypharmacy (>6 drugs for 






Generic Name  
 Fluoroquinolone use Yes/No Prescription 
Drug Claims 
AHFS  
 Other antibiotic use 




National Drug Codes  
 Sulfonylurea use 
 DPP4 inhibitor use 
 Thiazolidines use 
 Pregabalin Yes/No Prescription 
Drug Claims 
National Drug Codes 
 Gabapentin 
 Acute myocardial infarction, arrhythmia, arthritis, 
asthma, cancer, chronic kidney disease, COPD, 
coronary artery disease, dementia, diabetes, hepatitis, 
hyperlipidemia, hypertension, osteoporosis, stroke, 
sleep disorders 






















Abbreviations: HMO: Health maintenance organization; ER: emergency room; AHFS: American Hospital Formulary Service; 








Baseline Characteristics of Study Cohort   
By Incident Heart Failure 
Postmenopausal Women (Age > 50 Years) 
Optum Clinformatics Data Mart 10% Sample (2007-2016) 
Row Percentages 
 Incident HF No Incident HF P-value 
 N % N %  
ALL 3,213 2.1 149,379 97.9  
Biological Factors 
Age in years     <0.001 
 50-64 years 78 0.3 25,284 99.7  
 65-79 years 770 1.0 73,083 99.0  
 80 years and older 2,365 4.4 51,012 95.6  
Access to Care Factors 
Medicare insurance     <0.001 
 Yes 69 11.6 528 88.4  
 No 3,144 2.1 148,851 97.9  
Medication-related Factors 
Polypharmacy     <0.001 
 Yes 1,324 5.1 24,519 94.9  
 No 1,889 1.5 124,860 98.5  
Fluoroquinolone use     <0.001 
 Yes 661 3.2 19,896 96.8  
 No 2,552 1.9 129,483 98.1  
Other antibiotic use     0.884 
 Yes 994 2.1 46,033 97.9  
 No 2,219 2.1 103,346 97.9  
Metformin use     <0.001 
 Yes 449 3.4 12,717 96.6  
 No 2,764 2.0 136,662 98.0  
Sulfonylurea use     <0.001 
 Yes 324 4.8 6,358 95.2  
 No 2,889 2.0 143,021 98.0  
Thiazolidines use     <0.001 
 Yes 74 3.7 1,952 96.3  
 No 3,139 2.1 147,427 97.9  
DPP4 inhibitor use     <0.001 
 Yes 99 4.0 2,386 96.0  
 No 3,114 2.1 146,993 97.9  
Pregabalin     <0.001 
 Yes 67 3.8 1,685 96.2  
 No 3,146 2.1 147,694 97.9  
Gabapentin     <0.001 
 Yes 294 4.4 6,346 95.6  
 No 2,919 2.0 143,033 98.0  
Health-related Risk Factors 
Hypertension     <0.001 
 Yes 2,536 3.3 73,634 96.7  
 No 677 0.9 75,745 99.1  
Coronary artery disease     <0.001 
 Yes 824 8.1 9,288 91.9  
 No 2,389 1.7 140,091 98.3 Continued 




Acute myocardial infarction     <0.001 
 Yes 69 11.6 528 88.4  
 No 3,144 2.1 148,851 97.9  
Arrhythmia     <0.001 
 Yes 926 6.4 13,624 93.6  
 No 2,287 1.7 135,755 98.3  
Stroke     <0.001 
 Yes 411 5.5 7,048 94.5  
 No 2,802 1.9 142,331 98.1  
Hyperlipidemia     <0.001 
 Yes 1,942 2.6 72,232 97.4  
 No 1,271 1.6 77,147 98.4  
Diabetes     <0.001 
 Yes 1,330 3.8 33,476 96.2  
 No 1,883 1.6 115,903 98.4  
COPD     <0.001 
 Yes 736 5.9 11,636 94.1  
 No 2,477 1.8 137,743 98.2  
Chronic kidney disease     <0.001 
 Yes 614 6.7 8,614 93.3  
 No 2,599 1.8 140,765 98.2  
Obesity     <0.001 
 Yes 309 3.3 9,132 96.7  
 No 2,904 2.0 140,247 98.0  
Any substance abuse     0.001 
 Yes 242 3.3 7,047 96.7  
 No 2,971 2.0 142,332 98.0  
Note: Based on 152,592 postmenopausal women aged 50 years and older. P-values were obtained from 
Chi-square test.   
Abbreviations: HF: Heart failure; HMO: Health maintenance organization; DPP-4 inhibitors: 













Performance of Cross-validated Logistic Regression, Random Forest, XGBoost, and Multivariable Logistic 
Regression Models on Incident Heart Failure 
Postmenopausal Women (Age > 50 Years) 
Optum Clinformatics Data Mart 10% Sample (2007-2016) 
Method Accuracy Sensitivity Specificity AUC 
CVLR 0.74 0.78 0.74 0.76 
RF 0.71 0.87 0.71 0.87 
XGBoost 0.70 0.82 0.69 0.84 
Multivariable logistic regression 0.72 0.78 0.71 0.82 
Note: Performance metrics of the multivariable logistic regression were based on 152,592 postmenopausal women 
aged 50 years and older. For machine learning models, performance metrics were obtained using the original test 
dataset consisting of 45,778 postmenopausal women aged 50 years and older.  
Abbreviations: CVLR: Cross-validated logistic regression; RF: Random forest; XGBoost: eXtreme Gradient 















Consistent Predictors Out of 15 Leading Predictors of Incident HF 
Postmenopausal Women (Age > 50 Years) 
Optum Clinformatics Data Mart 10% Sample (2007-2016) 
Predictor  CVLR RF XGBoost 
 Old age (> 80 years) 1 1 1 
 Arrhythmia 2 2 4 
 Polypharmacy 3 5 3 
 Medicare 5 4 2 
 COPD 4 3 7 
 CAD 6 6 8 
 Hypertension 7 8 5 
 CKD 9 7 11 
 Diabetes 11 15 10 
 Hyperlipidemia 8 x 6 
 Middle age (65-79 years) 10 9 x 
 HMO x 12 9 
 Stroke 12 10 x 
 Sulfonylureas 14 11 x 
 Midwest 13 x 15 
 South x 14 14 
 Antibiotic (other than fluoroquinolones)  x x 12 
 Dementia x 13 x 
 Arthritis x x 13 
 Obesity 15 x x 
Note: Based on  2,233 postmenopausal women aged 50 years and older (training dataset).  
Abbreviations: CVLR: Cross-validated logistic regression; RF: Random forest; XGBoost:  
extreme gradient boosting; COPD: Chronic obstructive pulmonary disease; CAD: Coronary 




Figure 1: Adjusted odds ratios and 95% confidence intervals of top predictors from cross-validated logistic 
regression on incident heart failure  
Postmenopausal Women (Age > 50 Years) 









Figure 2: Top predictors of incident heart failure from XGboost algorithm and SHAP values 
Postmenopausal Women (Age > 50 Years) 
Optum Clinformatics Data Mart 10% Sample (2007-2016) 
 
 
Note: Based on 2,233 postmenopausal women aged 50 years and older (training dataset).  













Figure 3: SHAP value summary plot for top predictors of incident heart failure 
Postmenopausal Women (Age > 50 Years) 
Optum Clinformatics Data Mart 10% Sample (2007-2016) 
 
Note: Based on 2,233 postmenopausal women aged 50 years and older (training dataset). Features in this plot are 
categorical (Yes/No). Yellow dots indicate “No” (i.e., absence) and purple dots indicate “Yes” (i.e., presence).  
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4. Predictors of Heart Failure-Related Emergency Room (ER) Use  
with Random Forest Classification Algorithm 
among Commercially Insured Postmenopausal Women 
4.1 Abstract 
Objective: To identify leading predictors of heart failure-related emergency room (HF-related 
ER) use among postmenopausal women using supervised machine learning methods with data 
from a large commercial insurance claims database in the United States. 
Methods: This is a retrospective cohort study with a 1-year baseline and 1-year follow-up 
period. We used de-identified health insurance claims data from Optum’s de-identified 
Clinformatics® Data Mart Database (Optum, Eden Prairie, MN) for the period (2015 – 2016). 
The study cohort consisted of postmenopausal women (age > 50 years) with HF during the 
baseline period. HF-related ER use was derived from the outpatient claims using revenue and 
ICD-9/ICD-10 codes. We used random forest algorithm for the primary analysis. We used 
interpretable machine learning techniques to explain the association of leading predictors to HF-
related ER use.  
Results: The study cohort consisted of 6,182 postmenopausal women with HF (mean age: 76.1 
years). During the follow-up period, 27.4% (N = 1,692) had HF-related ER use. Random forest 
algorithm had high predictive accuracy in the test dataset (Area Under the Curve 94%, sensitivity 
93%, 77% specificity, and accuracy 0.81). We found that the number of HF-related ER visits at 
baseline, fragmented care, age, insurance type (Health Maintenance Organization), and coronary 
artery disease were the top 5 predictors of HF-related ER use among postmenopausal women. 
Partial dependence plots suggested positive associations of the top predictors with HF-related ER 




Conclusion: The random forest classification algorithm showed very high predictive accuracy of 
HR-related ER use and identified subgroups of HF patients who are at high risk for HF-related 









































Nearly 50% of medical care is delivered in emergency rooms (ERs)1. However, ER visits 
are an important measure of the quality of care2, as many of these ER visits are preventable3.  On 
the other hand, providers in the ER make decisions about the hospitalization of a patient and ER 
utilization may present opportunities to reduce hospital utilization4. Notably, as heart failure 
(HF) is an ambulatory care sensitive condition that can be managed with primary care, hospital 
admissions for HF are considered preventable5. Beginning October 1, 2012, the Centers for 
Medicare and Medicaid Services (CMS) instituted the Hospital Readmissions Reduction 
Program (HRRP) that imposes fiscal penalties for excessive HF-related 30-day readmissions6. 
Therefore, ERs may be used to successfully managing HF exacerbations. However, there is some 
evidence that in the first few years following the implementation of HRRP, there was an increase 
in post-discharge ER visits and observation stays7. 
Although HF may be initially diagnosed in ERs8, a large population-based study found 
that nearly one-third of patients with HF used the ER frequently9. Despite the emergence of 
urgent care centers as an alternative for care when primary care physicians are not available, HF 
patients may get treatment from ERs due to their perceptions and seriousness of symptoms8. In 
2014, there were more than a million ER visits due to HF in the United States (US)10. Of those, 
about 37% were made by older women. In an analysis of 2017 discharge data from 
approximately 750 hospitals, it was reported that of the 70,092 ER visits for HF, nearly 57,534 
visits were avoidable11.  
Previous studies have identified factors contributing to ER use in general. For example, 
chronic physical conditions12,13, fragmented care14, mental illness15,16, polypharmacy12,17, and 




HF-related ER use. Yet, these studies are limited by use of older data (1992 – 2001)19, examining 
the combined use of ER and hospitalization20, and a narrow focus on specific states – California 
and Florida9.  
 A review of ER use in the US and UK, not specific to HF, elucidated that the reasons for 
ER are associated with the availability of primary care, perceptions of urgency, convenience, 
health system factors, and cost21. However, in this review, studies focusing on emerging risk 
factors such as polypharmacy and medications that can exacerbate HF symptoms leading to ER 
use were not available. Therefore, a study examining predictors of HF-related ER use is needed. 
In this study, we focused on postmenopausal women for several reasons. Unlike other ER 
visits22, HF-related ER visits are higher among older women than older men10. Further, women 
with HF have higher rates of readmission for HF mostly through ERs23. In addition to the HF-
related reasons, women have other risk factors that may increase the probability of ER use such 
as women’s special healthcare needs (e.g., vasomotor symptoms)24 and higher prevalence of 
mental illness compared to men25.  
To date, no study has evaluated the leading predictors of ER use among postmenopausal 
women. Examining leading predictors from available data during a clinical encounter may assist 
payers and policymakers to identify subgroups of women who may be at high risk for ER use 
and tailor interventions that could reduce ER utilization and enhance health outcomes as ER use 
is associated with poor health outcomes among HF patients20. Therefore, the primary objective 
of this study is to identify the leading predictors of HF-related ER use among postmenopausal 
women using supervised machine learning methods with data from large commercial insurance 
claims. We also used interpretable machine learning techniques to evaluate the associations of 





Study design  
This study used a retrospective cohort design with a 1-year baseline period (calendar year 
2015) and a 1-year follow-up period (calendar year 2016).  
Data source 
Data were obtained from de-identified health insurance claims data from Optum’s de-
identified Clinformatics® Data Mart Database (Optum, Eden Prairie, MN) for the period from 
January 2015 to December 2016. This database is geographically diverse and contains healthcare 
claims from a 10% sample of 47 million individuals; the majority of those individuals purchased 
insurance through their employers. In addition, this dataset includes individuals insured in 
Medicare Advantage plans. Some demographic characteristics, inpatient, outpatient, and 
pharmacy claims are available in the dataset26.  
Study Cohort 
The cohort was comprised of 6,182 postmenopausal women (age > 50 years) with HF. In 
this study, we used age of 50 years at baseline as a cut-off to define postmenopausal women. 
This is based on the average age of postmenopausal women in the US and prior research27,28. HF 
was identified using on ICD-9-CM (International Classification of Diseases, Ninth Revision, 
Clinical Modification) or ICD-10 CM (International Classification of Diseases, Tenth Revision, 
Clinical Modification) codes (i.e., ICD-9: 428; ICD-10: I50). Women who had at least one 
inpatient claim or two outpatient claims (30 days apart) for HF during the baseline period 
(calendar year 2015) were considered as having HF. Women had to be continuously enrolled in a 
commercial insurance plan with both medical and pharmaceutical benefits throughout the 





HF-related ER use (yes/no) 
We created a dichotomous variable with “1” indicating at least one HF-related ER visit 
and “0” indicating no HF-related ER visit during the follow-up period. HF-related ER use was 
identified from outpatient claims using the revenue codes of 0450 – 0459 and the HF diagnosis 
based on the ICD-9 and ICD-10 codes. 
Predictors of ER use  
A total of 37 predictors were selected based on the modified determinants of health 
outcome and chronic disease model, which was originally proposed by Wilkinson and Marmot29, 
and prior literature. These features include age, access to care, healthcare utilization, community 
resources, health status, health behavior, and treatment-related factors (see Table 1). To assess 
healthcare utilization during the baseline period, we used two features: 1) the number of HF-
related ER visits and 2) fragmented care. Fragmented care was measured using the 
Fragmentation of Care Index (FCI)14,30. This index measures the fragmented care of patients 
based on their total number of healthcare visits, the number of different providers visited, and the 
number of visits to each provider. The FCI score ranges from 0 to 1, where a higher FCI score 
indicates higher levels of fragmented care. Regarding prescription medication use, we selected 
medications among postmenopausal women that have been linked to HF in prior research31–35. 
These were oral antidiabetic medications (sulfonylureas and dipeptidyl peptidase-4 (DPP-4) 
inhibitors), antibiotics (fluoroquinolones and other antibiotics), antiepileptic medications 
(gabapentin). Although metformin was not among oral antidiabetics that tied to HF, we included 
it to examine if it has a protective effect and leads to lower HF-related ER use. We also included 




inhibitors, angiotensin-receptor blockers (ARBs), and diuretics) as well as antihyperlipidemic 
medications) because these may reduce HF exacerbations and reduce the risk of HF-related ER 
use. These medications were derived from prescription drugs file using National Drug Codes 
(NDCs) and American Hospital Formulary Service (AHFS) classification system codes 
(Appendix 6.3).  
Analytical approach 
Prediction of ER use with Random Forest (RF) Algorithm  
Several Machine learning algorithms have been used to predict ER utlization36–38. RF is a 
decision-tree based ensemble algorithm with many decision trees. These decisions trees are 
constructed using random sampling of training data points and random subsets of features when 
making the decision nodes. In the case of RF for binary target variables, each tree provides a 
prediction for each observation. At test time, the final prediction class (e.g., “Yes HF-related ER 
use” or “No HF-related ER use”) for an observation is obtained using the maximum number of 
times the test subject belonged to the class (e.g., “Yes HF-related ER use” vs“No HF-related ER 
use”). Feature importance was assessed using two measures: 1) the mean decrease in prediction 
accuracy without the variable in the model and 2) mean decrease in the Gini index, a measure of 
impurity of the dataset, by including the variable. For both measures, the higher the score, the 
more important the variable is.  
In machine learning, prediction, rather than the predictor-outcome relationships, is the 
main focus. As we are also interested in the direction of associations, we “unboxed” a random 
forest classifier to enhance interpretation by using “model-agnostic” partial dependence plots 




outcome (i.e., “Yes HF-related ER use” vs. “No HF-related ER use”). These plots do not only 
assess linear relationships, but also non-linear relationships39.  
Our dataset was randomly split into a 70% training dataset, which was internally 
validated (Out-of-bag –OOB sample), and a 30% test sample. OOB sample, was used to estimate 
the performance of RF models. For many classification machine learning algorithms, having a 
balanced outcome (i.e., 50% “Yes HF-related ER use” and 50% “No HF-related ER use”) is 
ideal. If one class has a much higher prevalence than another, the model will have better 
predictive accuracy only for the majority class. Our dataset was imbalanced with 27.4% of 
postmenopausal women having HF-related ER use during the follow-up period. Such imbalance 
can negatively affect the training of the RF classifier. To train the RF classifier on a balanced 
dataset, we used a down-sampling method to achieve 1:1 ratio of “Yes HF-related ER use” (N = 
1,185) and “No HF-related ER use” (N = 1,183) of the trained dataset. RF algorithm was trained 
using the down-sampled data set.   
All supervised machine learning algorithms require adjustments of “hyperparameters” for 
better predictive accuracy. In the RF algorithms, they are the number of trees and the number of 
variables used to make the decision nodes. We varied these hyperparameters while training. The 
final trained model consisted of 4 variables that were randomly split and 500 trees. However, the 
prediction was evaluated on the original test dataset. The predictive abilities of the RF algorithm 
were evaluated by obtaining the following measures using the test dataset: accuracy, sensitivity, 
specificity, and area under the ROC curve (AUC) using a test dataset. 
Our model included 37 features (Table 1). Dataset construction was performed using 





Use of multivariable logistic regression as comparator with random forest algorithm 
A multivariable logistic regression model was built in SAS 9.4. This model served as a 
base model to compare the performance of our RF model. The comparison was based on their 
predictive abilities. We also reported the significant predictors of HF-related ER use from the 
multivariable logistic regression.  
4.4 Results 
Description of the study cohort by HF-related ER Use  
In our study cohort, 27.4% (N = 1,692) had at least one HF-related ER visit during the 
follow-up period. The characteristics of the study cohort by HF-related ER use during the 
follow-up period are described in Table 2. The mean age of postmenopausal women with HF-
related ER use was 75.8 years, and it was 76.2 years for those without HF-related ER use. On 
average, those with HF-related ER use during the follow-up period had an average of 3 HF-
related visits during the baseline period. On the other hand, those without HF-related ER use 
during the follow-up period had an average of 1 HF-related ER visit during the baseline period. 
The average score of FCI was 0.68 among those with HF-related ER use, whereas it was 0.62 
among those without HF-related ER use. With regard to the type of health insurance, 20.5% of 
postmenopausal women with HMO had at least one HF-related ER visit, while 32.5% of those 
with no HMO had HF-related ER use during the follow-up period. As compared to those with no 
chronic kidney disease, postmenopausal women with chronic kidney disease had a higher 
proportion of HF-related ER use (30.9% vs. 24.9%). We also observed that those with COPD 
had a higher percentage of HF-related ER use than those without COPD. Postmenopausal 
women with coronary artery disease had a higher proportion (32.1%) of HF-related ER use as 




percentage of postmenopausal women with diabetes had HF-related ER use during the follow-up 
period compared to those without diabetes (30.6% vs. 23.8%).  
Performance of random forest and multivariable logistic regression 
For our RF model, the accuracy was 81%; the sensitivity was 93%; the specificity was 
77%. The AUC of the RF model was 94%. Using multivariable logistic regression on the same 
dataset, we obtained the following results: the accuracy was 66%; the sensitivity was 65%; the 
specificity was 67%, and the AUC was 73%. 
Leading predictors of HF-related ER use 
Based on feature importance from the RF model, we observed that the number of HF-
related ER visits during the baseline period and fragmented care were the top 2 predictors of HF-
related ER use during the follow-up period. In addition, age and HMO were identified as leading 
predictors of HF-related ER use. In terms of chronic conditions, coronary artery disease, 
arrhythmia, chronic kidney disease, arthritis, COPD, diabetes, and cancer were found to predict 
HF-related ER use. With regard to prescription medications, diuretics were among the top 15 
predictors of HF-related ER use (Figure 1).  
Significant predictors of HF-related ER use were also obtained from multivariable 
logistic regression. Based on this model, fragmented care, region, Medicare insurance, number of 
HF-related ER visits during the baseline period, acute myocardial infarction, coronary artery 
disease, arrhythmia, chronic kidney disease, diabetes, hypertension, and diuretics were positively 
associated with HF-related ER use among postmenopausal women. Figure 2 summarizes the 
adjusted odds ratios and 95% confidence intervals for the significant predictors of HF-related ER 





Associations of features to HF-related ER use 
Partial dependence plots (PDPs) generated by RF showed the non-linear relationships 
between the number of HF-related ER visits during the baseline period and fragmented care, and 
age with HF-related ER use during the follow-up period (Figure 3). In these plots, the Y-axis 
expresses the log of the fraction of the votes that indicate the presence of HF-related ER use. The 
X-axis expresses the value of the predictor, which is 0 or 1 for categorical features. For example, 
the PDP shows that the presence of chronic kidney disease was associated with a higher 
likelihood of being classified as having HF-related ER use. PDPs also suggested positive 
associations of coronary artery disease, arrhythmia, chronic kidney disease, arthritis, COPD, 
diabetes, and cancer, regions (i.e., Midwest and South) to HF-related ER use. However, HMO 
was found to be negatively associated with HF-related ER use. PDPs of prescription medications 
indicated that sulfonylureas and DPP-4 were positively associated with HF-related ER use 
(Figure 4).  
4.5 Discussion 
In our large population-based cohort of postmenopausal women, 27.4% had HF-related 
ER use in 2016. We identified the number of HF-related ER visits during the baseline period as 
the leading predictor of HF-related ER use in the subsequent year. Although we did not explore 
the reasons for HF-related ER use, prior studies indicate that a majority of HF patients report 
frailty, and those with frailty are more likely to use ERs even a year after diagnosis40.  It is also 
possible that HF patients may perceive that their condition required the resources and facilities 
offered by the ER21. As concluded by a review of reviews, multimodal interventions (support for 
self-management practices, education, and strong primary care) may be needed to reduce the risk 




option to reduce the risk of ER use. In a matched cohort study, there were no differences in care 
received by patients with chest pain between telehealth and in-person screening42. 
Another leading predictor of HF-related ER use was fragmented care. The relationship of 
fragmented care and ER use has been observed in prior research14,43. In our cohort study, HF 
patients had multiple chronic conditions consistent with the published research44. Multimorbidity 
often leads to receiving care from multiple providers. About half of older individuals with 
Medicare receive care from two to five different providers with 12% receiving care from ten or 
more different providers45. Without effective collaboration between providers (e.g., a 
cardiologist and mental health provider), the quality of care decreases, and HF-related ER use 
may increase46,47. To overcome this, prior research suggested implementing transition of care 
interventions including patient education, telephone follow-up, medication reconciliation, and 
home visits48,49. Our study findings have implications for predictive analytics in identifying high-
risk ER use patients and the opportunity to implement targeted care-coordination interventions to 
reduce the risk of ER use50.  
The PDPs revealed non-linear relationships of age, care fragmentation, and baseline ER 
visits. For example, the likelihood of ER visits increased with increased levels of fragmentation 
of care and leveled off at very high levels of care fragmentation. These findings suggest that very 
high levels of fragmented care may reflect the high clinical need and “heightened surveillance” 
that may have reduced the risk of ER use. The likelihood of HF-related ER use was high from 
the age of 50 to 55 years, and then it decreased from age of 56 to 64 years. After that, age was 
positively associated with HF-related ER use. Given the fact that HF is a progressive disease, 




In this study of HF-related ER use among postmenopausal women with HF, The RF 
algorithm outperformed the multivariable logistic regression. This better performance of the RF 
algorithm can be due to its ability to detect non-linear relationships between study features and 
HF-related ER use.  
 Potential limitations and strengths of this study should be noted. One limitation of our 
study was that we did not include the type and severity of HF in our models. This study also did 
not include socioeconomic characteristics, which have been found to predict ER use. This study 
had several strengths. This was the first study to use a comprehensive list of factors including 
prescription medications to predict HF-related ER use among postmenopausal women. RF 
classifier model was able to detect non-linear relationships. In statistical learning methods, each 
additional test run on the data (e.g., stratification, interaction) increases the statistical error.  
However, as RF is based on an algorithmic approach, we were able to detect non-linear 
relationships without loss of power.  
4.6 Conclusion 
Using the RF classification algorithm, we were able to predict HF-related ER use among 
postmenopausal women with high accuracy. Our findings show the complex relationships 
between predictors of HF-related ER use, suggesting there is a need to identify high-risk patients 
with predictive algorithms and developing targeted interventions to reduce the risk of ER visits 










Baseline Study Features  
Postmenopausal Women with Heart Failure (Age > 50 Years) 
Optum Clinformatics Data Mart 10% Sample (2015 – 2016) 
 Mean SD 
Age 76.1 9.0 
Number of HF-related ER visits 1.6 3.3 
Fragmented care (FCI) 0.64 0.18 
 N % 
Medicare insurance   
 Yes 5,794 93.7 
HMO   
 Yes 2,655 42.9 
Polypharmacy   
 Yes 2,403 38.9 
Antihyperlipidemic use   
 Yes 3,317 53.7 
Beta blocker use   
 Yes 3,843 62.2 
ACE inhibitor use   
 Yes 2,060 33.3 
ARB use   
 Yes 1,492 24.1 
Diuretic use   
 Yes 3,916 63.3 
Fluoroquinolone use   
 Yes 1,767 28.6 
Other antibiotic use   
 Yes 1,932 31.3 
Gabapentin use   
 Yes 960 15.5 
Metformin use   
 Yes 802 13.0 
Sulfonylurea use   
 Yes 586 9.5 
DPP4 inhibitor use   
 Yes 294 4.8 
Hypertension   
 Yes 5,711 92.4 
Coronary artery disease   
 Yes 3,182 51.5 
Acute myocardial infarction   
 Yes 467 7.6 
Arrhythmia   
 Yes 3,984 64.4 
Stroke   
 Yes 1,374 22.2 
Hyperlipidemia   
 Yes 4,538 73.4 
Diabetes   
 Yes 3,271 52.9 
Cancer   
 Yes 1,407 22.8 




Asthma   
 Yes 1,038 16.8 
COPD   
 Yes 2,449 39.6 
Arthritis   
 Yes 2,619 42.4 
Osteoporosis   
 Yes 1,108 17.9 
Chronic kidney disease   
 Yes 2,539 41.1 
Anxiety   
 Yes 1,229 19.9 
Depression   
 Yes 1,635 26.4 
Dementia   
 Yes 1,029 16.6 
Sleep disorders   
 Yes 1,444 23.4 
Obesity   
 Yes 1,559 25.2 
Any substance abuse   
 Yes 648 10.5 
Region of residence   
 Northeast 846 13.7 
 Midwest 1,491 24.1 
 South 2,199 35.6 
 West 1,646 26.6 
Note: Based on 6,182 postmenopausal women (age > 50 years) with heart failure 
enrolled in commercial insurance plans, alive, with continuous enrollment in pharmacy 
and medical benefits in 2015 and 2016.  
Abbreviations: FCI: Fragmentation of Care Index; HMO: Health maintenance 
organization; ACE inhibitors: angiotensin-converting-enzyme inhibitors; ARBs: 
Angiotensin II receptor blockers; DPP-4 inhibitors: Dipeptidyl Peptidase-4 inhibitors; 














Baseline Characteristics of Study Cohort   
By Heart Failure-related Emergency Room Use During the Follow-up Period 
Postmenopausal Women with HF (age > 50 years) 
Optum Clinformatics Data Mart 10% Sample (2015-2016) 
Row Percentages 
 HF-related ER Use 
(N=1,692) 
 27.4% 




Continuous Features  
 Mean SD Mean SD P-value 
Age in years 75.80 9.27 76.21 8.84 0.115 
Number of HF-related ER visits 3.02 4.35 1.04 2.58 <0.001 
Care fragmentation (FCI) 0.68 0.14 0.62 0.19 <0.001 
Categorical Features 
 N % N % P-value 
Medicare insurance     <0.001 
 Yes 1,621 28.0 4,173 72.0  
 No 71 18.3 317 81.7  
HMO     <0.001 
 Yes 544 20.5 2,111 79.5  
 No 1,148 32.5 2,379 67.5  
Polypharmacy     <0.001 
 Yes 780 32.5 1,623 67.5  
 No 912 24.1 2,867 75.9  
Antihyperlipidemic     0.249 
 Yes 928 28.0 2,389 72.0  
 No 764 26.7 2,101 73.3  
Beta blockers     0.008 
 Yes 1,097 28.5 2,746 71.5  
 No 595 25.4 1,744 74.6  
ACE inhibitors      0.680 
 Yes 557 27.0 1,503 73.0  
 No 1,135 27.5 2,987 72.5  
ARBs     0.221 
 Yes 390 26.1 1,102 73.9  
 No 1,302 27.8 3,388 72.2  
Diuretics     <0.001 
 Yes 1,151 29.4 2,765 70.6  
 No 541 23.9 1,725 76.1  
Fluoroquinolone use     <0.001 
 Yes 548 31.0 1,219 69.0  
 No 1,144 25.9 3,271 74.1  
Other antibiotics     0.431 
 Yes 516 26.7 1,416 73.3  
 No 1,176 27.7 3,074 72.3  
Gabapentin use     0.001 
 Yes  307 32.0 653 68.0  
 No 1,385 26.5 3,837 73.5  
Metformin use     0.252 
 Yes 233 29.1 569 70.9  
 No 1,459 27.1 3,921 72.9  
       




Sulfonylurea use     <0.001 
 Yes 197 33.6 389 66.4  
 No 1,495 26.7 4,101 73.3  
DPP4 inhibitor use     0.070 
 Yes 94 32.0 200 68.0  
 No 1,598 27.1 4,290 72.9  
Hypertension     <0.001 
 Yes 1,619 28.3 4,092 71.7  
 No 73 15.5 398 84.5  
Coronary artery disease     <0.001 
 Yes 1,023 32.1 2,159 67.9  
 No 669 22.3 2,331 77.7  
Acute myocardial infarction      0.126 
 Yes 142 30.4 325 69.6  
 No 1,550 27.1 4,165 72.9  
Arrhythmia     <0.001 
 Yes 1,197 30.0 2,787 70.0  
 No 495 22.5 1,703 77.5  
Stroke     0.006 
 Yes 416 30.3 958 69.7  
 No 1,276 26.5 3,532 73.5  
Hyperlipidemia     <0.001 
 Yes 1,337 29.5 3,201 70.5  
 No 355 21.6 1,289 78.4  
Diabetes     <0.001 
 Yes 1,000 30.6 2,271 69.4  
 No 692 23.8 2,219 76.2  
Cancer     0.004 
 Yes 427 30.3 980 69.7  
 No 1,265 26.5 3,510 73.5  
Asthma     <0.001 
 Yes 371 35.7 667 64.3  
 No 1,321 25.7 3,823 74.3  
COPD     <0.001 
 Yes 821 33.5 1,628 66.5  
 No 871 23.3 2,862 76.7  
Arthritis     <0.001 
 Yes 788 30.1 1,831 69.9  
 No 904 25.4 2,659 74.6  
Osteoporosis     0.926 
 Yes 302 27.3 806 72.7  
 No 1,390 27.4 3,684 72.6  
Chronic kidney disease     <0.001 
 Yes 784 30.9 1,755 69.1  
 No 908 24.9 2,735 75.1  
Anxiety     <0.001 
 Yes 423 34.4 806 65.6  
 No 1,269 25.6 3,684 74.4  
Depression     <0.001 
 Yes 515 31.5 1,120 68.5  
 No 1,177 25.9 3,370 74.1  
       




Dementia     0.461 
 Yes 272 26.4 757 73.6  
 No 1,420 27.6 3,733 72.4  
Sleep disorders     <0.001 
 Yes 489 33.9 955 66.1  
 No 1,203 25.4 3,535 74.6  
Obesity      
 Yes 480 30.8 1,079 69.2 0.001 
 No 1,212 26.2 3,411 73.8  
Any substance abuse     <0.001 
 Yes 227 35.0 421 65.0  
 No 1,465 26.5 4,069 73.5  
Region of residence     <0.001 
 Northeast 242 28.6 604 71.4  
 Midwest 521 34.9 970 65.1  
 South 668 30.4 1,531 69.6  
 West 261 15.9 1,385 84.1  
Note: Based on 6,182 postmenopausal women (age > 50 years) with heart failure enrolled in commercial insurance 
plans, alive, with continuous enrollment in pharmacy and medical benefits in 2015 and 2016.  
-values were obtained from t-test foe continuous features and Chi-square test for categorical features.   
Abbreviations: FCI: Fragmentation of Care Index; HMO: Health maintenance organization; ACE inhibitors: 
angiotensin-converting-enzyme inhibitors; ARBs: Angiotensin II receptor blockers; DPP-4 inhibitors: Dipeptidyl 


















Figure 1: Top predictors of heart failure-related emergency room use from the random forest 
Postmenopausal Women with heart failure (Age > 50 Years) 




Note: Based on postmenopausal women (age > 50 years) with heart failure enrolled in commercial insurance plans, 
alive, with continuous enrollment in pharmacy and medical benefits in 2015 and 2016 using the training dataset (N 
= 2,368).    
Abbreviations: HMO: Health maintenance organization; CKD: Chronic kidney disease; CAD: Coronary artery 



























Figure 2:  Adjusted odds ratios and 95% confidence intervals of top predictors from multivariable logistic 
regression on heart failure-related emergency room use  
Postmenopausal Women with heart failure (Age > 50 Years) 
Optum Clinformatics Data Mart 10% Sample (2015-2016) 
 
 
Abbreviations: AMI: Acute myocardial infarction; CAD: Coronary artery disease; COPD: Chronic obstructive 





















Figure 3: Partial dependence plots of predictors of heart failure-related emergency room use  
Postmenopausal Women with heart failure (Age > 50 Years) 





Note: Based on postmenopausal women (age > 50 years) with heart failure enrolled in commercial insurance plans, 
alive, with continuous enrollment in pharmacy and medical benefits in 2015 and 2016 using the training dataset (N 




Figure 4: Partial dependence plots of prescription medications associated with HF-related ER use 
Postmenopausal Women with heart failure (Age > 50 Years) 
Optum Clinformatics Data Mart 10% Sample (2015-2016) 
 
 
Note: Based on postmenopausal women (age > 50 years) with heart failure enrolled in commercial insurance plans, 
alive, with continuous enrollment in pharmacy and medical benefits in 2015 and 2016 using the training dataset (N 
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5. Summary and Conclusion 
5.1 Summary of Findings and Discussion  
Machine learning approaches to modeling of epidemiologic and healthcare data are 
becoming very common. In this dissertation, we applied natural language processing, 
unsupervised machine learning algorithms, specifically topic modeling, to identify research gaps 
in the published literature, supervised machine learning algorithms to accurately predict the 
diagnosis of incident HF and healthcare utilization among postmenopausal women. Although the 
purpose of machine learning algorithms is “prediction” rather than predictor-outcome 
relationships, we “unboxed” the algorithms with interpretable machine learning techniques. 
Women over 50 years, about the age of natural menopause, are at increased risk for 
cardiovascular disease including HF due to a decline in the natural hormone estrogen, which has 
been shown to be cardio-protective in women1. In 2017, 1 in every 5 female deaths were due to 
CVD2. Specifically, heart failure (HF) is a chronic, progressive condition accounts for 35% of all 
CVD deaths among women3.   
Understudied research topics in the literature of heart failure (HF) among women  
Although studies report significant sex differences in HF etiology, risk factors, and HF 
disease burden, women are underrepresented in HF-related clinical trials4,5 and observational 
studies, which may result in significant knowledge gaps in women-specific HF research.    
Utilizing unsupervised machine learning methods, our study identified knowledge gaps in the 
literature of heart failure (HF) among women. Based on the published HF studies in PubMed 
between 1959 until 3 December 2019, the top three most understudied topics were (1) atrial 




phenotypes. The co-occurrence of atrial fibrillation and HF is common in clinical practice6 and 
may lead to worse symptoms, poorer prognosis, high healthcare utilization, and all-cause 
mortality7–10. Nevertheless, our analysis revealed that treatments and interventions specific to 
those with HF and atrial fibrillation have not been well-studied in the literature as the prior 
research in this area focused on the epidemiology of atrial fibrillation, role of natriuretic peptide, 
and risk of stroke in patients with atrial fibrillation and HF.  
Substantial knowledge gaps in the literature of HF among postmenopausal women  
In our study, we only identified 77 articles on HF in postmenopausal women compared to 
32,946 in women in general. Among the 77 articles, the most understudied topic was stress-
induced cardiomyopathy, which can be due to the rarity of this condition. However, stress-
induced cardiomyopathy is more common in women than men11–15. Other understudied areas 
were about the effect of breast cancer and chemotherapy on HF and the incidence of HF in 
postmenopausal women.   
Leading predictors of incident HF among postmenopausal women 
Our review also identified only 7 studies that have exclusively focused on incident HF 
among postmenopausal women3,16–21 with 3 studies using data from Women’s Health Initiative 
(WHI)16,18. While these studies have shed light on modifiable and non-modifiable risk factors, 
emerging evidence from case reports and observational studies suggest that some prescription 
medications (e.g., oral antidiabetics, antibiotics, and antiepileptic medications) may confer a high 
risk for HF. Therefore, we examined the risk of incident HF among postmenopausal women with 
a comprehensive list of risk factors and several machine learning approaches (cross-validated 
logistic regression, random forest, extreme Gradient Boosting (XGBoost)) using a commercial 




In our cohort study, 2.1% of postmenopausal women developed HF during the 2-year 
follow-up period consistent with published studies22. Polypharmacy, older age, and arrhythmia 
were consistent predictors of incident HF across all machine learning algorithms. In addition to 
established risk factors, we identified some novel predictors of incident HF among 
postmenopausal women. For example, polypharmacy ranked 3rd, after older age and arrhythmia, 
as a leading predictor of incident HF. Although not a leading predictor, sulfonylurea use 
predicted incident HF. Antibiotic use other than fluoroquinolones was identified as a predictor in 
one of the three machine learning models. 
Identification of HF patients at high risk for heart failure-related emergency room use 
(HF-related ER use) 
ER use is associated with negative health outcomes23. Specifically, HF is considered as 
an ambulatory sensitive condition and some ER visits may be preventable24. Therefore, we 
analyzed predictors of HF-related ER use among postmenopausal women using a large 
commercial insurance claims database and random forest for classification, a machine learning 
algorithm. Findings from our study have indicated that the number of HF-related ER visits at 
baseline, fragmented care, age, insurance type (Health Maintenance Organization)), and coronary 
artery disease were the key predictors of HF-related ER use among postmenopausal women. 
These predictors, except HMO, were found to be positively associated with HF-related ER use.  
5.2 Implications and Suggestions for Future Research  
Our study findings unveiled the gaps in HF research among women and highlight the 
need for research focusing on the treatment and management of women who concomitantly have 
atrial fibrillation and HF. Given the small proportion of articles published on HF among 




study postmenopausal women and leverage big data and electronic health records. Conducting 
studies focusing on postmenopausal women can enhance our understanding of the needs of this 
population and improve their health outcomes.  
Furthermore, results of this study underscore the importance of medication management 
among postmenopausal women. Given the high prevalence of polypharmacy and its negative 
effects on HF risk among postmenopausal women, our results have implications for promoting 
evidence-based methods to reduce polypharmacy such as medication utilization review and 
patient education. Although this study identified some prescription medications (i.e., 
sulfonylureas and antibiotics other than fluoroquinolones) as predictors of incident HF, these 
findings need to be confirmed in future research.  
Our machine learning models were able to identify HF patients at high risk for ER use 
with high predictive accuracy. This suggests the use of predictive analytics in identifying high-
risk ER use patients. Identification of those at high risk for ER use can assist payers and 
policymakers to tailor interventions that could decrease ER use and improve health outcomes. As 
the top two predictors of HF-related ER use were healthcare utilization features (i.e., number of 
HF-related ER visits at baseline and fragmented care), our findings have implications for 
implementing interventions that can reduce fragmented care and ER utilization (e.g., telehealth).  
A novel and unique contribution of our study is the application of machine learning 
methods. Findings from all three studies suggest that machine learning algorithms can achieve 
comparable and, in some cases, better predictive accuracy compared to traditional statistical 
models. Our study on research gaps in women with HF confirmed the feasibility of using 
unsupervised machine learning methods (i.e., topic modeling). Our hybrid method was not only 




method. Even though when only used one database (i.e., PubMed), our approach is promising 
and effective for the discovery of knowledge gaps in medical research. Future research should 
collect data from multiple databases to capture all published articles in the literature. In terms of 
supervised machine learning methods, our findings have shown better predictive abilities of 
machine learning methods compared to traditional methods.  
Moreover, this study used interpretable machine learning techniques (i.e., SHapley 
Additive exPlanations (SHAP) and partial dependence plots) to explain the association between 
study features and the target feature. With such high predictive abilities and enhancement in the 
interpretability of machine learning algorithms, the use of machine learning methods may 
continue to expand in the HF area.  
5.3 Strengths and Limitations  
This present study has several strengths: 1) it is the first study to identify knowledge gaps 
in HF research among women, especially postmenopausal women, using unsupervised machine 
learning methods and articles published in PubMed database; 2) use of NLP and text mining 
techniques to screen and identify relevant articles and extract the objective(s) of each study from 
PubMed abstract; 3) use of nationally representative real-world data of commercially insured 
postmenopausal women (aged > 50 years); 4) use of a retrospective cohort study design to track 
postmenopausal women over time; 4) including a comprehensive set of risk factors (e.g., 
polypharmacy and specific prescription medications); and 5) use of several machine learning 
classifiers to increase the rigor, robustness, and precision of our investigation.  
In contrast, this study has some potential limitations. First, no evaluation metrics were used to 
assess the accuracy of clusters yielded from the unsupervised machine learning model. To 




and labeling clusters yielded from our model. In addition, we only searched one database (i.e., 
PubMed) to retrieve HF articles, which might impact on the number of articles included in this 
study. Our data lacked some important variables including clinical factors (e.g., type and severity 
of HF, laboratory findings, and severity of chronic conditions), socioeconomic characteristics 
(e.g., income and education), and race. Not including these variables might influence the 
performance of our models.  
5.4 Conclusion  
In the HF research area, women, specifically postmenopausal women, are understudied. 
The co-occurrence of atrial fibrillation with HF in women and stress-induced cardiomyopathy in 
postmenopausal women are the most understudied topics in the literature. Among 
postmenopausal women, polypharmacy was identified as a major risk factor for incident HF; 
Among postmenopausal women with HF, the number of HF-related ER use at baseline and 
fragmented care were the top two predictors of the HF-related ER use in the subsequent year.  
Collectively, our study findings identified risk factors that can be modified to reduce the 
risk of incident HF and suboptimal utilization (ER visits) of healthcare resources. Furthermore, 
our studies highlighted the usefulness of machine learning methods as promising tools in health 
outcomes research. These methods outperform traditional methods (e.g., expert-based manual 
literature review and statistical methods). With the ongoing enhancement in the interpretability 
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import pandas as pd 
import numpy as np 
import datetime 
 
#search pubmed and get the count of articles via python using Biopython 
from Bio import Entrez 
Entrez.email = 'khaled_al-hussain@hotmail.com' 
handle = Entrez.egquery(term="(heart failure[MeSH Terms] OR congestive heart failure[MeSH Terms] OR cardiac 
failure[MeSH Terms] OR ejection fraction AND hasabstract[text] AND Humans[Mesh] AND Female[MeSH 
Terms])") 
record =Entrez.read(handle) 
for row in record ['eGQueryResult']: 
    if row['DbName']=='pubmed': 
        record_count = (row["Count"]) 
        print(record_count) #we can compare this count to the count we get from the website 
 
#search pubmed and get the count of articles via python using Biopython 
from Bio import Entrez 
Entrez.email = 'khaled_al-hussain@hotmail.com' 
handle = Entrez.egquery(term="(heart failure[MeSH Terms] OR congestive heart failure[MeSH Terms] OR cardiac 
failure[MeSH Terms] OR ejection fraction AND hasabstract[text] AND Humans[Mesh] AND Female[MeSH 
Terms])") 
record =Entrez.read(handle) 
for row in record ['eGQueryResult']: 
    if row['DbName']=='pubmed': 
        record_count = (row["Count"]) 
        print(record_count) #we can compare this count to the count we get from the website 
 
#retrieve IDs of all articles 
handle = Entrez.esearch(db='pubmed', term="(heart failure[MeSH Terms] OR congestive heart failure[MeSH 
Terms] OR cardiac failure[MeSH Terms] OR ejection fraction AND hasabstract[text] AND Humans[Mesh] AND 
Female[MeSH Terms])", retmax = 300000) 
record =Entrez.read(handle) 
handle.close() 
idlist = record["IdList"] 
print(idlist) 
len(idlist) #double check 
 
#divde id lists into multiple files 
record_count = int(record_count) 
file_count = (record_count/10000) 
 
idlist_1 = idlist[:10000] 
idlist_2 = idlist[10000:20000] 
idlist_3 = idlist[20000:30000] 
idlist_4 = idlist[30000:40000] 
idlist_5 = idlist[40000:50000] 
idlist_6 = idlist[50000:60000] 





#import necessary packages for retrieving the content of articles 
from Bio import Medline 
 
#retrieve the 1st 10000 articles 
handle_1 = Entrez.efetch(db="pubmed", id = idlist_1, rettype = "medline", retmode = "text") 
records_1 = Medline.parse(handle_1) 
records_1 = list(records_1) 
#save titles & abstracts in a txt file - 1st 10000 articles 
with open("//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations1_fem.txt", "w") as file1: 
    for record in records_1: 
        x = record.get("AB", "?") 
        x = x.lower().split(".") 
        str1 = ''.join(x) 
        y = re.split('methods: |methods:: |material and methods: |material and methods |materials and methods: 
|materials and methods |methods and materials: | methods and materials |methods & materials: |methods & materials 
|patients and materials |patients and methods |methods and results: |study design: |design: |patients: |participants: 
settings:| setting',str1) 
        obj = y[0] 
        obj_1 = obj.translate(str.maketrans('', '', string.punctuation)) 
        file_1 = record.get("PMID", "?") + " &&& " + record.get("TI", "?") + " &&& "  + record.get("AB", "?") + " 
&&& " + obj_1 + "\n" 
        file1.write(str(file_1)) 
 
#retrieve the 2nd 10000 articles 
handle_2 = Entrez.efetch(db="pubmed", id = idlist_2, rettype = "medline", retmode = "text") 
records_2 = Medline.parse(handle_2) 
records_2 = list(records_2) 
#save titles & abstracts in a txt file - 2nd 10000 articles 
with open("//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations2_fem.txt", "w") as file2: 
    for record in records_2: 
        x = record.get("AB", "?") 
        x = x.lower().split(".") 
        str1 = ''.join(x) 
        y = re.split('methods: |methods:: |material and methods: |material and methods |materials and methods: 
|materials and methods |methods and materials: | methods and materials |methods & materials: |methods & materials 
|patients and materials |patients and methods |methods and results: |study design: |design: |patients: |participants: 
settings:| setting',str1) 
        obj = y[0] 
        obj_2 = obj.translate(str.maketrans('', '', string.punctuation)) 
        file_2 = record.get("PMID", "?") + " &&& " + record.get("TI", "?") + " &&& "  + record.get("AB", "?") + " 
&&& " + obj_2 + "\n" 
        file2.write(str(file_2)) 
 
#retrieve the 3rd 10000 articles 
handle_3 = Entrez.efetch(db="pubmed", id = idlist_3, rettype = "medline", retmode = "text") 
records_3 = Medline.parse(handle_3) 
records_3 = list(records_3) 
#save titles & abstracts in a txt file - 3rd 10000 articles 
with open("//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations3_fem.txt", "w") as file3: 
    for record in records_3: 
        x = record.get("AB", "?") 
        x = x.lower().split(".") 
        str1 = ''.join(x) 
        y = re.split('methods: |methods:: |material and methods: |material and methods |materials and methods: 




|patients and materials |patients and methods |methods and results: |study design: |design: |patients: |participants: 
settings:| setting',str1) 
        obj = y[0] 
        obj_3 = obj.translate(str.maketrans('', '', string.punctuation)) 
        file_3 = record.get("PMID", "?") + " &&& " + record.get("TI", "?") + " &&& "  + record.get("AB", "?") + " 
&&& " + obj_3 + "\n" 
        file3.write(str(file_3)) 
 
#retrieve the 4th 10000 articles 
handle_4 = Entrez.efetch(db="pubmed", id = idlist_4, rettype = "medline", retmode = "text") 
records_4 = Medline.parse(handle_4) 
records_4 = list(records_4) 
#save titles & abstracts in a txt file - 4th 10000 articles 
with open("//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations4_fem.txt", "w") as file4: 
    for record in records_4: 
        x = record.get("AB", "?") 
        x = x.lower().split(".") 
        str1 = ''.join(x) 
        y = re.split('methods: |methods:: |material and methods: |material and methods |materials and methods: 
|materials and methods |methods and materials: | methods and materials |methods & materials: |methods & materials 
|patients and materials |patients and methods |methods and results: |study design: |design: |patients: |participants: 
settings:| setting',str1) 
        obj = y[0] 
        obj_4 = obj.translate(str.maketrans('', '', string.punctuation)) 
        file_4 = record.get("PMID", "?") + " &&& " + record.get("TI", "?") + " &&& "  + record.get("AB", "?") + " 
&&& " + obj_4 + "\n" 
        file4.write(str(file_4)) 
 
#retrieve the 5th 10000 articles 
handle_5 = Entrez.efetch(db="pubmed", id = idlist_5, rettype = "medline", retmode = "text") 
records_5 = Medline.parse(handle_5) 
records_5 = list(records_5) 
#save titles & abstracts in a txt file - 5th 10000 articles 
with open("//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations5_fem.txt", "w") as file5: 
    for record in records_5: 
        x = record.get("AB", "?") 
        x = x.lower().split(".") 
        str1 = ''.join(x) 
        y = re.split('methods: |methods:: |material and methods: |material and methods |materials and methods: 
|materials and methods |methods and materials: | methods and materials |methods & materials: |methods & materials 
|patients and materials |patients and methods |methods and results: |study design: |design: |patients: |participants: 
settings:| setting',str1) 
        obj = y[0] 
        obj_5 = obj.translate(str.maketrans('', '', string.punctuation)) 
        file_5 = record.get("PMID", "?") + " &&& " + record.get("TI", "?") + " &&& "  + record.get("AB", "?") + " 
&&& " + obj_5 + "\n" 
        file5.write(str(file_5)) 
 
#retrieve the 6th 10000 articles 
handle_6 = Entrez.efetch(db="pubmed", id = idlist_6, rettype = "medline", retmode = "text") 
records_6 = Medline.parse(handle_6) 
records_6 = list(records_6) 
#save titles & abstracts in a txt file - 6th 10000 articles 
with open("//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations6_fem.txt", "w") as file6: 
    for record in records_6: 




        x = x.lower().split(".") 
        str1 = ''.join(x) 
        y = re.split('methods: |methods:: |material and methods: |material and methods |materials and methods: 
|materials and methods |methods and materials: | methods and materials |methods & materials: |methods & materials 
|patients and materials |patients and methods |methods and results: |study design: |design: |patients: |participants: 
settings:| setting',str1) 
        obj = y[0] 
        obj_6 = obj.translate(str.maketrans('', '', string.punctuation)) 
        file_6 = record.get("PMID", "?") + " &&& " + record.get("TI", "?") + " &&& "  + record.get("AB", "?") + " 
&&& " + obj_6 + "\n" 
        file6.write(str(file_6)) 
 
#retrieve the 7th 10000 articles 
handle_7 = Entrez.efetch(db="pubmed", id = idlist_7, rettype = "medline", retmode = "text") 
records_7 = Medline.parse(handle_7) 
records_7 = list(records_7) 
#save titles & abstracts in a txt file - 7th 10000 articles 
with open("//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations7_fem.txt", "w") as file7: 
    for record in records_7: 
        x = record.get("AB", "?") 
        x = x.lower().split(".") 
        str1 = ''.join(x) 
        y = re.split('methods: |methods:: |material and methods: |material and methods |materials and methods: 
|materials and methods |methods and materials: | methods and materials |methods & materials: |methods & materials 
|patients and materials |patients and methods |methods and results: |study design: |design: |patients: |participants: 
settings:| setting',str1) 
        obj = y[0] 
        obj_7 = obj.translate(str.maketrans('', '', string.punctuation)) 
        file_7 = record.get("PMID", "?") + " &&& " + record.get("TI", "?") + " &&& "  + record.get("AB", "?") + " 
&&& " + obj_7 + "\n" 
        file7.write(str(file_7)) 
 
#combine all content files 
filenames1 = ["//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations1_fem.txt", 
"//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations2_fem.txt", "//Users/khalidabdullah 
1/Desktop/Health Outcomes Research/SLR/citations3_fem.txt"] 
with open("//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations1-3_fem.txt", "w") as outfile: 
    for fname in filenames1: 
        with open(fname) as infile: 
            for line in infile: 
                outfile.write(line) 
 
#combine all content files 
filenames2 = ["//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations4_fem.txt", 
"//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations5_fem.txt", "//Users/khalidabdullah 
1/Desktop/Health Outcomes Research/SLR/citations6_fem.txt", "//Users/khalidabdullah 1/Desktop/Health 
Outcomes Research/SLR/citations7_fem.txt"] 
with open("//Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/citations4-7_fem.txt", "w") as outfile: 
    for fname in filenames2: 
        with open(fname) as infile: 
            for line in infile: 
                outfile.write(line) 
 
 
#convert text into a dataframe 




import pandas as pd 
content_data = StringIO("""PMID&&&title&&&abstract&&&objective 
""") 
 
df = pd.read_csv(content_data, sep="&&&") 
path="/Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/df1_fem.csv" 
df_csv=df.to_csv(path) 
 
#import all csv datasets 
import pandas as pd 
df1 = pd.read_csv("/Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/df1_fem.csv") 
df2 = pd.read_csv("/Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/df2_fem.csv") 
 
#merge all dataframs 
df_all = pd.concat([df1, df2]) 
 




df_all['abstract'] = df_all['abstract'].apply(lambda x : x.strip().lower()) 
#exclude citations without abstract 
df_all = df_all[df_all['abstract'] != "?"] 
#check # of articles after removing citations with no abstracts 
df_all 
 
# drop duplicate values by title 
df_all.drop_duplicates(subset="title", keep='first', inplace=True) 
#check no. of articles after removing duplicates 
df_all 
 
#Detect missing values 
missing_data = df_all.isnull() 
 
for column in missing_data. columns.values.tolist(): 
 print (column) 
 print (missing_data[column].value_counts()) 
 print (" ") 
 
#replace missing values in objective with abstract 
df_all['objective'].fillna(df_all.abstract, inplace = True) 
 
#remove punctuations from titles 
import string 
df_all['title'] = df_all['title'].apply(lambda x : x.strip().capitalize().translate(str.maketrans('', '', string.punctuation))) 
 
#add new columns for preprocessed titles, abstracts & objectives 
preprocessed_title = df_all['title'] 
df_all['preprocessed_title'] = preprocessed_title 
preprocessed_abstract = df_all['abstract'] 
df_all['preprocessed_abstract'] = preprocessed_abstract 
preprocessed_objective = df_all['objective'] 
df_all['preprocessed_objective'] = preprocessed_objective 
 
#text preprocessing 




df_all['preprocessed_title'] = df_all['preprocessed_title'].apply(lambda x : x.strip().lower()) 
df_all['preprocessed_abstract'] = df_all['preprocessed_abstract'].apply(lambda x : x.strip().lower()) 
df_all['preprocessed_objective'] = df_all['preprocessed_objective'].apply(lambda x : x.strip().lower()) 
 
#remove punctuations 
df_all['preprocessed_abstract'] = df_all['preprocessed_abstract'].apply(lambda x : x.translate(str.maketrans('', '', 
string.punctuation))) 
#remove numbers 
df_all['preprocessed_title'] = df_all['preprocessed_title'].str.replace('\d+', '') 
df_all['preprocessed_abstract'] = df_all['preprocessed_abstract'].str.replace('\d+', '') 





from nltk.corpus import stopwords 
#add more stopwords 

































































































































df_all['preprocessed_title'] = df_all['preprocessed_title'].apply(lambda x: ' '.join([word for word in x.split() if word 
not in (stop_words)])) 
df_all['preprocessed_abstract'] = df_all['preprocessed_abstract'].apply(lambda x: ' '.join([word for word in x.split() if 
word not in (stop_words)])) 
df_all['preprocessed_objective'] = df_all['preprocessed_objective'].apply(lambda x: ' '.join([word for word in 
x.split() if word not in (stop_words)])) 
 
#tokenize 
from nltk.tokenize import word_tokenize 
df_all['preprocessed_title'] = df_all['preprocessed_title'].apply(word_tokenize) 
df_all['preprocessed_abstract'] = df_all['preprocessed_abstract'].apply(word_tokenize) 
df_all['preprocessed_objective'] = df_all['preprocessed_objective'].apply(word_tokenize) 
 
#lemmatize 
from nltk.stem import WordNetLemmatizer 
lemmatizer = WordNetLemmatizer() 
 
def word_lemmatizer(text): 
    lem_text = [lemmatizer.lemmatize(i) for i in text] 
    return lem_text 
 
df_all['preprocessed_title'] = df_all['preprocessed_title'].apply(lambda x: word_lemmatizer(x)) 
df_all['preprocessed_abstract'] = df_all['preprocessed_abstract'].apply(lambda x: word_lemmatizer(x)) 
df_all['preprocessed_objective'] = df_all['preprocessed_objective'].apply(lambda x: word_lemmatizer(x)) 
 
 





df_all = df_all.drop("Unnamed: 0", axis=1) 
df_all 
 
#export the merged and preprocessed dataframe 
path = "/Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/df_nodup_fem_clean.csv" 
df_all_csv = df_all.to_csv(path) 
 
 
#import all csv datasets 
df_all = pd.read_csv("/Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/df_nodup_fem_clean.csv") 
 
#filter by keywords 
df_all['HF'] = np.where(df_all.objective.str.contains('heart failure'), 1, 
                            np.where(df_all.objective.str.contains('HF'), 1, 
                            np.where(df_all.objective.str.contains('cardiac failure'), 1, 
                            np.where(df_all.objective.str.contains('congestive heart failure'), 1, 
                            np.where(df_all.objective.str.contains('CHF'), 1, 
                                 0))))) 
 
df_HF_all = df_all[df_all.HF == 1] 
 
#export the merged and preprocessed dataframe 
path = "/Users/khalidabdullah 1/Desktop/Health Outcomes Research/SLR/df_nodup_hf_all_hfilter.csv" 
df_all_csv = df_HF_all.to_csv(path) 
 
#import 





df_HF_all = pd.read_csv("/Users/khalidabdullah 1/Desktop/Health Outcomes 
Research/SLR/df_nodup_hf_all_hfilter.csv") 
 
begin_time = datetime.datetime.now() 
#NMF model 
from sklearn.feature_extraction.text import TfidfVectorizer 
tfidf_vect = TfidfVectorizer(ngram_range=(1,2), max_df=0.8, min_df=2, stop_words='english') 
doc_term_matrix_1 = tfidf_vect.fit_transform(df_HF_all['preprocessed_objective'].values.astype('U')) 
 
from sklearn.decomposition import NMF 
nmf = NMF(n_components=15, random_state=42) 
nmf.fit(doc_term_matrix_1) 
 
for i,topic in enumerate(nmf.components_): 
    print(f'Top 20 words for topic #{i}:') 
    print([tfidf_vect.get_feature_names()[i] for i in topic.argsort()[-20:]]) 
    print('\n') 
 
#add the topics to the dataset and displays the first five rows: 
topic_values = nmf.transform(doc_term_matrix_1) 
df_HF_all['Topic'] = topic_values.argmax(axis=1) 
df_HF_all.head() 
 





#random articles from each group 
tp_0 = df_HF_all[df_HF_all.Topic == 0] 
tp_0.sample(40) 
tp_0 = tp_0.sample(40) 
#export 
path = "/Users/khalidabdullah 1/Desktop/Health Outcomes Research/Aim1/individual clusters/topic0_40rs.csv" 
df_all_csv = tp_0.to_csv(path) 
 
tp_2 = df_HF_all[df_HF_all.Topic == 2] 
tp_2.sample(40) 
tp_2 = tp_2.sample(40) 
#export 
path = "/Users/khalidabdullah 1/Desktop/Health Outcomes Research/Aim1/individual clusters/topic2_40rs.csv" 
df_all_csv = tp_2.to_csv(path) 
 
tp_6 = df_HF_all[df_HF_all.Topic == 6] 
tp_6.sample(40) 
tp_6 = tp_6.sample(40) 
#export 
path = "/Users/khalidabdullah 1/Desktop/Health Outcomes Research/Aim1/individual clusters/topic6_40rs.csv" 




















ICD-9-CM and ICD-10-CM Codes for Identifying Heart Failure and Heart Valve Disorders 
Diagnosis ICD-9-CM code ICD-10-CM code 
Heart failure 428 I50 
Mitral valve insufficiency and aortic valve insufficiency 396.3 I08.0 
Multiple involvement of mitral and aortic valves 396.8 I08.8 
Mitral and aortic valve diseases, unspecified 396.9 I08.9 
Other and unspecified mitral valve diseases 394.9 I05.8 
Mitral valve disorders 424.0 I34 
























Measurements of Prescription Medications 







(Glimepiride, Glipizide, Glyburide, 














Fluoroquinolones AHFS classification ‘081218’ 
Other antibiotics AHFS classification '520404', '081202', '081206', '081207', '081208', 
'081212', '081216', '081220', '081224', '081228', 
'082400' 
 
Heart Failure Medications 
ACE inhibitors AHFS classification ‘243204’ 
Beta-blockers AHFS classification ‘242400’ 
ARBs AHFS classification ‘243208’ 
Diuretics AHFS classification ‘402800’, ‘402808’, ‘402810’, ‘402812’, ‘402816’, 
‘402820’, ‘402824’, ‘402892’ 
Other medications 
Antihyperlipidemic medications AHFS classification ‘240600’,’ 240604’, 240605’,’ 240606’,’ 240608’, 
‘240692’ 
Abbreviations: NDCs: National Drug Codes; AHFS: American Hospital Formulary Service; DPP-4 inhibitors: Dipeptidyl 














R Codes for Machine Learning Algorithms to Identify Predictors of Incident Heart Failure among 
Postmenopausal Women 
A. CVLR Algorithm: Predictors of Incident HF 
#read data 
library(haven) 













#convert to factor variable---for logistic regression code the dv as 0(no) and 1 
(yes)# 
library(plyr) 
hf$hf_fu12  <-factor(hf$hf_fu12) 
hf$hf_fu12 <- revalue(hf$hf_fu12, c("1"= "1", "2"= "0")) #changing label 2 to 0 
hf$hf_fu12 <- relevel(hf$hf_fu12, ref = "0") #changing reference category for log reg 
summary(hf$hf_fu12) 
##      0      1  
## 149379   3213 
table(hf$hf_fu12) 
##  
##      0      1  
## 149379   3213 
#recode indep variables to indicate categorical status to R# 
hf$abrx_3grp    <-factor(hf$abrx_3grp) 
hf$antiep_grp   <-factor(hf$antiep_grp) 
hf$metrx_any    <-factor(hf$metrx_any) 
hf$tzd_any  <-factor(hf$tzd_any) 





hf$ins_mcare    <-factor(hf$ins_mcare) 
hf$hmo  <-factor(hf$hmo) 
hf$region_grp4  <-factor(hf$region_grp4) 
hf$anx_any  <-factor(hf$anx_any) 
hf$bipolar  <-factor(hf$bipolar) 
hf$psycho   <-factor(hf$psycho) 
hf$deprn    <-factor(hf$deprn) 
hf$schiz    <-factor(hf$schiz) 
hf$ipot_arth    <-factor(hf$ipot_arth) 
hf$ipot_asth    <-factor(hf$ipot_asth) 






hf$ipot_copd    <-factor(hf$ipot_copd) 
hf$ipot_dementia    <-factor(hf$ipot_dementia) 
hf$ipot_hepatitis   <-factor(hf$ipot_hepatitis) 
hf$ipot_hilipid <-factor(hf$ipot_hilipid) 
hf$ipot_htn <-factor(hf$ipot_htn) 
hf$ipot_diabetes    <-factor(hf$ipot_diabetes) 
hf$ipot_stroke  <-factor(hf$ipot_stroke) 
hf$ipot_osteop  <-factor(hf$ipot_osteop) 
hf$ipot_cad <-factor(hf$ipot_cad) 
hf$ipot_mi  <-factor(hf$ipot_mi) 
hf$sleep    <-factor(hf$sleep) 
hf$obesity  <-factor(hf$obesity) 
 
#create reference grps for R# 
hf$abrx_3grp    <-C(hf$abrx_3grp,contr.treatment, base = 3) 
hf$antiep_grp   <-C(hf$antiep_grp,contr.treatment, base = 4) 
hf$metrx_any    <-C(hf$metrx_any,contr.treatment, base = 2) 
hf$tzd_any  <-C(hf$tzd_any,contr.treatment, base = 2) 
hf$dpp4_any     <-C(hf$dpp4_any,contr.treatment, base = 2) 
hf$sulf_any <-C(hf$sulf_any,contr.treatment, base = 2) 
hf$age_3grp <-C(hf$age_3grp,contr.treatment, base = 1) 
hf$polyrx_gn_ge6 <-C(hf$polyrx_gn_ge6,contr.treatment, base = 2) 
hf$anyabuse <-C(hf$anyabuse,contr.treatment, base = 2) 
hf$ins_mcare    <-C(hf$ins_mcare,contr.treatment, base = 2) 
hf$hmo  <-C(hf$hmo,contr.treatment, base = 2) 
hf$region_grp4  <-C(hf$region_grp4,contr.treatment, base = 4) 
hf$anx_any  <-C(hf$anx_any,contr.treatment, base = 2) 
hf$bipolar  <-C(hf$bipolar,contr.treatment, base = 2) 
hf$psycho   <-C(hf$psycho,contr.treatment, base = 2) 
hf$deprn    <-C(hf$deprn,contr.treatment, base = 2) 
hf$schiz    <-C(hf$schiz,contr.treatment, base = 2) 
hf$ipot_arth    <-C(hf$ipot_arth,contr.treatment, base = 2) 
hf$ipot_asth    <-C(hf$ipot_asth,contr.treatment, base = 2) 
hf$ipot_cancer  <-C(hf$ipot_cancer,contr.treatment, base = 2) 
hf$ipot_c_arrhy <-C(hf$ipot_c_arrhy,contr.treatment, base = 2) 
hf$ipot_cad <-C(hf$ipot_cad,contr.treatment, base = 2) 
hf$ipot_mi  <-C(hf$ipot_mi,contr.treatment, base = 2) 
hf$ipot_ckd <-C(hf$ipot_ckd,contr.treatment, base = 2) 
hf$ipot_copd    <-C(hf$ipot_copd,contr.treatment, base = 2) 
hf$ipot_dementia    <-C(hf$ipot_dementia,contr.treatment, base = 2) 
hf$ipot_hepatitis   <-C(hf$ipot_hepatitis,contr.treatment, base = 2) 
hf$ipot_hilipid <-C(hf$ipot_hilipid,contr.treatment, base = 2) 
hf$ipot_htn <-C(hf$ipot_htn,contr.treatment, base = 2) 
hf$ipot_diabetes    <-C(hf$ipot_diabetes,contr.treatment, base = 2) 
hf$ipot_stroke  <-C(hf$ipot_stroke,contr.treatment, base = 2) 
hf$ipot_osteop  <-C(hf$ipot_osteop,contr.treatment, base = 2) 
hf$sleep    <-C(hf$sleep,contr.treatment, base = 2) 
hf$obesity  <-C(hf$obesity,contr.treatment, base = 2) 
 
#check the target feature distribution in the dataset 






##      0      1  
## 149379   3213 
barplot(prop.table(table(hf$hf_fu12)), 
        col = rainbow(2), 
        ylim = c(0,1), 
        main = "Class Distribution") 
 
table(hf$hf_fu12) 
##      0      1  
## 149379   3213 
prop.table(table(hf$hf_fu12))    
##          0          1  
## 0.97894385 0.02105615 
#data partition into 70% train and 30% test (original dataset)  
set.seed(123)  #set seed to make the analyses repeatable# 
library(caret) 
hf1 = sort(sample(nrow(hf),nrow(hf)*0.7)) 
hforig_train = hf[hf1,]   #training dataset 
hforig_test = hf[-hf1,]   #test dataset 
#fix the imbalanced dataset with undersampling 
library(ROSE) 
set.seed(999) 
hf_us <- ovun.sample(hf_fu12~., data=hf, method="under",N=6426)$data 
table(hf_us$hf_fu12) 
##    0    1  
## 3213 3213 
#data partition into 70% train and 30% test#  
set.seed(123)  #set seed to make the analyses repeatable# 
library(caret) 
hf1 = sort(sample(nrow(hf_us),nrow(hf_us)*0.7)) 
hftrain = hf_us[hf1,]   #training dataset 
hftest = hf_us[-hf1,]   #test dataset 
 
#check the target feature distribution in the training dataset 
table(hftrain$hf_fu12) 
##    0    1  
## 2265 2233 




#10-fold cross-validation#  
library(caret) 












              data=hftrain,  
              method = "glm",  
              family = "binomial",  
              trControl = ctrl) 
 





## Deviance Residuals:  
##     Min       1Q   Median       3Q      Max   
## -2.8612  -0.7810  -0.3026   0.8435   2.4337   
##  
## Coefficients: 
##                  Estimate Std. Error z value Pr(>|z|)     
## (Intercept)     -2.796897   0.181712 -15.392  < 2e-16 *** 
## age_3grp2        0.642593   0.173342   3.707  0.00021 *** 
## age_3grp3        1.750022   0.182275   9.601  < 2e-16 *** 
## ins_mcare1       0.715658   0.108248   6.611 3.81e-11 *** 
## hmo1             0.142801   0.089972   1.587  0.11247     
## er_nbr          -0.003399   0.026568  -0.128  0.89821     
## polyrx_gn_ge61   0.701036   0.094113   7.449 9.42e-14 *** 
## abrx_3grp1       0.121424   0.111663   1.087  0.27686     
## abrx_3grp2      -0.081598   0.086050  -0.948  0.34300     
## antiep_grp1      0.702288   0.381580   1.840  0.06570 .   
## antiep_grp2      0.319651   0.156795   2.039  0.04148 *   
## antiep_grp3     -0.596341   0.573773  -1.039  0.29865     
## metrx_any1      -0.244137   0.146225  -1.670  0.09500 .   
## sulf_any1        0.416069   0.170084   2.446  0.01443 *   
## tzd_any1         0.638198   0.289101   2.208  0.02728 *   
## dpp4_any1       -0.429273   0.246374  -1.742  0.08144 .   
## ipot_htn1        0.428963   0.091124   4.707 2.51e-06 *** 
## ipot_cad1        0.739214   0.115368   6.407 1.48e-10 *** 
## ipot_mi1         0.225317   0.394528   0.571  0.56793     
## ipot_c_arrhy1    0.799263   0.102256   7.816 5.44e-15 *** 
## ipot_stroke1     0.370826   0.145890   2.542  0.01103 *   
## ipot_hilipid1   -0.390490   0.085371  -4.574 4.78e-06 *** 
## ipot_diabetes1   0.327725   0.099818   3.283  0.00103 **  
## ipot_cancer1    -0.226106   0.102585  -2.204  0.02752 *   




## ipot_copd1       0.824661   0.114153   7.224 5.04e-13 *** 
## ipot_arth1       0.057651   0.086488   0.667  0.50504     
## ipot_osteop1    -0.181306   0.107703  -1.683  0.09230 .   
## ipot_ckd1        0.545173   0.121357   4.492 7.05e-06 *** 
## ipot_hepatitis1 -0.671336   0.397109  -1.691  0.09092 .   
## anx_any1        -0.212897   0.138642  -1.536  0.12464     
## deprn1          -0.031554   0.115025  -0.274  0.78384     
## bipolar1         0.292729   0.391997   0.747  0.45521     
## psycho1         -0.629779   0.289058  -2.179  0.02935 *   
## schiz1           0.026756   0.589883   0.045  0.96382     
## ipot_dementia1   0.283585   0.168020   1.688  0.09145 .   
## sleep1           0.167869   0.126929   1.323  0.18599     
## obesity1         0.333359   0.142255   2.343  0.01911 *   
## anyabuse1        0.103839   0.158753   0.654  0.51305     
## region_grp41     0.191831   0.134815   1.423  0.15476     
## region_grp42     0.260797   0.104771   2.489  0.01280 *   
## region_grp43     0.195617   0.095451   2.049  0.04042 *   
## region_grp45    -0.336468   0.492044  -0.684  0.49409     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
##  
## (Dispersion parameter for binomial family taken to be 1) 
##  
##     Null deviance: 6235.3  on 4497  degrees of freedom 
## Residual deviance: 4600.5  on 4455  degrees of freedom 
## AIC: 4686.5 
##  
## Number of Fisher Scoring iterations: 4 
exp(cv_model$finalModel$coefficients) #to get the ORs 
##     (Intercept)       age_3grp2       age_3grp3      ins_mcare1            hmo1  
##      0.06099905      1.90140549      5.75472803      2.04553301      1.15350058  
##          er_nbr  polyrx_gn_ge61      abrx_3grp1      abrx_3grp2     antiep_grp1  
##      0.99660700      2.01583916      1.12910332      0.92164273      2.01836540  
##     antiep_grp2     antiep_grp3      metrx_any1       sulf_any1        tzd_any1  
##      1.37664661      0.55082321      0.78337995      1.51599061      1.89306720  
##       dpp4_any1       ipot_htn1       ipot_cad1        ipot_mi1   ipot_c_arrhy1  
##      0.65098204      1.53566462      2.09428912      1.25271952      2.22390132  
##    ipot_stroke1   ipot_hilipid1  ipot_diabetes1    ipot_cancer1      ipot_asth1  
##      1.44893121      0.67672541      1.38780672      0.79763335      1.25929235  
##      ipot_copd1      ipot_arth1    ipot_osteop1       ipot_ckd1 ipot_hepatitis1  
##      2.28110647      1.05934508      0.83417978      1.72490613      0.51102551  
##        anx_any1          deprn1        bipolar1         psycho1          schiz1  
##      0.80823972      0.96893890      1.34007901      0.53270928      1.02711738  
##  ipot_dementia1          sleep1        obesity1       anyabuse1    region_grp41  
##      1.32788156      1.18278189      1.39564893      1.10942207      1.21146547  
##    region_grp42    region_grp43    region_grp45  
##      1.29796440      1.21606071      0.71428873 
#variable importance 
#returns the absolute value of the t-statistic for each model parameter 
varImp(cv_model) 
## glm variable importance 
##  
##   only 20 most important variables shown (out of 42) 
##  




## age_3grp3       100.00 
## ipot_c_arrhy1    81.32 
## polyrx_gn_ge61   77.48 
## ipot_copd1       75.13 
## ins_mcare1       68.71 
## ipot_cad1        66.58 
## ipot_htn1        48.79 
## ipot_hilipid1    47.39 
## ipot_ckd1        46.54 
## age_3grp2        38.32 
## ipot_diabetes1   33.88 
## ipot_stroke1     26.13 
## region_grp42     25.57 
## sulf_any1        25.13 
## obesity1         24.05 
## tzd_any1         22.63 
## ipot_cancer1     22.59 
## psycho1          22.33 
## region_grp43     20.97 
## antiep_grp2      20.86 
#Summarize the accuracy and kappa 
cv_model 
## Generalized Linear Model  
##  
## 4498 samples 
##   35 predictor 
##    2 classes: '0', '1'  
##  
## No pre-processing 
## Resampling: Cross-Validated (10 fold, repeated 1 times)  
## Summary of sample sizes: 4047, 4048, 4048, 4049, 4049, 4048, ...  
## Resampling results: 
##  
##   Accuracy   Kappa     
##   0.7385647  0.4771807 
#calculate accuracy 
calc_acc = function(actual,predicted) { 
  mean(actual == predicted) 
} 
 
#Make predictions on test data 
head(predict(cv_model, newdata = hftest, type = "prob")) 
##            0         1 
## 3  0.6470469 0.3529531 
## 4  0.8122266 0.1877734 
## 6  0.4899400 0.5100600 
## 7  0.7985798 0.2014202 
## 9  0.5175976 0.4824024 
## 10 0.1741712 0.8258288 
#test accuracy of predictions 
calc_acc(actual = hftest$hf_fu12,  
         predicted = predict(cv_model, newdata = hftest)) 
## [1] 0.7349585 
#get confusion matrix using test dataset 




confusionMatrix(data=pred, hftest$hf_fu12, positive = '1') 
## Confusion Matrix and Statistics 
##  
##           Reference 
## Prediction   0   1 
##          0 683 246 
##          1 265 734 
##                                            
##                Accuracy : 0.735            
##                  95% CI : (0.7147, 0.7545) 
##     No Information Rate : 0.5083           
##     P-Value [Acc > NIR] : <2e-16           
##                                            
##                   Kappa : 0.4696           
##                                            
##  Mcnemar's Test P-Value : 0.4259           
##                                            
##             Sensitivity : 0.7490           
##             Specificity : 0.7205           
##          Pos Pred Value : 0.7347           
##          Neg Pred Value : 0.7352           
##              Prevalence : 0.5083           
##          Detection Rate : 0.3807           
##    Detection Prevalence : 0.5182           
##       Balanced Accuracy : 0.7347           
##                                            
##        'Positive' Class : 1                
##  
#calculate accuracy 
#Make predictions on original test data 
head(predict(cv_model, newdata = hforig_test, type = "prob")) 
##           0          1 
## 1 0.9515797 0.04842035 
## 2 0.9636499 0.03635011 
## 3 0.8924323 0.10756772 
## 4 0.9094337 0.09056626 
## 5 0.8949819 0.10501811 
## 6 0.5559103 0.44408974 
#test accuracy of predictions 
calc_acc(actual = hforig_test$hf_fu12,  
         predicted = predict(cv_model, newdata = hforig_test)) 
## [1] 0.7360741 
#get confusion matrix using original test dataset 
pred2 = predict(cv_model, newdata=hforig_test) 
confusionMatrix(data=pred2, hforig_test$hf_fu12, positive = '1') 
## Confusion Matrix and Statistics 
##  
##           Reference 
## Prediction     0     1 
##          0 32914   225 
##          1 11857   782 
##                                           
##                Accuracy : 0.7361          
##                  95% CI : (0.732, 0.7401) 




##     P-Value [Acc > NIR] : 1               
##                                           
##                   Kappa : 0.077           
##                                           
##  Mcnemar's Test P-Value : <2e-16          
##                                           
##             Sensitivity : 0.77656         
##             Specificity : 0.73516         
##          Pos Pred Value : 0.06187         
##          Neg Pred Value : 0.99321         
##              Prevalence : 0.02200         
##          Detection Rate : 0.01708         
##    Detection Prevalence : 0.27609         
##       Balanced Accuracy : 0.75586         
##                                           
##        'Positive' Class : 1               
#ROC# 
library (cvAUC) 
print(auc_value <-cvAUC(as.numeric(pred2), as.numeric(hforig_test$hf_fu12), 
label.ordering = NULL, folds = 10)) 
## $perf 
## A performance instance 
##   'False positive rate' vs. 'True positive rate' (alpha: 'Cutoff') 
##   with 3 data points 
## $fold.AUC 
## [1] 0.7558637 
##  
## $cvAUC 
## [1] 0.7558637 
#Plot fold AUCs 
plot(auc_value$perf, col="grey82", lty=3, main="10-fold CV AUC") 
 
#Plot CV AUC 








B. Random Forest Algorithm: Predictors of incident HF among Postmenopausal Women 
#read data 
library(haven) 





hf <- df[c('hf_fu12','pregabarx_any','gabarx_any','fqrx_any','abrx_othr', 
           'metrx_any','tzd_any','dpp4_any','sulf_any', 
           
'age_old','age_middle','polyrx_gn_ge6','anyabuse','ins_mcare','er_nbr','hmo','midwest
','northeast','south','anx_any','bipolar','psycho','deprn','schiz', 
           
'ipot_arth','ipot_asth','ipot_cancer','ipot_cad','ipot_mi','sleep','obesity', 
           
'ipot_c_arrhy','ipot_ckd','ipot_copd','ipot_dementia','ipot_hepatitis','ipot_hilipid'
, 
           'ipot_htn','ipot_diabetes','ipot_stroke','ipot_osteop')] 
 
#convert to factor variable 
library(plyr) 
hf$hf_fu12  <-factor(hf$hf_fu12) 
hf$hf_fu12 <- revalue(hf$hf_fu12, c("1"= "1", "2"= "0")) #changing label 2 to 0 
hf$hf_fu12 <- relevel(hf$hf_fu12, ref = "0") 
table(hf$hf_fu12) 
##      0      1  
## 149379   3213 
#recode indep variables to indicate categorical status to R# 
hf$fqrx_any <-factor(hf$fqrx_any) 
hf$abrx_othr    <-factor(hf$abrx_othr) 
hf$gabarx_any   <-factor(hf$gabarx_any) 
hf$pregabarx_any    <-factor(hf$pregabarx_any) 
hf$metrx_any    <-factor(hf$metrx_any) 
hf$tzd_any  <-factor(hf$tzd_any) 
hf$dpp4_any     <-factor(hf$dpp4_any) 
hf$sulf_any <-factor(hf$sulf_any) 
hf$age_old  <-factor(hf$age_old) 
hf$age_middle   <-factor(hf$age_middle) 
hf$polyrx_gn_ge6 <-factor(hf$polyrx_gn_ge6) 
hf$anyabuse <-factor(hf$anyabuse) 
hf$hmo  <-factor(hf$hmo) 
hf$ins_mcare    <-factor(hf$ins_mcare) 
hf$midwest  <-factor(hf$midwest) 
hf$south    <-factor(hf$south) 
hf$notheast <-factor(hf$northeast) 
hf$anx_any  <-factor(hf$anx_any) 
hf$bipolar  <-factor(hf$bipolar) 
hf$psycho   <-factor(hf$psycho) 
hf$deprn    <-factor(hf$deprn) 




hf$ipot_arth    <-factor(hf$ipot_arth) 
hf$ipot_asth    <-factor(hf$ipot_asth) 
hf$ipot_cancer  <-factor(hf$ipot_cancer) 
hf$ipot_c_arrhy <-factor(hf$ipot_c_arrhy) 
hf$ipot_ckd <-factor(hf$ipot_ckd) 
hf$ipot_copd    <-factor(hf$ipot_copd) 
hf$ipot_dementia    <-factor(hf$ipot_dementia) 
hf$ipot_hepatitis   <-factor(hf$ipot_hepatitis) 
hf$ipot_hilipid <-factor(hf$ipot_hilipid) 
hf$ipot_htn <-factor(hf$ipot_htn) 
hf$ipot_diabetes    <-factor(hf$ipot_diabetes) 
hf$ipot_stroke  <-factor(hf$ipot_stroke) 
hf$ipot_osteop  <-factor(hf$ipot_osteop) 
hf$ipot_cad <-factor(hf$ipot_cad) 
hf$ipot_mi  <-factor(hf$ipot_mi) 
hf$sleep    <-factor(hf$sleep) 
hf$obesity  <-factor(hf$obesity) 
#fix the imbalanced dataset with undersampling 
library(ROSE) 
set.seed(999) 
hf_us <- ovun.sample(hf_fu12~., data=hf, method="under",N=6426)$data 
table(hf_us$hf_fu12) 
##    0    1  
## 3213 3213 
#data partition into 70% train and 30% test#  
set.seed(123)  #set seed to make the analyses repeatable# 
library(caret) 
hf1 = sort(sample(nrow(hf_us),nrow(hf_us)*0.7)) 
hftrain = hf_us[hf1,]   #training dataset 
hftest = hf_us[-hf1,]   #test dataset 
 
#check the target feature distribution in the training dataset 
table(hftrain$hf_fu12) 
##  
##    0    1  
## 2265 2233 
print('distribution in the training dataset',prop.table(table(hftrain$hf_fu12))) 
# Algorithm Tune (tuneRF) 
library(randomForest)  
set.seed(111) 
x <- hftrain[c('abrx_othr','fqrx_any', 
'gabarx_any','pregabarx_any','metrx_any','tzd_any','dpp4_any','sulf_any','age_old','a
ge_middle', 
               
'polyrx_gn_ge6','anyabuse','ins_mcare','hmo','midwest','south','northeast','er_nbr', 
               
'anx_any','bipolar','psycho','deprn','schiz','ipot_arth','ipot_asth','ipot_cancer','i
pot_c_arrhy','ipot_ckd', 
               
'ipot_copd','ipot_dementia','ipot_hepatitis','ipot_hilipid','ipot_htn','ipot_diabetes
','ipot_stroke', 
               'ipot_osteop','ipot_cad','ipot_mi','sleep','obesity')] 
y <- hftrain$hf_fu12 
   




## mtry = 6  OOB error = 26.35%  
## Searching left ... 
## mtry = 4     OOB error = 25.66%  
## 0.02616034 1e-05  
## mtry = 3     OOB error = 26.17%  
## -0.01993068 1e-05  
## Searching right ... 
## mtry = 9     OOB error = 26.77%  
## -0.04332756 1e-05 
 
print(bestmtry) 
##       mtry  OOBError 
## 3.OOB    3 0.2616719 
## 4.OOB    4 0.2565585 
## 6.OOB    6 0.2634504 
## 9.OOB    9 0.2676745 
#random forest method 
library(randomForest) 





                                      
+anyabuse+ins_mcare+hmo+midwest+south+northeast+er_nbr 
                                      +anx_any+bipolar+psycho+deprn 
+schiz+ipot_arth+ipot_asth+ipot_cancer+ipot_c_arrhy+ipot_ckd 
                                      
+ipot_copd+ipot_dementia+ipot_hepatitis+ipot_hilipid+ipot_htn+ipot_diabetes+ipot_stro
ke 
                                      +ipot_osteop+ipot_cad+ipot_mi+sleep+obesity, 
                                      data=hftrain, 
                                      ntreeTry = 500, 
                                      mtry =4, 
                                      importance = TRUE) 
 
#Print results from tuned Model 
print(rf_model2_tuned) 
## Call: 
##  randomForest(formula = hf_fu12 ~ age_old + age_middle + abrx_othr +      fqrx_any 




polyrx_gn_ge6 + anyabuse + ins_mcare +      hmo + midwest + south + northeast + 
er_nbr + anx_any + bipolar +      psycho + deprn + schiz + ipot_arth + ipot_asth + 
ipot_cancer +      ipot_c_arrhy + ipot_ckd + ipot_copd + ipot_dementia + 
ipot_hepatitis +      ipot_hilipid + ipot_htn + ipot_diabetes + ipot_stroke + 
ipot_osteop +      ipot_cad + ipot_mi + sleep + obesity, data = hftrain, ntreeTry = 
500,      mtry = 4, importance = TRUE)  
##                Type of random forest: classification 
##                      Number of trees: 500 
## No. of variables tried at each split: 4 
##  
##         OOB estimate of  error rate: 26.41% 
## Confusion matrix: 
##      0    1 class.error 
## 0 1589  676   0.2984547 
## 1  512 1721   0.2292880 




#predict and specify model we created using training data# 
pred_model2 <-predict(rf_model2_tuned,hftrain) 
confusionMatrix(pred_model2,hftrain$hf_fu12, positive = "1") 
## Confusion Matrix and Statistics 
##           Reference 
## Prediction    0    1 
##          0 1973  285 
##          1  292 1948 
##                                            
##                Accuracy : 0.8717           
##                  95% CI : (0.8616, 0.8814) 
##     No Information Rate : 0.5036           
##     P-Value [Acc > NIR] : <2e-16           
##                                            
##                   Kappa : 0.7434           
##                                            
##  Mcnemar's Test P-Value : 0.8028           
##                                            
##             Sensitivity : 0.8724           
##             Specificity : 0.8711           
##          Pos Pred Value : 0.8696           
##          Neg Pred Value : 0.8738           




##          Detection Rate : 0.4331           
##    Detection Prevalence : 0.4980           
##       Balanced Accuracy : 0.8717           
##                                            
##        'Positive' Class : 1                
##  
#predict for test data# 
pred_test2<-predict(rf_model2_tuned,hftest) 
#get confusion matrix for test# 
confusionMatrix(pred_test2,hftest$hf_fu12, positive = "1") 
## Confusion Matrix and Statistics 
##  
##           Reference 
## Prediction   0   1 
##          0 648 227 
##          1 300 753 
##                                            
##                Accuracy : 0.7267           
##                  95% CI : (0.7062, 0.7465) 
##     No Information Rate : 0.5083           
##     P-Value [Acc > NIR] : < 2.2e-16        
##                                            
##                   Kappa : 0.4525           
##                                            
##  Mcnemar's Test P-Value : 0.001711         
##                                            
##             Sensitivity : 0.7684           
##             Specificity : 0.6835           
##          Pos Pred Value : 0.7151           
##          Neg Pred Value : 0.7406           
##              Prevalence : 0.5083           
##          Detection Rate : 0.3906           
##    Detection Prevalence : 0.5462           
##       Balanced Accuracy : 0.7260           
##                                            
##        'Positive' Class : 1                
#predict for original test data 
pred_test3<-predict(rf_model2_tuned,hforig_test) 
#get confusion matrix for test# 
confusionMatrix(pred_test3,hforig_test$hf_fu12, positive = "1") 
## Confusion Matrix and Statistics 
##  
##           Reference 
## Prediction     0     1 
##          0 31757   135 
##          1 13014   872 
##                                            
##                Accuracy : 0.7128           
##                  95% CI : (0.7086, 0.7169) 
##     No Information Rate : 0.978            
##     P-Value [Acc > NIR] : 1                
##                                            
##                   Kappa : 0.0793           
##                                            




##                                            
##             Sensitivity : 0.86594          
##             Specificity : 0.70932          
##          Pos Pred Value : 0.06280          
##          Neg Pred Value : 0.99577          
##              Prevalence : 0.02200          
##          Detection Rate : 0.01905          
##    Detection Prevalence : 0.30333          
##       Balanced Accuracy : 0.78763          
##                                            






oob.votes2 <- predict(rf_model2_tuned,hforig_test,type="prob") 
head(oob.votes2) 
##       0     1 
## 1 0.974 0.026 
## 2 0.950 0.050 
## 3 0.996 0.004 
## 4 0.900 0.100 
## 5 0.898 0.102 
## 6 0.452 0.548 








#plot the ROC curve 
perf_ROC2=performance(pred2,"tpr","fpr")  
plot(perf_ROC2, main="ROC plot Model2") 
text(0.5,0.5,paste("AUC = ",format(AUC2, digits=5, scientific=FALSE))) 
 





##                          0           1 MeanDecreaseAccuracy MeanDecreaseGini 
## age_old        19.05924285 40.65633157           38.7364207       157.114257 
## age_middle     -8.73625341 23.47211445           21.2255557        58.496222 
## abrx_othr       5.33158982 -1.52785455            2.7096516        30.039318 
## fqrx_any        4.75607086 -0.66063327            3.1151737        23.660686 
## gabarx_any      8.12408140  4.17010484            9.2107646        18.006772 
## pregabarx_any   6.11173866 -1.16578795            3.7627089         6.480584 
## metrx_any       8.18065924 -5.29870143            2.9358726        19.279095 
## tzd_any         1.11546102  1.47035173            2.0028788         6.826976 
## dpp4_any        5.36795920  1.26300673            5.2599164         9.640396 
## sulf_any       15.04692278 -1.09202125           13.3134333        19.856049 
## polyrx_gn_ge6  30.07587914  6.47092282           30.0666369        75.660382 
## anyabuse        1.70508333  4.61712991            4.9983531        17.054730 
## ins_mcare      16.90783146 23.92616409           30.1654214       116.635570 
## hmo            12.14584020  1.21548703           13.0455428        38.836338 
## midwest         2.36875931  1.02100583            2.3837802        24.857204 
## south           9.71304487  4.48977061           10.3598085        29.556802 
## northeast       0.40334598 -0.92297131           -0.4541694        18.554312 
## er_nbr         14.81981339 -2.03859619            9.4621374        53.316327 
## anx_any         0.03399209  4.05870640            3.4391783        18.389866 
## bipolar         5.33497462 -4.08829291            1.7843846         4.164862 
## psycho          6.80132383 -1.69399152            3.9590919         7.409968 
## deprn           6.78041033 -2.70402681            2.7650871        23.088709 
## schiz           2.12869053 -0.61966009            1.0702105         2.108506 
## ipot_arth       1.10069519  4.17567945            4.1372278        30.696912 
## ipot_asth       5.22647497 -1.25764437            3.2283363        19.046154 
## ipot_cancer     3.70165849 -1.20016877            1.5842526        25.968135 
## ipot_c_arrhy   33.35711299  9.58333354           32.0595909        64.518867 
## ipot_ckd       26.01593250  2.01322700           25.7445972        39.691864 
## ipot_copd      29.22903354 12.78705115           31.8242289        53.533113 
## ipot_dementia  13.98423969 -2.91090089           11.2422955        16.749594 
## ipot_hepatitis  1.13262081  0.06937672            0.8537319         4.176250 
## ipot_hilipid   -4.21136260  7.45178545            3.5418554        30.699301 
## ipot_htn       10.70859892 16.66928201           25.2759936        71.918921 
## ipot_diabetes   8.85301124  2.60112764           10.2976553        39.858353 
## ipot_stroke    26.39645319 -6.01529528           20.9933682        26.842238 
## ipot_osteop     4.64829449 -2.11561456            1.6423567        23.459672 
## ipot_cad       25.36288727  8.65254521           28.1031499        58.671870 
## ipot_mi         7.32955525 -5.75995424            1.8741233         4.948871 
## sleep           1.76454427  5.07874536            5.2185984        22.077589 
## obesity        -0.33433954  2.69630979            1.8475211        18.686181 






C. XGBoost: Predictors of Incident HF among Postmenopausal Women 
#read data# 




#read sas data---must install package haven and load library haven# 
df <- 
read_sas("Z:/OPTUM_10pct/projects/Khalid_phd/Aim_2/sasdata/hfree_2007_2016_xg.sas7bda
t", NULL) #converted all variables to 0s and 1s and made dummy variables where 
necessary 
 
hf <- df[c('hf_fu12','abrx_othr','fqrx_any', 
'gabarx_any','pregabarx_any','metrx_any','tzd_any','dpp4_any','sulf_any','age_old','a
ge_middle', 
          'midwest','south','northeast', 
           'polyrx_gn_ge6','anyabuse','ins_mcare','hmo','er_nbr', 
           
'anx_any','bipolar','psycho','deprn','schiz','omi','ipot_arth','ipot_asth','ipot_canc
er','ipot_c_arrhy','ipot_ckd', 
           'ipot_copd','ipot_dementia','ipot_hepatitis','ipot_hilipid', 




hf[is.na(hf)] = 0 #setting missing values to zero along with other missing values 
 
#look at structure of data# 
dim(hf) 
## [1] 152592     42 
head(hf) #pay attention to all potential categorical variables to ensure they are 




## # A tibble: 6 x 42 
##   hf_fu12 abrx_othr fqrx_any gabarx_any pregabarx_any metrx_any tzd_any dpp4_any 
##     <dbl>     <dbl>    <dbl>      <dbl>         <dbl>     <dbl>   <dbl>    <dbl> 
## 1       0         0        0          0             0         0       0        0 
## 2       0         0        1          0             0         0       0        0 
## 3       0         0        0          0             0         0       0        0 
## 4       0         0        0          0             0         0       0        0 
## 5       0         0        0          0             0         0       0        0 
## 6       0         1        0          1             0         0       0        0 
## # ... with 34 more variables: sulf_any <dbl>, age_old <dbl>, age_middle <dbl>, 
## #   midwest <dbl>, south <dbl>, northeast <dbl>, polyrx_gn_ge6 <dbl>, 
## #   anyabuse <dbl>, ins_mcare <dbl>, hmo <dbl>, er_nbr <dbl>, anx_any <dbl>, 
## #   bipolar <dbl>, psycho <dbl>, deprn <dbl>, schiz <dbl>, omi <dbl>, 
## #   ipot_arth <dbl>, ipot_asth <dbl>, ipot_cancer <dbl>, ipot_c_arrhy <dbl>, 
## #   ipot_ckd <dbl>, ipot_copd <dbl>, ipot_dementia <dbl>, ipot_hepatitis <dbl>, 
## #   ipot_hilipid <dbl>, ipot_htn <dbl>, ipot_diabetes <dbl>, ipot_stroke <dbl>, 
## #   ipot_osteop <dbl>, ipot_cad <dbl>, ipot_mi <dbl>, sleep <dbl>, 
## #   obesity <dbl> 
         #also make sure that variables with multiple categories are converted to 
dummy vars e.g. age_4grp, region 
#str(hf) 
#Keep only required vars and create a subset of the dataset #make sure all variables are numeric 
#select only required vars for the ease of analysis 
hf_select = hf[,c('hf_fu12','abrx_othr','fqrx_any', 
'gabarx_any','pregabarx_any','metrx_any','tzd_any','dpp4_any','sulf_any','age_old','a
ge_middle', 
           'midwest','south','northeast', 
           'polyrx_gn_ge6','anyabuse','ins_mcare','hmo','er_nbr', 
           
'anx_any','bipolar','psycho','deprn','schiz','ipot_arth','ipot_asth','ipot_cancer','i
pot_c_arrhy','ipot_ckd', 
           'ipot_copd','ipot_dementia','ipot_hepatitis','ipot_hilipid', 




## [1] 152592     41 
#dependent variable labels 
#1st set of variables 
hf_select$hf_fu12 <- as.factor(hf_select$hf_fu12) 
levels(hf_select$hf_fu12)<- list("no" = "0" , "yes" = "1") #caret requires labels 
head(hf_select$hf_fu12) 
## [1] no no no no no no 
## Levels: no yes 
table(hf_select$hf_fu12) #make sure labels are correct 
##     no    yes  
## 149379   3213 
#1st set of variables 
set.seed(123) 
hf_select1 <- as.data.frame(hf_select) #converting to a data frame for sampling; 
random sampling does not work otherwise 
n = nrow(hf_select1) #get total no. of rows 
 





#original training data set 
set.seed(123) 
hforig_train_data <- hf_select1[train.index,] #this will select rows in train.index 
head(hforig_train_data) 
##        hf_fu12 abrx_othr fqrx_any gabarx_any pregabarx_any metrx_any tzd_any 
## 134058     yes         1        0          1             0         0       0 
## 124022      no         0        0          0             0         0       0 
## 103065      no         0        0          0             0         0       0 
## 124507      no         0        0          0             0         0       0 
## 45404       no         1        0          0             0         1       0 
## 65161       no         0        0          0             0         0       0 
##        dpp4_any sulf_any age_old age_middle midwest south northeast 
## 134058        0        0       1          0       0     0         0 
## 124022        0        0       0          1       0     1         0 
## 103065        0        0       0          1       0     0         0 
## 124507        0        0       1          0       0     0         1 
## 45404         1        0       0          1       0     1         0 
## 65161         0        0       1          0       0     0         0 
##        polyrx_gn_ge6 anyabuse ins_mcare hmo er_nbr anx_any bipolar psycho deprn 
## 134058             1        0         1   1      0       0       0      0     1 
## 124022             0        0         1   1      0       0       0      0     0 
## 103065             0        0         0   0      0       0       0      0     0 
## 124507             0        0         1   0      0       0       0      0     0 
## 45404              1        0         0   0      0       0       0      0     0 
## 65161              1        0         1   1      1       0       0      0     0 
##        schiz ipot_arth ipot_asth ipot_cancer ipot_c_arrhy ipot_ckd ipot_copd 
## 134058     0         1         0           0            1        1         1 
## 124022     0         0         0           0            0        0         0 
## 103065     0         0         0           0            0        0         0 
## 124507     0         0         0           0            0        0         0 
## 45404      0         0         0           1            0        0         1 
## 65161      0         0         0           0            0        0         0 
##        ipot_dementia ipot_hepatitis ipot_hilipid ipot_htn ipot_diabetes 
## 134058             1              0            0        1             0 
## 124022             0              0            0        0             0 
## 103065             0              0            0        0             0 
## 124507             0              0            0        0             0 
## 45404              0              0            1        1             1 
## 65161              0              0            0        1             0 
##        ipot_stroke ipot_osteop ipot_cad ipot_mi sleep obesity 
## 134058           0           0        0       0     0       0 
## 124022           0           0        0       0     0       0 
## 103065           0           0        0       0     0       0 
## 124507           0           0        0       0     0       0 
## 45404            0           0        0       0     1       0 
## 65161            0           0        0       0     0       0 
dim(hforig_train_data) 
## [1] 106814     41 
#original test data set 
set.seed(123) 
hforig_test_data <- hf_select1[-train.index,] #this will select those rows not in 
train.index 
head(hforig_test_data) 
##    hf_fu12 abrx_othr fqrx_any gabarx_any pregabarx_any metrx_any tzd_any 




## 4       no         0        0          0             0         0       0 
## 5       no         0        0          0             0         0       0 
## 6       no         1        0          1             0         0       0 
## 9       no         0        1          0             0         0       0 
## 11      no         1        0          0             0         0       0 
##    dpp4_any sulf_any age_old age_middle midwest south northeast polyrx_gn_ge6 
## 3         0        0       0          0       0     0         0             0 
## 4         0        0       0          0       1     0         0             0 
## 5         0        0       0          1       0     0         0             0 
## 6         0        0       0          1       0     0         0             0 
## 9         0        0       0          0       0     0         0             0 
## 11        0        0       1          0       0     0         0             1 
##    anyabuse ins_mcare hmo er_nbr anx_any bipolar psycho deprn schiz ipot_arth 
## 3         0         0   0      0       0       0      0     0     0         0 
## 4         0         0   1      0       1       0      0     0     0         0 
## 5         0         0   0      0       0       0      0     0     0         0 
## 6         0         0   0      0       0       0      0     0     0         0 
## 9         1         0   0      0       0       0      0     0     0         0 
## 11        0         0   0      0       0       0      0     0     0         0 
##    ipot_asth ipot_cancer ipot_c_arrhy ipot_ckd ipot_copd ipot_dementia 
## 3          0           0            0        0         0             0 
## 4          0           0            0        0         0             0 
## 5          0           0            0        0         0             0 
## 6          0           0            0        0         0             0 
## 9          0           0            0        0         0             0 
## 11         0           1            0        0         0             0 
##    ipot_hepatitis ipot_hilipid ipot_htn ipot_diabetes ipot_stroke ipot_osteop 
## 3               0            0        0             0           0           1 
## 4               1            0        0             0           0           0 
## 5               0            1        1             0           0           0 
## 6               0            1        0             0           0           0 
## 9               0            0        1             0           0           0 
## 11              0            0        1             0           0           0 
##    ipot_cad ipot_mi sleep obesity 
## 3         0       0     0       0 
## 4         0       0     0       0 
## 5         0       0     0       0 
## 6         0       0     0       0 
## 9         0       0     0       0 
## 11        0       0     0       0 
dim(hforig_test_data) 
## [1] 45778    41 
#fix the imbalanced dataset with undersampling 
library(ROSE) 
set.seed(999) 
hf_select_us <- ovun.sample(hf_fu12~., data=hf_select, method="under",N=6426)$data 
table(hf_select_us$hf_fu12) 
##  
##   no  yes  
## 3213 3213 
#1st set of variables 
set.seed(123) 
hf_select_us<- as.data.frame(hf_select_us) #converting to a data frame for sampling; 
random sampling does not work otherwise 





train.index = sample(n,floor(0.7*n)) #randomly select 70% rows from hf_select 
 
#undersampled training data set 
set.seed(123) 
hftrain_data <- hf_select_us[train.index,] #this will select rows in train.index 
head(hftrain_data) 
##      hf_fu12 abrx_othr fqrx_any gabarx_any pregabarx_any metrx_any tzd_any 
## 2463      no         1        0          0             0         0       0 
## 2511      no         1        0          0             0         0       0 
## 2227      no         0        0          0             0         0       0 
## 526       no         0        1          0             0         0       0 
## 4291     yes         0        0          0             0         0       0 
## 2986      no         0        0          0             0         0       0 
##      dpp4_any sulf_any age_old age_middle midwest south northeast polyrx_gn_ge6 
## 2463        0        0       1          0       0     0         0             0 
## 2511        0        0       1          0       0     0         1             0 
## 2227        0        0       0          1       0     1         0             0 
## 526         0        0       0          1       0     0         1             0 
## 4291        0        0       1          0       1     0         0             0 
## 2986        0        0       0          0       0     0         1             1 
##      anyabuse ins_mcare hmo er_nbr anx_any bipolar psycho deprn schiz ipot_arth 
## 2463        0         1   0      0       0       0      0     0     0         0 
## 2511        0         1   0      1       0       0      0     0     0         0 
## 2227        0         0   0      0       0       0      0     0     0         0 
## 526         0         1   0      0       0       0      0     0     0         0 
## 4291        0         1   1      0       0       0      0     0     0         0 
## 2986        0         1   0      1       1       1      0     0     0         1 
##      ipot_asth ipot_cancer ipot_c_arrhy ipot_ckd ipot_copd ipot_dementia 
## 2463         0           0            1        0         0             0 
## 2511         0           0            0        0         0             0 
## 2227         0           0            0        0         0             0 
## 526          0           0            0        0         0             0 
## 4291         0           0            1        0         0             0 
## 2986         0           0            0        0         0             0 
##      ipot_hepatitis ipot_hilipid ipot_htn ipot_diabetes ipot_stroke ipot_osteop 
## 2463              0            1        0             0           0           0 
## 2511              0            1        1             0           1           0 
## 2227              0            0        0             0           0           0 
## 526               0            0        1             1           0           0 
## 4291              0            1        1             0           0           0 
## 2986              0            1        0             0           0           0 
##      ipot_cad ipot_mi sleep obesity 
## 2463        0       0     0       0 
## 2511        0       0     0       0 
## 2227        0       0     0       0 
## 526         0       0     0       0 
## 4291        0       0     0       0 
## 2986        0       0     0       0 
dim(hftrain_data) 
## [1] 4498   41 
#undersampled test data set 
set.seed(123) 






##    hf_fu12 abrx_othr fqrx_any gabarx_any pregabarx_any metrx_any tzd_any 
## 3       no         0        0          0             0         0       0 
## 4       no         0        0          0             0         0       0 
## 6       no         1        0          0             0         0       0 
## 7       no         1        0          0             0         0       0 
## 9       no         0        0          0             0         0       0 
## 10      no         0        1          0             0         0       0 
##    dpp4_any sulf_any age_old age_middle midwest south northeast polyrx_gn_ge6 
## 3         0        0       0          1       1     0         0             0 
## 4         0        0       0          1       1     0         0             0 
## 6         0        0       0          1       0     1         0             0 
## 7         0        0       0          1       0     0         0             0 
## 9         0        0       1          0       1     0         0             0 
## 10        1        1       0          1       0     1         0             1 
##    anyabuse ins_mcare hmo er_nbr anx_any bipolar psycho deprn schiz ipot_arth 
## 3         0         1   1      0       0       0      0     0     0         0 
## 4         0         0   0      0       0       0      0     0     0         0 
## 6         0         1   1      0       0       0      0     1     0         0 
## 7         0         1   1      0       0       0      0     0     0         0 
## 9         0         1   0      0       0       0      0     0     0         0 
## 10        0         1   0      0       0       0      0     0     0         0 
##    ipot_asth ipot_cancer ipot_c_arrhy ipot_ckd ipot_copd ipot_dementia 
## 3          0           0            0        0         0             0 
## 4          0           0            0        0         0             0 
## 6          0           0            0        0         1             0 
## 7          0           0            0        0         0             0 
## 9          0           0            0        0         0             0 
## 10         0           0            1        0         1             0 
##    ipot_hepatitis ipot_hilipid ipot_htn ipot_diabetes ipot_stroke ipot_osteop 
## 3               0            0        1             0           0           0 
## 4               0            0        1             0           0           0 
## 6               0            0        1             0           0           0 
## 7               0            0        0             0           0           0 
## 9               0            0        0             0           0           0 
## 10              0            1        1             1           0           0 
##    ipot_cad ipot_mi sleep obesity 
## 3         0       0     0       0 
## 4         0       0     0       0 
## 6         0       0     0       0 
## 7         0       0     0       0 
## 9         0       0     0       0 
## 10        0       0     0       0 
dim(hftest_data) 
## [1] 1928   41 
#install.packages("SHAPforxgboost") 
library(SHAPforxgboost) 
#Running the same xgboost model with the following command due to to non-numeric var 
error with shap.values function 
library(xgboost) 
library(ggplot2) 






## [1] 4498   40 
hftrain_label <- hftrain_data[,"hf_fu12"] #capture labels of the dv 
head(hftrain_label) 
## [1] no  no  no  no  yes no  
## Levels: no yes 
hftest <- subset(hftest_data, select = -c(hf_fu12)) #copy hftest_data and drop the DV 
dim(hftest)  
## [1] 1928   40 
hftest_label <- hftest_data[,"hf_fu12"] #capture labels of the dv 
head(hftest_label) 
## [1] no no no no no no 
## Levels: no yes 
hforig_test <- subset(hforig_test_data, select = -c(hf_fu12)) #copy hforig_test_data 
and drop the DV 
dim(hforig_test)  
## [1] 45778    40 
hforig_test_label <- hforig_test_data[,"hf_fu12"] #capture labels of the dv 
head(hforig_test_label) 
## [1] no no no no no no 
## Levels: no yes 
#hyperparameter tuning results from the final model tuned using caret package 
params <- list (objective = "multi:softprob", 
                nrounds = 700, 
                eta = 0.01, 
                max_depth = 3, 
                gamma = 0, 
                subsample = 0.5, 
                colsample_bytree = 1, 
                min_child_weight = 1, 
                eval_metric = "auc" 
                ) 
 
#run the xgboost model 
xgb_train <- xgboost::xgboost(data = as.matrix(hftrain), 
                         label = hftrain_label, 
                         xgb_param = params, 
                         nrounds = params$nrounds, 
                         verbose = FALSE 
                         ) 
## [22:12:29] WARNING: amalgamation/../src/learner.cc:480:  
## Parameters: { xgb_param } might not be used. 
##  
##   This may not be accurate due to some parameters are only used in language 
bindings but 
##   passed down to XGBoost core.  Or some parameters are not used but slip through 
this 
##   verification. Please open an issue if you find above cases. 
#print the model 
xgb_train 
## ##### xgb.Booster 
## raw: 2.7 Mb  
## call: 
##   xgb.train(params = params, data = dtrain, nrounds = nrounds,  
##     watchlist = watchlist, verbose = verbose, print_every_n = print_every_n,  




##     save_period = save_period, save_name = save_name, xgb_model = xgb_model,  
##     callbacks = callbacks, xgb_param = ..1) 
## params (as set within xgb.train): 
##   xgb_param = "multi:softprob", validate_parameters = "700", xgb_param = "0.01", 
validate_parameters = "3", xgb_param = "0", validate_parameters = "0.5", xgb_param = 
"1", validate_parameters = "1", xgb_param = "auc", validate_parameters = "TRUE" 
## xgb.attributes: 
##   niter 
## callbacks: 
##   cb.evaluation.log() 
## # of features: 40  
## niter: 700 
## nfeatures : 40  
## evaluation_log: 
##     iter train_rmse 
##        1   0.835650 
##        2   0.653909 
## ---                 
##      699   0.209106 
##      700   0.209073 
#run the xgboost model 
xgb_test <- xgboost::xgboost(data = as.matrix(hftest), 
                         label = hftest_label, 
                         xgb_param = params, 
                         nrounds = params$nrounds, 
                         verbose = FALSE 
                         ) 
## [22:12:35] WARNING: amalgamation/../src/learner.cc:480:  
## Parameters: { xgb_param } might not be used. 
##  
##   This may not be accurate due to some parameters are only used in language 
bindings but 
##   passed down to XGBoost core.  Or some parameters are not used but slip through 
this 
##   verification. Please open an issue if you find above cases. 
#print the model 
xgb_test 
## ##### xgb.Booster 
## raw: 2.7 Mb  
## call: 
##   xgb.train(params = params, data = dtrain, nrounds = nrounds,  
##     watchlist = watchlist, verbose = verbose, print_every_n = print_every_n,  
##     early_stopping_rounds = early_stopping_rounds, maximize = maximize,  
##     save_period = save_period, save_name = save_name, xgb_model = xgb_model,  
##     callbacks = callbacks, xgb_param = ..1) 
## params (as set within xgb.train): 
##   xgb_param = "multi:softprob", validate_parameters = "700", xgb_param = "0.01", 
validate_parameters = "3", xgb_param = "0", validate_parameters = "0.5", xgb_param = 
"1", validate_parameters = "1", xgb_param = "auc", validate_parameters = "TRUE" 
## xgb.attributes: 
##   niter 
## callbacks: 
##   cb.evaluation.log() 
## # of features: 40  




## nfeatures : 40  
## evaluation_log: 
##     iter train_rmse 
##        1   0.844361 
##        2   0.659897 
## ---                 
##      699   0.151722 
##      700   0.151700 
#run the xgboost model using original dataset 
xgb_test_orig <- xgboost::xgboost(data = as.matrix(hforig_test), 
                         label = hforig_test_label, 
                         xgb_param = params, 
                         nrounds = params$nrounds, 
                         verbose = FALSE 
                         ) 
## [22:12:40] WARNING: amalgamation/../src/learner.cc:480:  
## Parameters: { xgb_param } might not be used. 
##  
##   This may not be accurate due to some parameters are only used in language 
bindings but 
##   passed down to XGBoost core.  Or some parameters are not used but slip through 
this 
##   verification. Please open an issue if you find above cases. 
#print the model 
xgb_test_orig 
## ##### xgb.Booster 
## raw: 2.8 Mb  
## call: 
##   xgb.train(params = params, data = dtrain, nrounds = nrounds,  
##     watchlist = watchlist, verbose = verbose, print_every_n = print_every_n,  
##     early_stopping_rounds = early_stopping_rounds, maximize = maximize,  
##     save_period = save_period, save_name = save_name, xgb_model = xgb_model,  
##     callbacks = callbacks, xgb_param = ..1) 
## params (as set within xgb.train): 
##   xgb_param = "multi:softprob", validate_parameters = "700", xgb_param = "0.01", 
validate_parameters = "3", xgb_param = "0", validate_parameters = "0.5", xgb_param = 
"1", validate_parameters = "1", xgb_param = "auc", validate_parameters = "TRUE" 
## xgb.attributes: 
##   niter 
## callbacks: 
##   cb.evaluation.log() 
## # of features: 40  
## niter: 700 
## nfeatures : 40  
## evaluation_log: 
##     iter train_rmse 
##        1   0.392997 
##        2   0.293120 
## ---                 
##      699   0.097959 
##      700   0.097957 
#Get SHAP values and ranked features by mean|SHAP| for train data 
set.seed(222) 





meanshap_trn <- shapvalues_trn$mean_shap_score 
 
#Prepare long form data for dependende plot 
#shaplong_trn <- shap.prep(xgb_train, X_train = hftrain) 
 
#plot the SHAP value summmary plot 
shap.plot.summary.wrap1(xgb_train, as.matrix(hftrain), top_n = 10) #dilute helps when 
there are a lot of data points 
 
#Plot of meaan SHAP score vs top 10 predictors 
library(ggplot2) 
trainshap_names <- as.data.frame(names(meanshap_trn[1:15])) #get names of all 
features sorted by mean SHAP score 
trainshap_val <- as.data.frame(unname(meanshap_trn[1:15])) #get sorted mean SHAP 
values 
trainshap <- cbind(trainshap_names, trainshap_val) 
colnames(trainshap) <- c("feature", "meanSHAP") #copied this table then to Excel to 




















R Codes for Random Forest Algorithm to Identify Predictors of Heart Failure-related Emergency Room Use 
among Postmenopausal Women 
#read data# 




#read sas data---must install package haven and load library haven# 
df <- read_sas("Z:/OPTUM_10pct/projects/Khalid_phd/Aim_3/sasdata/hf2015_2016_hfxg.sas












# convert NA to 0 
hf[is.na(hf)] <- 0 
#convert to factor variable---for RF 1 is hfer 0 is no hfer#  
# required for caret package 
table(hf$hfer_use) #before changing the levels 
##    0    1  
## 4490 1692 
hf$hfer_use<-as.factor(hf$hfer_use) 
 
#recode indep variables to indicate categorical status to R# 
hf$hfer_use_base <-factor(hf$hfer_use_base) 
hf$lipdrx_any   <-factor(hf$lipdrx_any) 
hf$bbrx_any <-factor(hf$bbrx_any) 
hf$acerx_any    <-factor(hf$acerx_any) 
hf$arbrx_any    <-factor(hf$arbrx_any) 
hf$diurx_any        <-factor(hf$diurx_any) 
hf$abrx_3grp    <-factor(hf$abrx_3grp) 
hf$fqrx_any <-factor(hf$fqrx_any) 
hf$abrx_othr    <-factor(hf$abrx_othr) 
hf$abrx_3grp    <-factor(hf$abrx_3grp) 
hf$antiep_grp   <-factor(hf$antiep_grp) 
hf$gabarx_any   <-factor(hf$gabarx_any) 
hf$metrx_any    <-factor(hf$metrx_any) 
hf$tzd_any  <-factor(hf$tzd_any) 
hf$dpp4_any     <-factor(hf$dpp4_any) 
hf$sulf_any <-factor(hf$sulf_any) 
hf$age_3grp <-factor(hf$age_3grp) 
hf$age_old  <-factor(hf$age_old) 






hf$ins_mcare    <-factor(hf$ins_mcare) 
hf$hmo  <-factor(hf$hmo) 
hf$region_grp4  <-factor(hf$region_grp4) 
hf$midwest  <-factor(hf$midwest) 
hf$northeast    <-factor(hf$northeast) 
hf$south    <-factor(hf$south) 
hf$anx_any  <-factor(hf$anx_any) 
hf$deprn    <-factor(hf$deprn) 
hf$ipot_arth    <-factor(hf$ipot_arth) 
hf$ipot_asth    <-factor(hf$ipot_asth) 
hf$ipot_cancer  <-factor(hf$ipot_cancer) 
hf$ipot_cad <-factor(hf$ipot_cad) 
hf$ipot_mi  <-factor(hf$ipot_mi) 
hf$ipot_c_arrhy <-factor(hf$ipot_c_arrhy) 
hf$ipot_ckd <-factor(hf$ipot_ckd) 
hf$ipot_copd    <-factor(hf$ipot_copd) 
hf$ipot_dementia    <-factor(hf$ipot_dementia) 
hf$ipot_hilipid <-factor(hf$ipot_hilipid) 
hf$ipot_htn <-factor(hf$ipot_htn) 
hf$ipot_diabetes    <-factor(hf$ipot_diabetes) 
hf$ipot_stroke  <-factor(hf$ipot_stroke) 
hf$ipot_osteop  <-factor(hf$ipot_osteop) 




hf$age <- as.numeric(hf$age) 
hf$carefrag2015 <- as.numeric (hf$carefrag2015) 
hf$hfer_nbr_base <- as.numeric (hf$hfer_nbr_base) 
 
 
#look at structure of data# 
dim(hf) 
## [1] 6182   51 
head(hf) #pay attention to all potential categorical variables to ensure they are cod
ed as 0 and 1 
## # A tibble: 6 x 51 
##   hfer_use hfer_use_base hfer_nbr_base ip_nbr_base carefrag2015 lipdrx_any 
##   <fct>    <fct>                 <dbl>       <dbl>        <dbl> <fct>      
## 1 0        0                         0           1        0.479 0          
## 2 0        1                         6           4        0.86  1          
## 3 0        0                         0           0        0.571 0          
## 4 0        0                         0           0        0.679 1          
## 5 0        0                         0           0        0.681 1          
## 6 0        1                         2           1        0.627 1          
## # ... with 45 more variables: bbrx_any <fct>, acerx_any <fct>, arbrx_any <fct>, 
## #   diurx_any <fct>, abrx_3grp <fct>, fqrx_any <fct>, abrx_othr <fct>, 
## #   antiep_grp <fct>, pregabarx_any <dbl>, gabarx_any <fct>, metrx_any <fct>, 
## #   tzd_any <fct>, dpp4_any <fct>, sulf_any <fct>, age <dbl>, age_3grp <fct>, 
## #   age_old <fct>, age_middle <fct>, age_young <dbl>, polyrx_gn_ge6 <fct>, 
## #   anyabuse <fct>, ins_mcare <fct>, hmo <fct>, region_grp4 <fct>, 




## #   ipot_arth <fct>, ipot_asth <fct>, ipot_cancer <fct>, ipot_c_arrhy <fct>, 
## #   ipot_cad <fct>, ipot_mi <fct>, ipot_ckd <fct>, ipot_copd <fct>, 
## #   ipot_dementia <fct>, ipot_hilipid <fct>, ipot_htn <fct>, 
## #   ipot_diabetes <fct>, ipot_stroke <fct>, ipot_osteop <fct>, 
## #   sleep_2015 <fct>, obesity_2015 <fct> 
#also make sure that variables with multiple categories are converted to dummy  
#str(hf) 
#select only required vars for the ease of analysis 










## [1] 6182   42 
set.seed(100) 
hf_select1 <- as.data.frame(hf_select) #converting to a data frame for sampling; rand
om sampling does not work otherwise 
n = nrow(hf_select1) #get total no. of rows 
 
train.index = sample(n,floor(0.7*n)) #randomly select 70% rows from hf_select 
 
#training data set 
hforig_train <- hf_select1[train.index,] #this will select rows in train.index 
head(hforig_train) 
##      hfer_use hfer_nbr_base carefrag2015 lipdrx_any bbrx_any acerx_any 
## 3786        0             0    0.6047431          0        1         0 
## 503         0             0    0.7472527          0        1         0 
## 3430        1             3    0.7574595          0        0         0 
## 3696        0             1    0.6900585          1        1         1 
## 6131        1             2    0.7526316          0        0         0 
## 4090        1             2    0.7564103          1        1         0 
##      arbrx_any diurx_any fqrx_any abrx_othr gabarx_any metrx_any dpp4_any 
## 3786         0         1        0         0          0         0        0 
## 503          0         1        0         1          0         0        0 
## 3430         0         0        0         0          0         0        0 
## 3696         0         1        1         0          0         0        0 
## 6131         0         0        0         0          0         0        0 
## 4090         0         1        0         0          0         0        0 
##      sulf_any age age_old age_middle polyrx_gn_ge6 anyabuse ins_mcare hmo 
## 3786        0  68       0          1             0        0         1   1 
## 503         0  82       1          0             0        0         1   0 
## 3430        0  70       0          1             0        0         1   1 
## 3696        0  66       0          1             1        0         1   0 
## 6131        0  71       0          1             0        0         1   1 
## 4090        0  87       1          0             0        0         1   0 




## 3786       0         0     1       0     0         0         0           0 
## 503        0         1     0       0     0         0         0           1 
## 3430       0         0     0       0     1         1         0           1 
## 3696       0         0     1       1     1         0         0           0 
## 6131       0         0     1       0     0         1         0           0 
## 4090       1         0     0       0     0         1         0           1 
##      ipot_c_arrhy ipot_cad ipot_mi ipot_ckd ipot_copd ipot_dementia 
## 3786            0        0       0        0         0             0 
## 503             1        0       0        0         1             0 
## 3430            1        0       0        1         0             0 
## 3696            0        1       0        1         0             0 
## 6131            1        0       0        1         0             0 
## 4090            1        1       0        0         0             0 
##      ipot_hilipid ipot_htn ipot_diabetes ipot_stroke ipot_osteop sleep_2015 
## 3786            1        1             1           0           0          0 
## 503             0        1             0           0           1          0 
## 3430            0        1             1           0           1          1 
## 3696            1        1             1           0           0          0 
## 6131            1        1             0           1           0          1 
## 4090            1        1             1           1           0          0 
##      obesity_2015 
## 3786            0 
## 503             0 
## 3430            0 
## 3696            1 
## 6131            0 
## 4090            0 
dim(hforig_train) 
## [1] 4327   42 
#test data set 
hforig_test <- hf_select1[-train.index,] #this will select those rows not in train.in
dex 
head(hforig_test) 
##    hfer_use hfer_nbr_base carefrag2015 lipdrx_any bbrx_any acerx_any arbrx_any 
## 3         0             0    0.5714286          0        1         0         0 
## 5         0             0    0.6810631          1        1         0         1 
## 8         1             0    0.6000000          1        1         0         0 
## 11        0             0    0.5416667          0        0         1         0 
## 13        0             0    0.7500000          1        1         0         0 
## 15        0             0    0.6719368          0        0         0         0 
##    diurx_any fqrx_any abrx_othr gabarx_any metrx_any dpp4_any sulf_any age 
## 3          1        0         1          0         0        0        0  88 
## 5          1        1         0          1         0        0        0  70 
## 8          1        0         1          0         0        0        0  90 
## 11         1        1         0          1         0        0        0  83 
## 13         1        0         1          0         0        0        1  83 
## 15         0        0         0          0         0        0        0  85 
##    age_old age_middle polyrx_gn_ge6 anyabuse ins_mcare hmo midwest northeast 
## 3        1          0             0        0         1   0       1         0 
## 5        0          1             0        0         1   1       0         0 




## 11       1          0             0        0         1   1       0         0 
## 13       1          0             0        0         1   0       1         0 
## 15       1          0             0        0         1   1       0         1 
##    south anx_any deprn ipot_arth ipot_asth ipot_cancer ipot_c_arrhy ipot_cad 
## 3      0       0     0         1         0           1            1        1 
## 5      0       1     1         1         1           0            0        0 
## 8      0       0     0         0         0           0            1        0 
## 11     0       0     1         0         0           0            0        0 
## 13     0       0     0         0         1           1            1        0 
## 15     0       1     1         0         0           0            0        0 
##    ipot_mi ipot_ckd ipot_copd ipot_dementia ipot_hilipid ipot_htn ipot_diabetes 
## 3        0        1         0             0            0        0             0 
## 5        0        1         1             0            1        1             0 
## 8        0        0         1             1            0        0             0 
## 11       0        0         0             0            0        1             0 
## 13       0        0         1             0            1        1             1 
## 15       0        0         1             1            0        1             0 
##    ipot_stroke ipot_osteop sleep_2015 obesity_2015 
## 3            0           1          1            0 
## 5            0           0          0            0 
## 8            1           0          0            0 
## 11           0           0          0            0 
## 13           0           0          0            0 
## 15           1           0          0            0 
dim(hforig_test) 
## [1] 1855   42 
library(ROSE) 
set.seed(999) 
hf_select_us <- ovun.sample(hfer_use~., data=hf_select, method="under",N=3384)$data 
table(hf_select_us$hfer_use) 
 
##    0    1  
## 1692 1692 
#1st set of variables 
set.seed(123) 
hf_select_us<- as.data.frame(hf_select_us) #converting to a data frame for sampling; 
random sampling does not work otherwise 
n = nrow(hf_select_us) #get total no. of rows 
 
train.index = sample(n,floor(0.7*n)) #randomly select 70% rows from hf_select 
 
#undersampled training data set 
hftrain <- hf_select_us[train.index,] #this will select rows in train.index 
head(hftrain) 
##      hfer_use hfer_nbr_base carefrag2015 lipdrx_any bbrx_any acerx_any 
## 2463        1             0    0.7692308          1        1         1 
## 2511        1             0    0.6666667          0        0         1 
## 2227        1             6    0.6203067          0        0         1 




## 195         0             0    0.7229437          1        0         0 
## 2986        1             9    0.7331628          1        1         1 
##      arbrx_any diurx_any fqrx_any abrx_othr gabarx_any metrx_any dpp4_any 
## 2463         0         1        0         1          0         0        0 
## 2511         0         1        0         1          0         0        0 
## 2227         0         1        0         1          0         0        0 
## 526          0         1        0         0          0         0        0 
## 195          0         0        1         0          0         0        0 
## 2986         0         1        0         1          0         0        0 
##      sulf_any age age_old age_middle polyrx_gn_ge6 anyabuse ins_mcare hmo 
## 2463        0  84       1          0             0        0         1   0 
## 2511        0  87       1          0             0        0         1   0 
## 2227        0  89       1          0             1        0         1   0 
## 526         0  77       0          1             0        0         1   1 
## 195         0  78       0          1             1        0         1   1 
## 2986        0  57       0          0             1        0         1   1 
##      midwest northeast south anx_any deprn ipot_arth ipot_asth ipot_cancer 
## 2463       0         0     1       0     0         1         0           1 
## 2511       1         0     0       0     0         1         0           1 
## 2227       0         0     0       0     0         0         0           1 
## 526        0         0     0       0     0         1         0           0 
## 195        0         0     0       0     0         1         0           0 
## 2986       1         0     0       1     0         1         0           1 
##      ipot_c_arrhy ipot_cad ipot_mi ipot_ckd ipot_copd ipot_dementia 
## 2463            1        0       0        0         1             0 
## 2511            1        0       0        0         0             0 
## 2227            1        1       0        1         1             0 
## 526             0        0       0        1         0             0 
## 195             1        1       0        1         1             1 
## 2986            1        0       0        1         0             0 
##      ipot_hilipid ipot_htn ipot_diabetes ipot_stroke ipot_osteop sleep_2015 
## 2463            1        1             0           0           1          0 
## 2511            1        1             0           0           0          1 
## 2227            1        1             0           0           1          1 
## 526             0        1             0           0           0          0 
## 195             1        1             1           1           1          0 
## 2986            1        1             1           0           0          1 
##      obesity_2015 
## 2463            0 
## 2511            0 
## 2227            0 
## 526             1 
## 195             0 
## 2986            1 
dim(hftrain) 
## [1] 2368   42 
#undersampled test data set 
hftest <- hf_select_us[-train.index,] #this will select those rows not in train.index 
head(hftest) 
##    hfer_use hfer_nbr_base carefrag2015 lipdrx_any bbrx_any acerx_any arbrx_any 




## 6         0             0    0.6666667          1        1         0         1 
## 12        0             2    0.4000000          0        0         0         0 
## 14        0             0    0.4746377          1        1         0         0 
## 15        0             0    0.5454545          0        1         1         0 
## 22        0             0    0.5846154          1        1         1         0 
##    diurx_any fqrx_any abrx_othr gabarx_any metrx_any dpp4_any sulf_any age 
## 3          1        0         0          0         0        0        0  87 
## 6          0        0         0          0         0        0        0  75 
## 12         0        1         0          0         0        0        0  85 
## 14         0        1         0          0         0        0        1  68 
## 15         0        0         0          0         0        0        0  88 
## 22         1        1         0          1         0        0        0  83 
##    age_old age_middle polyrx_gn_ge6 anyabuse ins_mcare hmo midwest northeast 
## 3        1          0             1        0         1   0       0         0 
## 6        0          1             0        0         1   0       0         1 
## 12       1          0             1        0         1   0       0         0 
## 14       0          1             1        0         0   0       0         0 
## 15       1          0             0        0         1   1       0         1 
## 22       1          0             1        0         1   1       0         1 
##    south anx_any deprn ipot_arth ipot_asth ipot_cancer ipot_c_arrhy ipot_cad 
## 3      1       0     1         0         1           0            0        0 
## 6      0       0     0         0         0           0            0        1 
## 12     1       0     0         0         0           0            0        0 
## 14     1       0     0         1         0           0            0        1 
## 15     0       0     0         1         0           0            0        0 
## 22     0       0     1         0         1           0            0        0 
##    ipot_mi ipot_ckd ipot_copd ipot_dementia ipot_hilipid ipot_htn ipot_diabetes 
## 3        0        0         1             0            1        1             0 
## 6        0        0         0             0            1        1             1 
## 12       0        1         0             1            0        1             0 
## 14       0        1         1             0            1        1             1 
## 15       0        0         0             1            0        1             0 
## 22       0        1         1             0            0        1             0 
##    ipot_stroke ipot_osteop sleep_2015 obesity_2015 
## 3            0           0          0            1 
## 6            0           0          0            0 
## 12           0           0          0            1 
## 14           1           0          0            0 
## 15           0           0          0            0 
## 22           0           0          0            0 
dim(hftest) 
## [1] 1016   42 
#random forest method 
library(randomForest) 












bestmtry <- tuneRF(ind_vars, 
                   hftrain$hfer_use, 
                   stepFactor=1.5,  
                   improve=1e-5, 
                   ntree=500) 
## mtry = 6  OOB error = 33.74%  
## Searching left ... 
## mtry = 4     OOB error = 32.64%  
## 0.03254068 1e-05  
## mtry = 3     OOB error = 32.94%  
## -0.009055627 1e-05  
## Searching right ... 
## mtry = 9     OOB error = 33.78%  
## -0.03492885 1e-05 
 
print(bestmtry) 
##       mtry  OOBError 
## 3.OOB    3 0.3293919 
## 4.OOB    4 0.3264358 
## 6.OOB    6 0.3374155 
## 9.OOB    9 0.3378378 
#random forest method 
library(randomForest) 




                        +fqrx_any+abrx_othr+gabarx_any+metrx_any+sulf_any+dpp4_any+ag
e+polyrx_gn_ge6 
                        +ins_mcare+hmo 
                        +anx_any+deprn+ipot_arth+ipot_asth+ipot_cancer+ipot_c_arrhy+i
pot_cad+ipot_mi+ipot_ckd 
                        +ipot_copd+ipot_dementia+ipot_hilipid+ipot_htn+ipot_diabetes+
ipot_stroke+ipot_osteop 




                        data=hftrain, 
                        ntreeTry = 500, 
                        mtry = 4, 
                        importance = TRUE) 
 
#Print results from Model 1 
print(rf_model1_tuned) 
## Call: 
##  randomForest(formula = hfer_use ~ hfer_nbr_base + carefrag2015 +      lipdrx_any 
+ bbrx_any + acerx_any + arbrx_any + diurx_any +      fqrx_any + abrx_othr + gabarx_a
ny + metrx_any + sulf_any +      dpp4_any + age + polyrx_gn_ge6 + ins_mcare + hmo + a
nx_any +      deprn + ipot_arth + ipot_asth + ipot_cancer + ipot_c_arrhy +      ipot_
cad + ipot_mi + ipot_ckd + ipot_copd + ipot_dementia +      ipot_hilipid + ipot_htn + 
ipot_diabetes + ipot_stroke + ipot_osteop +      sleep_2015 + obesity_2015 + northeas
t + midwest + south,      data = hftrain, ntreeTry = 500, mtry = 4, importance = TRUE
)  
##                Type of random forest: classification 
##                      Number of trees: 500 
## No. of variables tried at each split: 4 
##  
##         OOB estimate of  error rate: 32.26% 
## Confusion matrix: 
##     0   1 class.error 
## 0 809 374   0.3161454 
## 1 390 795   0.3291139 








## 2463 2511 2227  526  195 2986  
##    1    1    1    0    0    1  





## [1] 1 1 1 0 0 1 
## Levels: 0 1 
confusionMatrix(pred_model1,hftrain$hfer_use, positive = "1") 
## Confusion Matrix and Statistics 
##  
##           Reference 
## Prediction    0    1 
##          0 1183    4 
##          1    0 1181 
##                                            
##                Accuracy : 0.9983           
##                  95% CI : (0.9957, 0.9995) 
##     No Information Rate : 0.5004           
##     P-Value [Acc > NIR] : <2e-16           
##                                            
##                   Kappa : 0.9966           
##                                            
##  Mcnemar's Test P-Value : 0.1336           
##                                            
##             Sensitivity : 0.9966           
##             Specificity : 1.0000           
##          Pos Pred Value : 1.0000           
##          Neg Pred Value : 0.9966           
##              Prevalence : 0.5004           
##          Detection Rate : 0.4987           
##    Detection Prevalence : 0.4987           
##       Balanced Accuracy : 0.9983           
##                                            
##        'Positive' Class : 1                
##  
#predict using original test data 
pred_test1<-predict(rf_model1_tuned,hforig_test) 
pred_test1_prob<-predict(rf_model1_tuned,hforig_test, type = "prob") 
head(pred_test1_prob) 
##        0     1 
## 3  0.560 0.440 
## 5  0.680 0.320 
## 8  0.258 0.742 
## 11 0.844 0.156 
## 13 0.712 0.288 
## 15 0.850 0.150 
pred_test1_prob <- pred_test1_prob[,"1"] 
head(pred_test1_prob) 
##     3     5     8    11    13    15  
## 0.440 0.320 0.742 0.156 0.288 0.150 
#get confusion matrix for original test# 




## Confusion Matrix and Statistics 
##  
##           Reference 
## Prediction    0    1 
##          0 1034   38 
##          1  311  472 
##                                            
##                Accuracy : 0.8119           
##                  95% CI : (0.7933, 0.8294) 
##     No Information Rate : 0.7251           
##     P-Value [Acc > NIR] : < 2.2e-16        
##                                            
##                   Kappa : 0.5953           
##                                            
##  Mcnemar's Test P-Value : < 2.2e-16        
##                                            
##             Sensitivity : 0.9255           
##             Specificity : 0.7688           
##          Pos Pred Value : 0.6028           
##          Neg Pred Value : 0.9646           
##              Prevalence : 0.2749           
##          Detection Rate : 0.2544           
##    Detection Prevalence : 0.4221           
##       Balanced Accuracy : 0.8471           
##                                            
##        'Positive' Class : 1                
##  
#Top predictors 







rocrpred<- prediction(pred_test1_prob,hforig_test$hfer_use)#, label.ordering = c("non
e", "any")) 
rocrperf<- performance(rocrpred, 'tpr', 'fpr') 






rocrauc<- performance(rocrpred, measure = 'auc') 
print(rocrauc@y.values) 
## [[1]] 
## [1] 0.9430702 
ci.auc <- ci.auc(hforig_test$hfer_use, pred_test1_prob) 
## Setting levels: control = 0, case = 1 
## Setting direction: controls < cases 
print(ci.auc) 
## 95% CI: 0.9316-0.9546 (DeLong) 
#confusion matrix 
library(caret) 
cm_rf <- confusionMatrix(pred_test1, hforig_test$hfer_use, positive = "1") 
cm_rf 
## Confusion Matrix and Statistics 
##           Reference 
## Prediction    0    1 
##          0 1034   38 
##          1  311  472 
##                                            
##                Accuracy : 0.8119           
##                  95% CI : (0.7933, 0.8294) 
##     No Information Rate : 0.7251           
##     P-Value [Acc > NIR] : < 2.2e-16        
##                                            
##                   Kappa : 0.5953           
##                                            
##  Mcnemar's Test P-Value : < 2.2e-16        
##                                            
##             Sensitivity : 0.9255           
##             Specificity : 0.7688           
##          Pos Pred Value : 0.6028           
##          Neg Pred Value : 0.9646           
##              Prevalence : 0.2749           




##    Detection Prevalence : 0.4221           
##       Balanced Accuracy : 0.8471           
##                                            
##        'Positive' Class : 1                
##  
cm_rf_pr <- confusionMatrix(pred_test1, hforig_test$hfer_use, mode = "prec_recall", p
ositive = "1") 
cm_rf_pr 
## Confusion Matrix and Statistics 
##  
##           Reference 
## Prediction    0    1 
##          0 1034   38 
##          1  311  472 
##                                            
##                Accuracy : 0.8119           
##                  95% CI : (0.7933, 0.8294) 
##     No Information Rate : 0.7251           
##     P-Value [Acc > NIR] : < 2.2e-16        
##                                            
##                   Kappa : 0.5953           
##                                            
##  Mcnemar's Test P-Value : < 2.2e-16        
##                                            
##               Precision : 0.6028           
##                  Recall : 0.9255           
##                      F1 : 0.7301           
##              Prevalence : 0.2749           
##          Detection Rate : 0.2544           
##    Detection Prevalence : 0.4221           
##       Balanced Accuracy : 0.8471           
##                                            
##        'Positive' Class : 1                
##  
Partial dependence plot for RF model 1 
library(pdp) 
## Warning: package 'pdp' was built under R version 3.6.3 
##  
## Attaching package: 'pdp' 
## The following object is masked from 'package:purrr': 
##  
##     partial 
#Top 10 variables original dataset 
set.seed(242) 





##                        0           1 MeanDecreaseAccuracy MeanDecreaseGini 
## hfer_nbr_base 37.9672413 31.69336327          44.08377548        137.03336 
## carefrag2015  10.4608211  4.24562341          10.89968741        130.09695 
## lipdrx_any    -2.5601229  4.78048639           2.04418855         22.33132 
## bbrx_any      -2.3729118  5.27503586           2.23643454         21.36956 
## acerx_any      0.1331093  1.71712378           1.30584286         22.31277 
## arbrx_any      1.8492774  0.30319629           1.68750788         20.09725 
## diurx_any     -5.0713278  9.39094258           4.32418246         21.42383 
## fqrx_any      -2.0382352  1.41728811          -0.30646592         20.05076 
## abrx_othr     -1.4625565  2.71553019           0.93644702         20.70491 
## gabarx_any    -3.7722654  0.49641120          -2.40978381         15.97759 
## metrx_any      2.2282682 -1.76665163           0.12370855         12.35641 
## sulf_any      -1.4856569  3.61339175           1.51202162         11.80321 
## dpp4_any       0.5362780  2.61770132           2.47009631          7.03576 
## age           -1.6994047  8.57539381           5.47750677        108.46775 
## polyrx_gn_ge6 -1.0989806  4.39272934           2.54858348         21.66605 
## ins_mcare      5.8584641  0.91159792           5.20582688          9.75016 
## hmo           15.8185951  2.59289870          14.09555785         29.86181 
## anx_any       -0.5070949  4.55717651           3.08334030         19.34062 
## deprn         -1.3965579  0.10010417          -0.90352708         21.11822 
## ipot_arth     -1.1000132  1.66661520           0.36980653         25.01414 
## ipot_asth      3.5929585  1.45577013           3.54877800         18.57081 
## ipot_cancer    2.7456150 -0.13317346           1.92121773         23.25871 
## ipot_c_arrhy   2.7190771 -0.08009677           1.95925267         24.38003 
## ipot_cad       0.2453323  5.83131669           4.23808921         26.23646 
## ipot_mi       -0.2403934  0.97937367           0.52862988         11.14757 
## ipot_ckd       4.5804428  4.24242907           6.42749927         25.50455 
## ipot_copd      1.3811830  3.05323679           3.24835354         23.73637 
## ipot_dementia  2.3347037 -1.74374286           0.48722012         17.46825 
## ipot_hilipid  -0.2331155  1.20571046           0.66311835         19.94742 
## ipot_htn      -1.8232423  2.67448562           0.51214389         10.27341 
## ipot_diabetes -0.8857299  5.07297520           3.08591910         23.90229 
## ipot_stroke    1.5296095 -0.22298623           0.88030321         21.21619 
## ipot_osteop    1.4972770 -1.35086018           0.05416766         18.87292 
## sleep_2015    -2.0024586  0.72516398          -0.70714800         20.60697 
## obesity_2015  -2.9784928  2.38712362          -0.42696839         20.21741 
## northeast     -1.4733704  5.01404526           2.74216816         14.73760 
## midwest        9.6635759  4.78474310          10.85688006         22.77794 
## south          1.2319487  5.58399229           5.20433935         22.64246 
impvar1 <- rownames(imp1) [order(imp1[, 1], decreasing=TRUE)] 
impvar1 
##  [1] "hfer_nbr_base" "hmo"           "carefrag2015"  "midwest"       
##  [5] "ins_mcare"     "ipot_ckd"      "ipot_asth"     "ipot_cancer"   
##  [9] "ipot_c_arrhy"  "ipot_dementia" "metrx_any"     "arbrx_any"     
## [13] "ipot_stroke"   "ipot_osteop"   "ipot_copd"     "south"         
## [17] "dpp4_any"      "ipot_cad"      "acerx_any"     "ipot_hilipid"  
## [21] "ipot_mi"       "anx_any"       "ipot_diabetes" "polyrx_gn_ge6" 
## [25] "ipot_arth"     "deprn"         "abrx_othr"     "northeast"     
## [29] "sulf_any"      "age"           "ipot_htn"      "sleep_2015"    
## [33] "fqrx_any"      "bbrx_any"      "lipdrx_any"    "obesity_2015"  




op <- par(mfrow=c(2,3)) 
for (i in seq_along(impvar1))  { 
     partialPlot(rf_model1_tuned, hftrain, impvar1[i],xlab = impvar1[i],  
                 main = paste("Partial Dependence on", impvar1[i]), which.class = "1"
) 
}  
 
